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Members of the tumour necrosis factor superfamily (TNFSF) are important regulators of 
inflammation and immunity. TL1A (TNFSF15), ligand for death receptor 3 (DR3), is 
the most recently discovered member of this superfamily and full understanding of its 
structure and the role in T cell mediated immune responses is currently incomplete. DR3 
expression is strongly up regulated on activated T cells, although it also is present on 
resting  CD4
+  T  cells,  while  the  expression  of  TL1A  is  rapidly  and  transiently  up 
regulated on activated cells of the immune system such as dendritic cells, monocytes and 
T cells. The research published to date shows that TL1A/DR3 interaction is involved in 
the pathogenesis of several autoimmune diseases and enhances activation of CD4
+ T 
cells, however very little is known about its role in co stimulation of CD8
+ T cells. 
Several studies showed that TL1A also acts as a polarizer of the immune response by 
inducing secretion of IFN γ, IL 4, IL 10 and/or IL 17A from activated CD4
+ T cells, 
although  the  results  vary  depending  on  the  conditions  of  a  given  experiment.  The 
research presented in this thesis identifies Toll like receptors 3 and 4 as the inducers of 
TL1A  expression  on  dendritic  cells.  Furthermore,  different  binding  patterns  of  anti 
TL1A  monoclonal  antibody  (raised  against  the  homotrimeric  form  of  TL1A)  and 
DR3.Fc construct to cells transfected with TL1A cDNA and cells naturally expressing 
TL1A suggest that TL1A may exist as a homo  and heterotrimeric protein. Ecotopic 
expression of TL1A on J558L tumour cells promotes their elimination in a CD8
+ T cell 
dependent manner and renders mice immune to a subsequent challenge with tumour 
cells. Moreover, TL1A promotes the proliferation and accumulation of antigen specific 
CD8
+ T cells both in vitro and in vivo as well as their activation and differentiation into 
cytotoxic  T  cells  in  vivo.  It  also  enhances  the  secondary  expansion  of  endogenous 
antigen specific  memory  CD8
+  T  cells.  The  studies  presented  here  also  show  that 
TL1A/DR3  interaction  enhances  the  proliferation  and  activation  of  CD4
+  T  cells. 
CD11c TL1A  transgenic  and  CD2 TL1A  transgenic  mice  that  constitutively  express 
TL1A on dendritic cells and T cells, respectively, show elevated levels of IL 13 and IL 
17A in the secondary lymphoid organs suggesting that in this setting TL1A skews the 
immune response toward Th2 and Th17 type.  Furthermore, CD11c TL1A transgenic 
mice  develop  a  striking  goblet  cell  hyperplasia  in  the  ileum.  TL1A  also  enhances 
regulatory T cell accumulation in vivo. The findings presented in this thesis show that 
TL1A may have the potential for enhancing vaccines that aim to elicit CD8
+ T cell 
responses and also identify mechanisms by which sustained expression of TL1A could 
promote pathogenesis in inflammatory bowel disease.  
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CHAPTER 1  
INTRODUCTION 
 
1.1.  Overview of the immune system 
  The role of the immune system is to protect organisms from invasion by pathogenic 
agents and growth of tumour cells. There are two main types of the immune response – the 
innate and the adaptive immunity. Evolutionarily older is the innate immunity, present 
from higher plants to mammals, which acts as the first line of defence against infection. 
The  innate  immune  system  is  less  precise  than  the  adaptive  one  but  responds  faster, 
without prior exposure to pathogens. The elements of the innate immune system comprise 
anatomic and physiological barriers separating organisms from the outside environment, 
chemotactic  and  pro inflammatory  cytokines  and  antimicrobial  proteins  secreted  by 
epithelial cells, phagocytes, such as macrophages and neutrophils and cytotoxic cells, such 
as  natural  killer  cells  or  eosinophils.  The  adaptive  immune  system,  present  in  all 
vertebrates, responds slower than the innate system, because it depends on selection and 
multiplication  of  T  and  B  lymphocytes  precisely  targeted  to  specific  pathogens.  The 
initiation of the adaptive immune response depends, however, on the innate system which 
first detects the presence of the infection. T cells arise from lymphoid progenitor cells 
which have differentiated from haematopoietic stem cells. T and B cells mature in the 
thymus and bone marrow, respectively. Naive mature lymphocytes circulate in blood and 
lymphatic  system.  They  are  activated  and  acquire  the  ability  to  migrate  to  peripheral 
tissues in secondary lymphoid organs such as lymph nodes or spleen which have distinct 
regions for the activation of T and B cells. There are also other, less structured forms of 
secondary lymphoid tissue such as mucosal associated lymphoid tissue or skin associated 
lymphoid  tissue.  The  adaptive  immune  response  consists  of  B  cell mediated  humoral 
response and T cell mediated cellular response which complement each other. There are 
two major types of T lymphocytes involved in the cellular arm of this response – cytotoxic 
T lymphocytes (CTLs) which kill target tumour cells or cells infected with pathogens and 
helper T cells which regulate the function of other lymphocytes. The adaptive immune 
response allows the generation of specialized memory lymphocytes that survive for years 
providing the host with faster adaptive response if it is exposed to the given pathogen for 
the second time.   2 
 
1.2.   Development of T cells 
 
  The  greater  part  of  T  cell  development  occurs  in  the  thymus.  Even  though  the 
thymus undergoes atrophy and is partially replaced by adipose tissue in mature individuals, 
the  development  of  new  T  cells  is  still  maintained  (although  slows  down)  and  T  cell 
numbers  are  maintained  through  cell  divisions  and  survival  of  mature  T  cells  in  the 
periphery. T cells differentiate from a common lymphoid progenitor that gives rise also to 
B  cells.  Stimulation  of  Notch 1  receptors  on  the  progenitor  cells  destins  them  to 
differentiate into T cells, leave the bone marrow and migrate to the thymus (1).  
  Progenitor cells that enter the thymus, lack most of the markers characteristic of T 
cells. During the initial phase of differentiation, they gain distinctive markers of the T cell 
lineage  (e.g.  CD2)  but  do  not  express  the  T  cell  receptor  (TCR)  or  CD4  and  CD8 
molecules, therefore are called “double negative” thymocytes (2). A fraction of these cells 
that expresses FoxP3 gives rise to natural T regulatory cells (nTregs) (3).  In mice, nTregs 
migrate  from  the  thymus  into  the  periphery  after  the  first  3  days  of  life  (4).  Double 
negative thymocytes undergo screening for successful rearrangement of the T cell receptor 
(TCR) β chain which is expressed together with the pre TCRα chain. This process is called 
β selection. The correct assembly of this pre TCR leads to intensive cell proliferation, the 
arrest of further rearrangements of β, γ and δ chains, and induces the expression of both 
CD4 and CD8 molecules. The cells which do not manage to correctly rearrange the β chain 
undergo apoptosis. Rearrangement of genes encoding the chains comprising TCR is the 
main  source  of  T  cell  diversity.  It  is  still  very  unclear  which  signals  induce  the 
differentiation of Tγδ cells. However, it is believed that this process begins before the 
rearrangement of TCR genes and Tγδ cells arise before Tαβ cells during thymic ontogeny 
(2,  5).  After  the  double  positive  cells  cease  to  proliferate,  they  express  recombination 
activating genes (RAG), rearrange the TCRα locus and down regulate the expression of the 
pre TCRα chain. Thymocytes, expressing the mature TCRαβ complex that does not bind to 
self peptide MHC  complexes  present  on  epithelial  cells  of  the  thymic  cortex,  die  by 
apoptosis  while  the  cells  that  are  able  to  interact  with  self peptide MHC  survive. 
Depending  on  whether  the  latter  interaction  is  with  MHC  class  I  or  class  II,  cells 
differentiate  to  either  CD8  or  CD4  single  positive  mature  lineages  (6).  Cells  migrate 
subsequently into thymic medulla where they undergo functional maturation and negative 
selection to eliminate self reactive clones (7). 
      3 
 
1.3.     Subsets of T cells   
 
T cells are divided into two main subsets based on the presence or absence of the 
co receptors  CD4  and  CD8.  After  activation,  naive  CD4
+  T  cells  differentiate  into 
functional subsets called T helper 1 (Th1), T helper 2 (Th2) or T helper 17 (Th17) which 
produce defined and specific sets of cytokines (8, 9). Another subset of CD4
+ T cells are 
regulatory  T  cells  (Tregs)  which  are  further  divided  into  natural  Tregs  (nTregs)  that 
develop in the thymus and inducible T regs (iTregs) that are induced from naive CD4
+ T 
cells in the periphery. There is, however, no reliable marker that would allow to distinguish 
nTregs from iTregs (9). Differentiation of CD4
+ T cells into different subsets is regulated 
primarily by cytokines secreted by activated antigen presenting cells. Signalling molecules, 
transcription factors and cytokines produced by different CD4
+ T cell subsets prevent the 
differentiation of other subsets of these cells (10, 11). 
  Th1 cells are protective against intracellular microbes and play a pathogenic role in 
chronic inflammatory disorders. These cells produce high levels of IFN γ, IL 2 and TNF, 
which are responsible for the activation of macrophages and play an important role in cell 
mediated immunity. However, it is not correct to say that Th1 cells are responsible only for 
cell mediated immunity since they also provide help for B cells in production of antibodies 
– they allow the production of IgG2a antibodies in mice and of IgM, IgA, IgG1, IgG2 and 
IgG3 in humans (10). IFN γ and IL 12 are powerful inducers of Th1 differentiation. IFN γ 
activates the signal transducer and activator of transcription 1 (STAT 1) in naive CD4
+ T 
cells  which  up regulates  the  Th1  master  regulator,  transcription  factor  T bet.  T bet  is 
responsible also for induction of IFN γ production and IL 12Rβ2 expression on CD4
+ T 
cells which can now directly respond to IL 12. STAT 4, an IL 12 signal transducer, is 
important for amplifying Th1 responses; it directly induces IFN γ production in activated 
Th1 cells which initiates the positive feedback loop in which IFN γ acting through T bet 
induces more IFN γ. In this way collaboration between IFN γ and IL 12 induces full Th1 
differentiation. Furthermore, IL 18 which is not involved in Th1 differentiation, synergizes 
with IL 12 in inducing IFN γ, implying that this cytokine also plays an important role in 
Th1 responses (10, 11).  
  Th2 cells mediate host defence against extracellular pathogens. Cytokines produced 
by Th2 cells mediate IgE class switching in B cells (IL 4 and IL 13), activate eosinophils 
(IL 5) and mast cells (IL 9), they also induce proliferation and antibody production by B 4 
 
cells (IL 4, IL 5, IL 10 and IL 13), notably IgG1 and IgE in mice and IgM, IgG4 and IgE 
in humans (10). Th2 cells produce also IL 17E which amplifies Th2 mediated responses 
(9 11). Differentiation of Th2 cells depends on IL 4 which activates STAT 6 which in turn 
up regulates the transcription factor GATA 3 which is the master regulator of Th2 genes 
expression. Another important regulator of Th2 differentiation is IL 2 induced STAT 5. 
Collaboration between GATA 3 and STAT 5 allows for full differentiation of Th2 cells 
(10, 11). 
  Th1 and Th2 cells are fully differentiated after 3 4 cell divisions. After that time, 
they cannot change their phenotype to the opposite one when they are treated with the 
appropriate set of Th1 or Th2 polarizing cytokines (12). Th cells are very heterogeneous, 
only a small proportion of cells expresses the full set of cytokines of a given subpopulation 
(9). Moreover, some Th1 cells can produce IL 10 while IFN γ production is maintained 
(9).  
  Th17  cells  mediate  immune  responses  against  fungi  and  extracellular  bacteria. 
They also participate in the induction of many  autoimmune disorders such as multiple 
sclerosis or rheumatoid arthritis. Th17 cells produce IL 17A, IL 17F, IL 21 and IL 22. IL 
17A induces the expression of many pro inflammatory cytokines. Both IL 17A and IL 17F 
recruit and activate neutrophiles during immune responses. Th17 differentiation is induced 
by TGF β and IL 6 which induce the expression of IL 21, IL 23R and the transcription 
factor RORγt which is responsible for the induction of IL 17A and IL 17F production. IL 
21 can replace IL 6 in inducing RORγt, therefore acts as an amplification cytokine for 
Th17 differentiation. Another important cytokine is IL 23 which is critical for survival and 
maintaining the function of Th17 cells, although it does not induce their differentiation. IL 
6, IL 21 and IL 23 act via common signal transducer, STAT 3, which is indispensable for 
Th17 differentiation (11). 
  Tregs are critical for regulating immune responses and maintaining self tolerance 
by suppressing a variety of both adaptive and innate immunity cells, including CD4
+ and 
CD8
+ T cells, dendritic cells (DCs), mast cells and NK cells. Tregs do not rely on only one 
mechanism  for  their  function  but  instead  use  many  alternate  mechanisms  to  control 
immune responses. They inhibit degranulation of mast cells via OX40/OX40L interaction 
(13) and directly kill DCs (14), B cells (15) and NK cells (16) via perforin and granzymes; 
the  same  mechanism  is  used  for  killing  of  effector  CD4
+  and  CD8
+  T  cells  (17). 
Interestingly, CD8
+, but not CD4
+ T cells, are killed by Tregs also by Fas/FasL interaction 
(18). Tregs suppress the activity of CD4
+ and CD8
+ T cells also by secretion of TGFβ 5 
 
which has an anti proliferative effect on T cells due to its ability to block the upregulation 
of high affinity IL 2 receptors on T cells and is therefore able to block the ability of T cells 
to respond to IL 2 stimulation (19). TGFβ upregulates also cell cycle inhibitors in T cells 
(20). Other cytokines secreted by Tregs, which interfere with T cell activation, are IL 10 
and IL 35. There are reports that stimulation of TCR activated T cells with IL 10 results in 
their  anergy  (17,  20)  while  IL 35  enhances  proliferation  of  Tregs  but  suppresses  the 
proliferation  of  TCR activated  CD4
+  CD25
   T  cells  (21,  22).  Finally,  due  to  the 
constitutive expression of CD25, a high affinity receptor for IL 2, Tregs remove IL 2 from 
the nearby environment and thereby prevent proliferation and differentiation of T cells 
(23). It is worth to emphasise that although the suppressive activity of Tregs requires their 
prior activation via TCR, once activated, they  suppress in a non antigen specific way. 
Thus, Tregs with one antigen specificity can suppress effector T cells with many other 
distinct antigen specificities (23). Tregs inhibit also maturation and cytokine production of 
DCs and in this way suppress indirectly also the activity of T cells. IL 10 and TGFβ, 
secreted by Tregs, inhibit the production of pro inflammatory cytokines and downregulate 
the  production  of  a  number  of  costimulatory  molecules  on  DCs,  including  CD80  and 
CD86; they also downregulate the expression of MHC class II by DCs which profoundly 
affects  the  ability  of  DCs  to  activate  effector  T  cells  (20).  Tregs  also  modulate  the 
metabolism of target cells via expression of nucleoside triphosphate diphosphohydrolase 1 
(CD39) and ecto 5’nucleotidase (CD73) (11, 24). During the normal course of an immune 
response, Tregs expand at the rate parallel to the effector cells (25), at the peak of the 
response,  their  relative  accumulation  can  even  exceed  that  of  effector  T  cells  (26). 
Homeostatic proliferation of Tregs auguments their ability to suppress target cells (27); 
therefore they gain full suppressive activity right after the peak of the response. Both in 
mice  and  humans,  Tregs  are  defined  as  CD4
+CD25
+FoxP3
+  cells.  They  constitutively 
express  high  levels  of  CD25  (IL 2Rα),  whereas  the  expression  of  this  molecule  on 
conventional CD4
+ T cells is much lower and transient (induced after the activation).  The 
distinguishing  feature  of  iTreg  differentiation  is  its  dependence  on  TGF β  (28).  High 
concentration of TGF β in the absence of pro inflammatory cytokines (e.g. IL 6) activates 
Smad 3, while TCR stimulation activates the transcription factor NFAT. NFAT cooperates 
with  Smad3  in  induction  of  FoxP3  which  is  a  transcription  factor  crucial  for  iTreg 
differentiation (11). Differentiation of nTregs in the thymus depends on TCR signalling of 
increased  strength  which  results  in  up regulation  of  CD25  (IL 2Rα)  and  increased 
responsiveness of IL 2; the other important factor is CD28 signalling. Activation of these 6 
 
pathways results in recruitment of NFAT, cRel, Creb and STAT 5 and consequently leads 
to the induction of FoxP3 expression in developing thymocytes (28).  
  CD8
+ T cells become cytotoxic T cells (CTLs) which recognize antigens presented 
by MHC class I molecules and kill tumour cells or cells infected with pathogens. They 
mediate  killing  of  target  cells  through  the  secretion  of  serine  proteases  (granzymes), 
perforin or molecules belonging to the tumour necrosis factor superfamily, such as FasL 
(29, 30). Perforin is a pore forming protein that is capable of membrane permeabilization 
(29). It causes little death at low concentrations, although at high concentrations, it can 
cause necrotic death of a cell due to the loss of membrane integrity (31). The main role of 
perforin, however, is delivery of granzymes into the cytosol of the target cell where they 
independently of each other trigger apoptosis (29, 31). For example, granzyme B mediates 
detachment of cells and causes cell death by anoikis (death due to the lack of extracellular 
contact).  It  also  cleaves  Bid  protein  to  its  truncated  form  (tBid)  which  activates 
mitochondrial pathway of apoptosis. Other target proteins for granzyme B are caspase 8 
and  caspase 3  which  cleavage  also  activates  apoptosis  (29).  Granzyme  A,  as  well  as 
granzyme B, directly cleave lamin B which maintains the structural integrity of the nuclear 
envelope  and  consequently  induce  apoptosis  independently  of  caspases  (32).  FasL 
mediated apoptotic death of target cells for CTLs is the consequence of triggering of Fas 
receptor on the surface of target cells. CTLs can release FasL in its membrane bound form 
into the synaptic cleft between a CTL and a target cell in a process mediated by secretory 
lysosomes. The transmembrane form of FasL is 1000 times more biologically active than 
the cleaved soluble form (30).  
CD8
+  T  cells  are  divided  into  conventional  Tαβ  and  Tγδ  cells  depending  on  the 
structure of their TCR; additionally CD8
+ Tγδ usually express CD8αα homodimer instead 
of CD8αβ heterodimer expressed on conventional CD8
+ Tαβ cells (33).  
Another subset of CTLs are natural killer T cells (NKT cells). Most of them are CD4
  
and CD8
 , although a small proportion of NKTs is CD4
+.
 NKT cells express TCRαβ and 
markers typical for natural killer (NK) cells (such as NK1.1 or CD49b in mice or CD16 
and CD56 in humans) and recognize glycolipids presented by antigen presenting cells by 
CD1 molecules (2, 34). Activation of NKT cells leads to rapid secretion of IFN γ, IL 4, IL 
2,  TNF  and  other  cytokines  that  regulate  the  immune  response.  They  also  up regulate 
expression of co stimulatory molecules, such as CD40L, thus contribute to activation of 
dendritic cells (35) and can directly kill target cells through cytolytic activity – by secretion 
of perforin and expression of FasL (2, 34).  7 
 
1.4.    T cell mediated immune response 
 
  T cells are recruited from blood vessels to secondary lymphoid organs such as the 
lymph nodes or the spleen where they interact with antigen presenting cells (e.g. dendritic 
cells) and become activated. The site of T cell activation is located in the paracortex region 
of the lymph nodes and in the white pulp surrounding the branches of the splenic arteries. 
Most cytotoxic T cells are CD8
+ lymphocytes that recognize antigens presented on MHC 
class  I  molecules.  For  activation,  these  cells  require  help  provided  by  CD4
+  T  helper 
lymphocytes  and  dendritic  cells.  Dendritic  cells  not  only  present  antigens  which  are 
recognized by T cell receptors (TCRs) cells but also express co stimulatory molecules that 
are indispensable for activation of T cells. The process of activation of CD4
+ and CD8
+ T 
cells is very similar although CD4
+ cells recognize antigens presented in the context of 
MHC class II while CD8
+ T cells in the context of MHC class I (2).   
  The interaction between T cells and dendritic cells occurs in three distinct phases. 
During the first phase, T cells migrate in random directions after entering the lymph node 
and  undergo  multiple  short  encounters  with  dendritic  cells.  In  this  way,  T  cells  scan 
dendritic cells to locate the one that is presenting the antigen recognised by a given clone 
of T cells. During the second phase, T cells form stable antigen dependent conjugates with 
dendritic cells and secrete IFN γ and IL 2. This phase is responsible for activation of T 
cells and promotion of their proliferation, survival and effector functions. Finally, during 
the  last  phase,  T  cells  resume  rapid  migration  and  their  proliferation  is  significantly 
increased (36).  
  The initial, antigen independent interaction between T cells and dendritic cells is 
facilitated by the interaction between adhesion molecules DC specific ICAM 3 grabbing 
integrin (DC SIGN) and ICAM 3 expressed on dendritic cells and T cells, respectively 
(37).  After  the  engagement  of  TCR,  cell  to  cell  contact  is  stabilised  through  adhesion 
between  integrins  (e.g.  LFA 1)  on  T  cells  and  ICAM  molecules  on  antigen presenting 
cells.  The  next  step  is  formation  of  an  immunological  synapse  which  leads  to  the 
development  of  a  ring  of  LFA 1/ICAM  complexes  surrounding  a  central  region  of 
increased density of TCR/antigen MHC complexes which auguments TCR occupancy by 
antigen MHC  complexes  and  enhances  cross talk  between  the  clustered  receptors,  thus 
promotes sustained signalling (38).  
  Help provided by CD4
+ T cells is required by CD8
+ T cells for efficient priming 
and memory development. There are reports showing that CD8
+ T cells can be successfully 8 
 
primed  without  CD4
+  T  cell help,  although  they  are  incapable  of  mounting  efficient 
secondary response in the absence of help provided by CD4
+ T cells during the initiation of 
the immune response (39, 40). CD4
+ T cells do not require direct contact to provide help 
for CD8
+ T cells. They provide an indirect help by secreting cytokines that increase their 
proliferation (e.g. IL 2) inducing activation of dendritic cells which in turn up regulate the 
expression of co stimulatory molecules.  
  Activation  of  T  cells  results  in  their  rapid  expansion  initiated  in  the  secondary 
lymphoid organs and development of effector functions (2). Effector CD8
+ T cells reduce 
the expression of L selectin (CD62L), up regulate chemokine receptors CCR2 and CCR5 
and gain the ability to migrate into inflamed tissues (41) where they kill target cells that 
express  antigens  recognised  by  them  in  the  context  of  MHC  class  I  molecules.  Non 
specific proliferation (i.e. proliferation which is not specific for a given clone) of T cells 
may  be  induced  by  mitogens  –  substances  that  trigger  mitotic  cell  division  (e.g. 
phytohaemagglutinin (PHA) or concavalin A (ConA)). Other class of substances that can 
trigger  non specific  proliferation  of  T  cells  are  superantigens,  produced  by  pathogenic 
microorganisms, which induce also a massive cytokine release from T cells. They bind 
directly to a specific β chain of a TCR or to the outer surface of MHC class II molecules. It 
is estimated that superantigens are capable of activating up to 20% of T cells present in the 
body (2). 
  The immune response is followed by a contraction phase during which ~90% of 
activated  T  cells  undergo  apoptosis.  This  is  the  result  of  activation induced  cell  death 
(AICD)  mediated  by  the  interaction  between  TNF  receptor  superfamily  members 
expressed  on  T  cells  and  TNF  superfamily  members  expressed  on  the  same  or 
neighbouring cells (FasL/Fas, CD30L/CD30, TNFR1/TNF and TNFR2/TNF) (42 44). This 
process is described in more detail in the section 1.8.2. The other mechanism that leads to 
death  of  activated  T  cells  is  activated  T  cell  autonomous  death  (ACAD),  also  termed 
“cytokine  withdrawal”,  which  is  controlled  by  the  balance  of  pro   and  anti apoptotic 
members  of  the  Bcl2  family  that  regulate  cell  death  by  inducing  or  inhibiting  the 
mitochondrial  pathway  of  apoptosis.  Limitation  of  IL 2  in  the  environment  during  the 
contraction  phase  results  in  the  decrease  of  anti apoptotic  protein  Bcl2  inside  the  cell. 
Activated cells show also elevated levels of a pro apoptotic protein Bim which, together 
with  Bax  and  Bak,  induces  the  release  of  apoptogenic  factors  from  mitochondria, 
downstream activation of caspase 9 and eventual cell death (43).  9 
 
  Around 10% of T cells survive the contraction phase of the immune response. They 
form a pool of memory cells that persists for years. In the absence of antigens, homeostatic 
proliferation of CD8
+ memory T cells depends on IL 15, whereas continual division of 
CD4
+ memory T cells appears to be IL 12 dependent (45). Memory T cells provide faster 
immune response when the host organism is exposed to the antigen for the second time (2). 
Compared to naive T cells, memory cells divide after a shorter lag time, have increased 
division rate and show more rapid and efficient development of effector functions (46).  
  Memory  T  cells  established  after  infection  can  be  divided  into  two  subsets  – 
effector memory T cells (TEM) and central memory T cells (TCM). TEM cells are terminally 
differentiated cells, present in peripheral tissues, that lack lymph node homing receptors 
(CD62L and CCR7) but express receptors that enable these cells to migrate to inflamed 
tissues,  such  as  CD44,  CCR4  or  CCR9.  TEM  cells  exert  immediate  effector  functions 
without  the  need  for  further  differentiation.  TCM  cells  circulate  through  the  secondary 
lymphoid organs (and show expression of both CD62L and CCR7), they lack immediate 
effector  functions  but  can  develop  the  phenotype  and  function  of  TEM  cells  after 
restimulation  with  antigen.  After  pathogen  clearance,  the  antigen specific  memory  cell 
pool consists mostly of TEM cells which convert into TCM cells over time (45, 47).  
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1.5.      Structure and signalling of the T cell receptor 
 
  T cell receptors (TCRs) are type I transmembrane dimeric proteins belonging to the 
immunoglobulin superfamily; the average number of TCRs present on a single T cell is 
5x10
4. Over 90% of peripheral blood T lymphocytes have TCRs composed of α and β 
(TCRαβ) chains, while in 1 10% of peripheral blood lymphocytes the receptor is composed 
of γ and δ chains (TCRγδ). There is also a very small proportion of T cells bearing TCRs 
composed of two γ chains, two β chains or β and γ chain (2). The dimeric structure of a 
TCR is stabilised by disulfide bridges formed between the two chains of the receptor. Each 
polypeptide  chain  consists  of  a  membrane  proximal  constant  domain  and  a  membrane 
distal variable domain which is composed of three complementarity determining regions 
(CDRs)  that  recognise  antigens  in  the  context  of  MHC  molecules.  The  hypervariable 
CDR3 is particularly important for antigen specificity of TCR, while CDR1 and CDR2 
seem to play a less important role in this process (2, 38). The cytoplasmic domains of 
TCRs are devoid of any signalling motifs, therefore TCRs are expressed in conjunction 
with CD3 molecules which contain immune tyrosine based activation motifs (ITAMs) and 
mediate  signalling  from  TCRs  (38).  CD3  molecules  are  organized  in  dimeric  units  of 
CD3γε, CD3δε and CD3ζζ which form a complex associated with two TCRs (48). TCRs 
are associated also with CD4 or CD8 molecules which bind to MHC class II or MHC class 
I molecules respectively (2).   
  During the interaction between TCR and antigen MHC complex, CD4 or CD8 co 
receptors bind to invariant regions of MHC class II or MHC class I, respectively. This 
interaction activates Lck kinase which is associated with the cytoplasmic tail of CD4 and 
CD8. Lck kinase phosphorylates tyrosine residues in the ITAM motifs of CD3ζ chains 
which  subsequently  bind  ξ chain associated  protein  kinase  70  (ZAP70)  that  is 
indispensable for activation of T cells. ZAP70 is then activated by phosphorylation by Lck 
and in turn phosphorylates itself and the ITAM motifs in other CD3 chains which now can 
also bind ZAP70. This kinase phosphorylates also adaptor proteins LAT and SLP76 which 
activate the transcription factor NF AT via other proteins such as Grb2, Grap and Vav. 
TCR  engagement  leads  also  to  phosphorylation  of  phospholipase  C γ  (PLC γ)  which 
catalyses  degradation  of  phosphatidylinositol 4,5 biphosphate  (PIP2)  to  inositol 1,4,5 
triphophate (IP3) and diacylglycerol (DAG). IP3 releases Ca
2+ ions from the endoplasmic 
reticulum which activates calcineurin via calmodulin. Calcineurin is a serine phosphatase 
that  can  activate  NF AT.  DAG  directly  activates  protein  kinase  C  θ  (PKCθ)  which, 11 
 
together with Ras and mitogen actived protein kinase (MAPK), takes part in activation of 
the  transcription  complex  AP 1  (2,  49).  PKCθ  activates  also  a  trimolecular  complex 
CARMA1 BCL10 MALT1 which promotes ubiquitinylation of NEMO – the regulatory 
subunit of I κB (inhibitor of κB) kinase (IKK) complex. This results in the activation of 
IKK complex, phosphorylation of I κB and activation of the transcription factor NF κB 
(50).  Activation  of  AP 1  and  NF AT  promotes  the  transcription  of  genes  involved  in 
proliferation and effector function of T cells. Additionally, the engagement of TCR induces 
polymerisation  of  actin  which  leads  to  changes  in  the  cytoskeleton  that  result  in  the 
decrease of T cell motility and consequently stronger contact between the T cell and the 


















1.6.  Presentation of antigens 
1.6.1.  Antigen presenting cells 
 
  All nucleated cells can present endogenous antigens in the context of MHC class I 
molecules. In this way, tumour cells or cells infected with pathogens can be recognised and 
killed  by  cytotoxic  T  lymphocytes.  There  are  also  several  cell  types,  called  antigen 
presenting cells, that express also MHC class II molecules and can initiate the adaptive 
immune response by presenting antigens to both CD4
+ and CD8
+ T lymphocytes. These 
cell  types  include  B  cells,  macrophages  and  dendritic  cells  (DCs)  (2).  Following  the 
antigenic  stimulation  of  a  B  cell  receptor,  B  cells  process  and  present  antigens  in  the 
context of MHC class II to recruit specific CD4
+ T helper cells in order to obtain their help 
in promoting proliferation and effector function (51). Macrophages are resident phagocytic 
cells present in both lymphoid and non lymphoid tissues. Unlike B cells and dendritic 
cells, they constitutively express very little MHC class II. Instead, they up regulate them 
following stimulation with IFN γ (2, 52). 
  Dendritic cells are called professional antigen presenting cells. In contrast to B cells 
and macrophages, they express co stimulatory molecules required for full activation of T 
cells, although B cells and macrophages can also act as antigen presenting cells for T cells 
that have been previously primed with DCs. Furthermore, B cells and macrophages (unlike 
DCs) are not present in the T cell areas of the secondary lymphoid organs and express 10 
100 fold lower level of MHC molecules than DCs (53). Dendritic cells are present in most 
tissues  or  can  migrate  to  the  sites  of  inflammation,  where  they  capture  antigens  by 
phagocytosis or endocytosis and subsequently process them and present in the context of 
MHC  class  II  or  MHC  class  I.  Following  the  antigen  uptake  and  stimulation  with 
pathogen associated molecular patterns or other factors that induce maturation of DCs (for 
example CD40L), DCs migrate to the secondary lymphoid organs, such as lymph nodes or 
spleen.  During  the  migration,  the  cells  undergo  maturation  which  results  in  a  reduced 
capacity to process antigens, up regulation of co stimulatory molecules, redistribution of 
MHC class II molecules from the intracellular endocytic compartments and secretion of 
cytokines that induce proliferation and effector function of T cells, and also may skew the 
immune response towards Th1, Th2 or Th17 type. They also regulate the differentiation 
and proliferation of regulatory T cells. Resting, immature DCs may take part in activation 
of T cells, although they are much less efficient compared to mature DCs. In the presence 13 
 
of negative co stimulatory signals (e.g. CTLA 4 or PD 1), dendritic cells induce tolerance 
to the presented antigens (54). 
 
1.6.2.  Presentation of antigens in the context of MHC class I molecules 
 
  MHC class I molecules are composed of a light chain (β2 microglobulin; 12 kDa) 
and a heavy chain (α chain; 40 45 kDa) which are bound by non covalent association. The 
extracellular part of the α chain has three 90 amino acids long domains – α1, α2 and α3. 
The  polymorphic  α1  and  α2  domains  form  a  cleft  which  binds  8 10  amino  acids long 
peptides.  The α3 domain is non polymorphic and binds β2 microglobulin (2). 
  MHC class I molecules present antigens derived from the breakdown of proteins 
synthesised  within  the  cell  (endogenous  antigens),  although  in  some  cases  exogenous 
peptides  can  be  diverted  to  the  MHC  class  I  pathway  in  a  process  termed  “cross 
presentation”. In vivo, only dendritic cells are capable of cross presentation (55). A single 
MHC class I molecule can bind many peptides that have different sequence but identical 
“docking amino acids” that take part in binding to the cleft of MHC class I. A normal, 
healthy cell presents normal cellular antigens on MHC class I molecules which does not 
induce killing by cytotoxic T lymphocytes (CTLs). However, presentation of foreign or 
altered antigens will result in activation of CTLs. Furthermore, reduction of the normal 
level of MHC class I expression, which occurs in tumour or virus infected cells, may result 
in killing of the cell by natural killer cells. 
  Proteins synthesised within a cell and destined for degradation are marked with 
ubiquitin which directs them to proteasomes. Proteasomes are 26S multisubunit complexes 
consisting of a 20S catalytic core and two 19S regulatory subunits which role is proteolysis 
of  proteins.  Their  main  function  is  degradation  of  unneeded  or  damaged  proteins  by 
proteolysis.  They  produce  short  peptides  which  can  be  then  be  further  trimmed  by 
additional amino peptidases. These peptides are subsequently translocated from the cytosol 
into the lumen of the endoplasmic reticulum and loaded onto MHC class I molecules. This 
process is mediated by the MHC class I loading complex which consists of MHC class I 
molecules,  the  transporter  associated  protein  (TAP),  calnexin,  calreticulin,  the  thiol 
oxidoreductase ERP57 and tapasin. TAP is a heterodimeric polypeptide  situated in the 
membrane  of  the  endoplasmic  reticulum  which  transports  the  peptides  into  its  lumen. 
Tapasin recruits MHC class I molecules to TAP and facilitates loading of MHC class I 
with antigenic peptides. Calnexin acts as a chaperone for the folding of the α chain of 14 
 
MHC class I and later is replaced by calreticulin which assists in further assembly of MHC 
class  I peptide  complex.  Correctly  assembled  MHC  class  I peptide  complexes  are 
subsequently exported to the cell surface (2).  
  In  the  process  of  cross presentation,  exogenous  peptides  are  translocated  to  the 
cytosol from early phagosomes where they are degraded in proteasomes and follow the 
endogenous route for MHC class I molecules. Alternatively, following the degradation in 
proteasomes, they may re enter the endocytic compartment for loading on MHC class I 
molecules. However, the drop in pH value in maturing endosomes and phagosomes results 
in the decrease of endoplasmic reticulum derived proteins and these compartments become 
incompetent for cross presentation. Instead, they acquire characteristic features required 
for loading peptides onto MHC class II molecules (55). 
 
1.6.3.  Presentation of antigens in the context of MHC class II molecules 
 
  MHC class II molecules are composed of α (33 kDa) and β (29 kDa) chains which 
are connected with each other by non covalent bonds. The external, polymorphic domains 
of each chain (α1 and β1) form a cleft similar to the one present in MHC class I molecules 
that can bind peptides up to the length of 20 amino acids. Similarly to MHC class I, MHC 
class  II  molecules  can  bind  broad  spectrum  of  peptides.  The  specificity  of  binding  is 
limited by the presence or absence of amino acid motifs in the peptide, required for binding 
of the peptide to a given allele of MHC class II  (2).  
  MHC class II molecules present exogenous peptides that are taken up by the cell by 
phagocytosis  or  pinocytosis.  The  proteins  are  degraded  in  endosomes  by  a  variety  of 
proteases. The peptide products are loaded onto MHC class II molecules in exchange for a 
fragment  of  an  invariant  chain  peptide  (CLIP)  which  prevents  binding  of  endogenous 
peptides to MHC class II molecules in a process catalysed by the MHC class II homologue 
DM (2, 56). MHC class II peptide complexes are transported to the cell surface via late 
endosomes and lisosomes. On the way, the peptide present in the cleft of MHC class II 
may still be trimmed by preoteases but the cleft protects it from full degradation (2).  
 
1.6.4.  Presentation of antigens in the context of CD1 molecules 
 
  CD1 molecules are encoded by five non polymorphic genes (CD1A – CD1E). Their 
structure is very similar to MHC class I molecules. CD1a, b and c molecules are present on 15 
 
monocytes, B cells and some dendritic cells, whereas CD1d molecules are expressed on 
intestinal epithelial cells. CD1 molecules present endogenous lipid and glycolipid antigens 
































1.7.    Costimulation of T cells 
  The interaction between an antigen presented by an MHC molecule and a T cell 
receptor  (TCR)  is  not  sufficient  to  drive  the  activation  of  naive  T  cells.  In  fact,  this 
interaction, termed signal 1, is inactivating when delivered alone. Naive T cells that are 
stimulated only through TCR are unable to sustain proliferation and become unresponsive 
(anergic) to stimulation or undergo apoptosis (57, 58). Costimulatory molecules provide 
additional  signals  (signal  2)  which  are  indispensable  for  proliferation,  survival  and 
differentiation  of  T  cells.  Full  activation  of  T  cells  is  achieved  only  by  integration  of 
signals  1  and  2.    Costimulatory  signals  may  also  be  defined  as  any  interaction  that 
enhances antigen receptor signalling, proliferation and/or effector function of T cells (59). 
Furthermore, differentiation into effector cells is generally dependent on a signal supplied 
by antigen presenting cells in soluble form (e.g. IL 12, IL 4 or IFN γ) (59, 60). There are 
also molecules known as negative costimulators which inhibit responses of T cells (59, 
61).  Thus,  costimulation  plays  a  critical  role  in  determining  whether  the  outcome  of 
antigen stimulation would be activation and anergy. The threshold for T cell activation is 
set by the balance of negative and positive costimulatory signals which is critical for aspect 
of regulation of T cells function (62). 
  Costimulatory signals act on particular aspects of T cell activation such as survival, 
proliferation and differentiation to effector or memory cells. The function of costimulatory 
molecules  is  related  to  the  timing  of  its  action;  therefore  their  expression  is  tightly 
regulated and depends on the activation status of the cell (60). Costimulatory molecules 
fall into two major families (Table 1.1.) – the immunoglobulin (Ig) superfamily (including 
B7.1,  B7.2,  CD28,  CD2  or  ICOS)  and  TNF/TNFR  superfamily  (59)  which  includes 
costimulatory molecules such as TL1A/DR3, CD70/CD27, OX40L/OX40 or 4 1BBL/4 










Receptor  Ligand  Superfamily 
Positive / negative 
costimulation 
CD28  CD80 (B7.1), CD86 (B7.2)  Ig SF  Positive 
CTLA 4 (CD152)  CD80 (B7.1), CD86 (B7.2)  Ig SF  Negative 
ICOS (CD278)  ICOS L (CD275, B7 H2)  Ig SF  Positive 
PD 1 (CD279) 
PD L1 (CD274, B7 H1), PD L2 
(CD273, B7 DC) 
Ig SF  Negative 
LFA 2 (CD2)  LFA 3 (CD48)  Ig SF  Positive 
LFA 1 (CD11a)  ICAM1, ICAM2, ICAM3  Ig SF  positive 
VLA 4  VCAM1  Ig SF  positive 
TLT 2  B7 H3  Ig SF  Negative 
Unknown  B7S1  Ig SF  Negative 
Unknown  B7S3  Ig SF  Negative 
Unknown  BTNL2  Ig SF  Negative 
CD27 (TNFRSF7)  CD70 (TNFSF7)  TNF/TNFRSF  Positive 
4 1BB 
(TNFRSF9) 
4 BBL (TNFSF9)  TNF/TNFRSF  Positive 
OX40 (TNFRSF4)  OX40L (TNFSF4)  TNF/TNFRSF  Positive 
GITR 
(TNFRSF18) 
GITRL (TNFSF18)  TNF/TNFRSF  Positive 
CD30 (TNFRSF8)  CD30L (TNFSF8)  TNF/TNFRSF  Positive 
HVEM 
(TNFRSF14) 
LIGHT (TNFSF14)  TNF/TNFRSF  Positive 
DR3 (TNFRSF25)  TL1A (TNFSF15)  TNF/TNFRSF  Positive 
CD40 (TNFRSF5)  CD40L (TNFSF5)  TNF/TNFRSF  Positive 
 
Table 1.1. Costimulatory molecules. 
 
  A classical example and the best characterized pathway of T cell costimulation is 
B7/CD28  system  which  is  critical  for  T  cell  activation.  CD28  is  a  disulfide linked 
homodimeric  glycoprotein  expressed  on  resting  T  cells  and  up regulated  after  their 
activation. Ligands for CD28 – B7.1 (CD80) and B7.2 (CD86) are expressed on antigen 
presenting cells activated with pathogen associated molecular patterns. Signal transduction 
from  CD28  results  in  the  activation  of  the  transcription  factor  NF κB  and  AP 1 
transcription  complex  which  are  important  for  promoting  cytokine  expression  and 
proliferation  (63).  Moreover,  CD28  forms  clusters  together  with  TCR,  recruits  protein 
kinase C θ (PKCθ) and retains it in the immunological synapse which results in sustained 
signals  for  T  cell  activation  (59).  Stimulation  of  CD28  on  T  cells  enhances  their 18 
 
proliferation via mediation of cell cycle progression and induction of IL 2 production. In 
vitro, IL 2 stimulation can even reverse the state of anergy (64). Also long term antigen 
stimulation  can  bypass  the  requirement  for  CD28  costimulation  (65).  CD28  prevents 
apoptosis  by  inducing  the  expression  of  an  anti apoptotic  molecule  Bcl xL  (63). 
Furthermore, CD28 costimulation reduces by approximately 7 fold the threshold number 
of TCRs required for activation which may be the consequence of synergy between the 
TCR and CD28 signalling pathways (66). It has also been shown that CD28 takes part in 
formation of mature immunological synapse by inducing cytoskeleton rearrangement (67). 
  Cytotoxic T lymphocyte associated antigen 4 (CTLA 4), a homolog of CD28, is a 
higher affinity binding partner for B7.1 and B7.2 molecules when compared to CD28 (Kd 
values  for  B7.1  binding  to  CTLA 4  and  CD28  are  12  and  200  nM,  respectively).  In 
contrast to CD28, CTLA 4 is not constitutively expressed on T cells (with the exception of 
regulatory  T  cells).  Instead,  it  is  up regulated  in  response  to  TCR  ligation  and,  in 
particular, to TCR/CD28 costimulation (63, 65). Despite its structural similarity to CD28, 
CTLA 4 has a dampening effect on T cell activation which protects against autoimmunity 
or  autoproliferative  diseases.  CTLA 4  signalling  inhibits  cell  cycle  progression  and 
activation of transcription factors NF κB, NF AT and AP 1. On the other hand, it also 
activates JNK and PKB which are known to be involved in promoting cell survival and 
proliferation  but,  on  the  contrary  to  CD28,  the  overall  effect  of  CTLA 4  signalling  is 
induction of non responsiveness or anergy of T cells. Coligation of TCR and CTLA 4 
blocks the formation of ξ chain associated protein kinase 70 (ZAP70) containing clusters 
in  T  cells  which  inhibits  TCR  signalling.  CTLA 4  also  increases  T  cell  adhesion  and 
motility,  thereby  can  reverse  the  TCR induced  “stop  signal”  needed  for  strong  contact 
between T cells and antigen presenting cells. The CTLA 4 induced limitation of contact 
between  T  cells  and  antigen  presenting  cells  results  in  elevated  threshold  for  TCR 
signalling (65). 
  Productive antigen recognition still occurs in mice deficient for CD28, indicating 
that there are other costimulatory molecules that can replace it (63). ICOS, a molecule 
structurally similar to CD28, is another crucial positive regulator of T cell activation. CD4
+ 
and CD8
+ T cells deficient for both ICOS and CD28 are severely impaired in proliferation 
(68). Expression of ICOS on T cells is induced following stimulation of TCR and CD28, 
although TCR signalling alone is sufficient for induction of ICOS expression. ICOS ligand 
(ICOS L) shows 20% homology with B7 molecules and is constitutively expressed on B 
cells, dendritic cells, macrophages, fibroblasts and endothelial cells (61). Function of ICOS 19 
 
is very similar to that of CD28. Both of these molecules induce production of IL 4, IL 5, 
IL 6 and IFN γ from T cells and enhance their proliferation. However, unlike CD28, ICOS 
does not increase the production of IL 2.  The reason for that is the inability of ICOS to 
bind growth factor receptor bound protein 2 (Grb2) which is required for activation of 
transcription factors required for the synthesis of IL 2 (61, 68).  
  There  are  also  several  negative  regulators  of  T  cell  activation  belonging  to  the 
immunoglobulin family  which inhibit activation, proliferation or effector function of T 
cells and are expressed on T cells either constitutively or are induced after the stimulation 
of TCR. Their ligands are expressed on antigen presenting cells or also on T cells. One of 
the negative regulators is PD 1 which binds PD L1 (B7 H1) and PD L2 (B7 DC) ligands. 
There  are,  however,  contradictory  reports  showing  that  PD L1  and  PD L2  can  either 
enhance or inhibit responses of T cells (69, 70). Most probably PD L1 and PD L2 bind 
also  to  an  unidentified  receptor  that  induces  T  cell  activation.  This  system  may  act 
similarly to the B7.1/B7.2:CD28/CTLA 4 system (71, 72). Other negative regulators of T 
cell responses include TLT 2, B7S1, B7S3 and BTNL2 (68). 
  Other molecules that take part in T cell activation are adhesion molecules such as 
LFA 1.  These  molecules  facilitate  the  interaction  between  a  T  cell  and  an  antigen 
presenting cell but do not act as direct co stimulatory molecules therefore do not provide a 
complete signal 2 (73).  
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1.8.    The TNF and TNFR superfamilies 
 
1.8.1.  Expression, structure and signalling 
 
  Majority of proteins belonging to the tumour necrosis factor (TNF) superfamily 
(TNFSF) and their receptors, constituting the TNF receptor superfamily (TNFRSF), are 
expressed on a variety of cells of the immune system including antigen presenting cells, 
NK  cells,  CD4
+  and  CD8
+  T  cells.  There  are  20  TNFSF  and  32  TNFRSF  members 
identified to date (Figure 1.1.) (74). Their expression was detected also on other cells, 
including  epithelial  cells,  endothelial  cells  and  muscle  cells  (74 76).  TNF/TNFRSF 
members  such  as  TL1A,  CD70,  OX40L  and  OX40  or  4 1BBL  and  4 1BB,  are  not 
constitutively expressed or are expressed at very low levels. Instead, their expression is 
induced on the cells of the immune system following their activation (74). 
 
 
Figure 1.1. Tumour necrosis factor superfamily members and their receptors. Figure taken from (77). 
 
  The ligands are type II transmembrane proteins with intracellular N terminus and 
extracellular  C terminus  but  many  of  them  can  be  processed  into  a  soluble  form  by  a 
proteolytic  cleavage  by  metalloproteinases  (75,  78).  The  only  known  exception  is 
lymphotoxin α (LTα) which exists only as a secreted protein. Most ligands are biologically 
active as homotrimers; only lymphotoxin β (LTβ) is a heterotrimer consisting of one α 21 
 
chain  (monomer  of  LTα)  and  two  β  chains  or  one  β  and  two  α  chains.  The  TNFSF 
members  share  a  150  amino  acid  long,  conserved  C terminal  TNF  homology  domain 
(THD) which is responsible for their trimerization and binding to the receptors. It contains 
a conserved framework of aromatic and hydrophobic residues and shows 20% 30% amino 
acid sequence homology between the members of TNFSF and a similar tertiary structure 
(75, 76, 78). External surfaces of the ligands show little similarity which accounts for their 
specificity (75, 76).  
Most receptors are type I transmembrane proteins (with intracellular C terminus 
and extracellular N terminus), although some of them can be enzymatically cleaved from 
the cell surface and some of them can be directly expressed as soluble isoforms lacking the 
transmembrane domain as the result of either alternative splicing (e.g. Fas, 4 1BB) or lack 
of  this  domain  in the  encoding  gene  (e.g.  DcR3)  (75,  78).  The  unique  features  of  the 
receptors are 1 6 cysteine rich domains (CRDs) present in their extracellular parts. They 
form intrachain disulphide bonds and are involved in binding to the THD domain present 
in the ligands (75, 76, 78, 79). The receptors bind trimeric ligands and are biologically 
active as trimers, although for some receptors, including Fas, TNFR2 and TRAIL, higher 
order oligomers may be required (80). Some members of the TNFRSF (e.g. Fas, TNFR1 
and TNFR2) pre assemble on the cell surface prior to ligand binding. This process requires 
an N terminal region, including a part of the first CRD, termed the pre ligand assembly 
domain (PLAD) which binds to another PLAD present on the other monomer (75). 
Members of the TNFRSF can be divided into two groups based on the presence or 
absence of the death domain (DD). It is a 60 amino acid long structure consisting of 6 
conserved α helices present in the intracellular part of the receptor. 
Multimerization of DD containing receptors leads to the recruitment of intracellular 
adaptor  proteins,  such  as  Fas associated  death  domain  (FADD)  and  TNF  receptor 
associated death domains (TRADD), that contain DD homology regions and take part in 
activation of the caspase cascade resulting in  apoptosis of a  cell. These receptors also 
recruit tumour necrosis factor receptor associated proteins (TRAFs) which serve as adaptor 
proteins and bind to TRADD. TRAF proteins initiate signal transduction pathways that 
lead to activation of transcription factors, such as AP 1 and NF κB; they also trigger MAP 
kinase  cascades  that  lead  to  activation  of  JNK  pathway.  In  addition,  TRAF  proteins 
directly bind inhibitors of apoptosis, such as A20 and c IAP which results in inhibition of 
caspase activation (81).  22 
 
A  classical  example  of  a  DD containing  receptor  is TNFR1;  it  is  also  the  best 
studied member of the TNFRSF (Figure 1.2.). Following the activation of the receptor, 
silencer  of  death  domain  (SODD)  dissociates  from  TNFR1  allowing  formation  of  a 
signalling complex with TRADD – an adaptor protein which binds to the DD present in the 
intracellular part of the receptor (82, 83). TRADD recruits two different factors – FADD 
and the TNF receptor associated factor 2 (TRAF2), although Jin and El Deiry (84) show 
that  FADD  is  dispensable  for  TNFR1 induced  apoptosis.  Following  the  binding  to 
TRADD,  FADD  recruits  pro caspase 8  via  homotypic  interaction  between  the  death 
effector domain (DED) present in pro caspase 8 and another DED present in FADD. Pro 
caspase 8 undergoes subsequent self cleavage leading to its activation which initiates the 
caspase  cascade.  Active  caspase 8  cleaves  inactive  pro forms  of  effector  caspases 
including caspase 3,  6 and  7, thereby activates them. Effector caspases, in turn cleave 
other protein substrates within the cell which triggers apoptotic death of the cell. Caspase 8 
also processes Bid protein to its truncated form (tBid) which inhibits anti apoptotic BCL 2 
family members and induces the release of cytochrome c from mitochondria. This leads to 
activation  of  initiator  caspase 9  and  effector  caspases  (85).  TRAF2  recruits  receptor 
interacting protein (RIP), although this protein may also bind directly to the death domain 
of the receptor (86). RIP activates I κB kinase (IKK) complex which is composed of two 
catalytic  subunits  with  kinase  activity  (IKK α  and  IKK β)  and  one  structural  and 
regulatory subunit (NEMO, also known as IKK γ). This process is most probably mediated 
by MEKK3 kinase (85). IKK complex phosphorylates the inhibitor of κB (IκB) which 
leads  to  its  ubiquitinylation  and  degradation  in  proteasomes.  This  process  releases  the 
transcription  factor  NF κB  which  translocates  to  the  nucleus  of  the  cell  and  activates 
transcription of several genes. Caspase 8 appears to play a role also in activation of NF κB 
– nuclear translocation of NF κB p65 subunit was delayed in caspase 8
 /  B cells after the 
stimulation  of  TLR4  (87).  Activation  of  NF κB  prevents  apoptosis  and  induces 
proliferation or differentiation of cells. However, NF κB also induces expression of pro 
apoptotic genes such as several death receptors and their ligands, p53 and c Myc (82). This 
adds  complexity  to  the  role  of  NF κB  in  the  regulation  of  apoptosis.  DD containing 
receptors  can  induce  either  cell  death  or  proliferation  and  activation  of  cells.  Their 
functional activity depends on the cellular context and the balance between pro  and anti 
apoptotic factors inside the cell. 
  The TNFRSF members that do not contain the DD, signal through TRAF proteins 
only which bind directly to the cytoplasmic domains of the receptors. Despite the lack of 23 
 
the DD, these receptors are also involved in both pro survival and pro apoptotic signalling 
(81). Some TRAF proteins which are involved in signal transduction from these receptors 
can  not  only  induce  activation  of  transcription  factors  but  also  activate  caspases.  For 
example C terminal TRAF domain of TRAF6 interacts with death effector domain of pro 




Figure 1.2. TNFR1 signalling 
 
1.8.2.  The role of TNFSF/TNFRSF members in T cell responses 
 
Structural attributes of the receptors and the ligands of the TNF superfamily link 
them to signalling pathways for survival, proliferation, differentiation or apoptosis. They 
play  an  important  role  in  maintaining  the  equilibrium  of  the  immune  system  whilst 
promoting  immune  responses  to  pathogens  by  exerting  influence  on  innate  immunity, 
organogenesis of secondary lymphoid organs, activation of antigen presenting cells and 
acting as pro inflammatory cytokines (75, 76, 79, 83, 89). TNF/TNFRSF members regulate 24 
 
T  cell  responses  by  providing  direct  signals  required  for  full  activation  of  T  cells, 
regulation of their expansion, contraction of the effector pool and survival of the memory 
cells.  
CD70/CD27,  4 1BBL/4 1BB,  OX40L/OX40  and  GITRL/GITR  interactions 
enhance proliferation of CD4
+ and CD8
+ T cells when combined with TCR engagement 
and CD28 signalling (89). It has been shown also that 4 1BB, GITR and OX40 signalling 
can replace CD28, although in the presence of CD28 the effect of co stimulation is more 
profound  (89,  90).  CD27  signalling  alone  is  neither  required  nor  sufficient  to  induce 
effector cell formation, it also is not required for the initial activation of T cells which is 
the  consequence  of  the  expression  pattern  of  CD70  which  is  transiently  induced  on 
activated T cells but is not present on naïve cells. Instead, CD27 triggering contributes to 
the formation of the effector cells by inducing proliferation and survival of activated T 
cells during the primary response by  collaborating with signals transduced from CD28 
(60).  Furthermore,  co administration  of  CD70  together  with  an  antigen  prevents  the 
induction of the tolerance which is observed when an antigen is administered alone (91). 
CD27 signalling induces Th1 gene expression profile in CD4
+ T cells (60). OX40L/OX40 
interaction directly promotes the proliferation of both CD4
+ and CD8
+ T cells although this 
effect is more profound in CD4
+ T cells which can be explained by the fact that expression 
of OX40 is much more transient on activated CD8
+ T cells compared to CD4
+ T cells. 
OX40 signalling does not control the initial activation of T cells; instead, it maintains their 
late proliferation and prolongs their survival. Engagement of OX40 CD4
+ T cells leads also 
their differentiation into Th2 cells which is driven by autocrine production of IL 4 induced 
by OX40. However, the type of antigen and exogenous IL 12 signals can overcome this 
effect  and  lead  to  generation  of  Th1  cells  (92).    LIGHT/HVEM  interactions  enhance 
proliferation and effector function of CD8
+ T cells (75, 89, 93). LIGHT stimulates also 
expansion of CD4
+ T cells and induces their differentiation into Th1 cells (94). HVEM, 
however,  acts  as  a  bi directional  switch  of  T  cell  activation.  Binding  of  B   and  T 
lymphocyte attenuator (BTLA) or CD160 (members of the immunoglobulin superfamily, 
expressed  mostly  on  NK,  NKT  and  T  cells)  to  HVEM  present  on  T  cells  results  in 
inhibition of activation of these cells. BTLA and CD160 bind to a different CRD region of 
HVEM (CRD1) than LIGHT (95).  
Survival signals from TNFSF/TNFRSF members are also required to maintain T 
cell  memory.  In  physiological  conditions,  4 1BBL  expands  CD8
+  memory  T  cells, 
however its overexpression in mice results in an increased frequency of both CD4
+ and 25 
 
CD8
+ memory T cells. CD30L and OX40L are required for maintaining of CD4
+ memory 
T cells. Expression of receptors for 4 1BBL (4 1BB) on CD8
+ memory T cells and CD30L 
(CD30)  and  OX40L  (OX40)  on  CD4
+  memory  T  cells  is  induced  by  IL 15  and  IL 7 
present in CD8
+ T cell or CD4
+ T cell memory niches, respectively (96). Moreover, OX40 
is involved in formation CD4
+ T effector memory cells but not of CD4
+ T central memory 
cells. It also takes part in activation of memory CD4
+ T cells and therefore is required for 
the initiation of the recall response. OX40 is critical for generation of both central and 
effector memory CD8
+ T cells; it also enhances their proliferation (92). Another TNFSF 
member involved in maintaining T cell memory is CD70 which increases frequency of 
both CD4
+ and CD8
+ memory T cells (97).  
The detailed mechanism of integration of TCR and TNFRSF members signalling 
pathways  remains  unknown  but  TCR  signalling  and  signalling  of  TNFRSF  members 
involved in costimulation leads to activation of the same transcription factors (NF κB and 
AP 1),  therefore  signal  transduction  elements  involved  in  their  activation  are  prime 
candidates  for  the  integration  of  signals  derived  from  TCR  and  TNFRSF  members.  A 
recent study suggests that one such protein is TRAF3 (98). TRAF3 deletion in T cells 
results in defective IgG1 response and impaired antigen specific CD8
+ and CD4
+ T cell 
responses  to  infection  with  Listeria  monocytogenes  in  mice.  TRAF3  is  recruited  to 
TCR/CD28 signalling complex but it binds also to cytoplasmic domains of almost all of 
TNFRSF  members  that  do  not  contain  the  death  domain,  including  the  ones  that  are 
involved in costimulation (4 1BB, CD27, OX 40, GITR, TNFR2 and CD30), therefore it 
remains  possible  that  the  role  of  TRAF3  in  signalling  of  TNFRSF  members  also 
contributes to the defective T cell immunity in TRAF3 deficient mice (98).  
TRAF3 binds directly to cytoplasmic domains of TNFRSF that do not contain the 
death domain and are involved in costimulation (4 1BB, CD27, TNFR2, GITR, OX 40 and 
CD30).  
  The  interaction  between  TNFSF  members  and  their  receptors  affects  also  the 
activity of regulatory T cells (Tregs). Stimulation of GITR, OX40 and 4 1BB present on 
Tregs results in loss of their suppressive activity and development of autoimmunity (74, 
99). Furthermore, OX40 down regulates the expression of FoxP3 and IL 10 in CD4
+ T 
cells and in this way contributes to inhibition of Treg differentiation (74).  
  FasL/Fas, CD30L/CD30, TNF/TNFR1 and TNF/TNFR2 interactions are involved 
in activation induced cell death of T lymphocytes (42 44). In this process, the majority of 
activated  T  cell  undergo  apoptosis  following  the  peak  of  an  immune  response.  FasL, 26 
 
CD30L or TNF bind to their receptors on the same or a neighbouring cell and trigger 
apoptosis  (42,  44,  100).  In  activated  cells,  high  levels  of  IL 2  sensitizes  cells  to  Fas 
induced apoptotic death by decreasing levels of c FLIP during S phase of the cell cycle 
(101). C FLIP is a protease deficient homologue of caspase 8 that competes with it for the 
recruitment to FADD and acts as an inhibitor of apoptosis. Also CD30L/CD30 interaction 
triggers AICD in vitro, in the presence of IL 2 (100). FasL/Fas interaction plays a minor 
role  in  the  death  of  activated  T  cells  responding  to  a  conventional  antigen,  instead  it 
controls mostly self reactive T cells in which repetitive stimulation with systemic antigen 
leads to increased levels of IL 2 and reduced levels of c FLIP (43).  
 
1.8.3.  TNFSF/TNFRSF members in autoimmune diseases and tumours 
 
Members of the TNF superfamily are involved in the pathogenesis of a number of 
autoimmune diseases. Interactions between OX40L and OX40, 4 1BBL and 4 1BB, and 
TL1A  and  DR3  increase  the  severity  of  inflammatory  bowel  disease  (IBD),  asthma, 
arthritis and experimental autoimmune encephalomyelitis (EAE) which is a mouse model 
of multiple sclerosis. Depletion of the ligands or blockade of the receptors by specific 
antibodies  results  in  a  reduced  disease  score  (74,  102).  Also  TNF  plays  a  role  in  the 
pathogenesis of several autoimmune diseases. Currently there are five TNF antagonists 
registered in the USA and in the European Union – infliximab (mouse/human chimeric α 
TNF monoclonal antibody), adalimumab (human α TNF monoclonal antibody), etanercept 
(fusion protein of TNFR2 and the Fc fragment of human IgG1), certolizumab (PEGylated 
Fab’ fragment of a humanized IgG1 α TNF monoclonal antibody) and golimumab (human 
α TNF  monoclonal  antibody).  They  are  used  in  therapies  against  rheumatoid  arthritis, 
ankylosing spondylitis, ulcerative colitis, Crohn’s disease and other autoimmune disorders 
(103,  104).  Neutralization  of  TNFSF/TNFRSF  interactions  results  in  suppression  of 
symptoms of an autoimmune disease but the possible side effect of this kind of therapy is 
increased susceptibility to infectious agents and tumours.  
The death receptor Fas is a key player in the induction of lymphocyte apoptosis. It 
maintains the homeostasis of lymphocytes by taking part in AICD (42, 43). Mutations in 
Fas, FasL or caspase 10 gene leading to a defective Fas induced apoptosis of lymphocytes 
can result in autoimmune lymphoproliferative syndrome (ALPS) which is characterized by 
autoimmunity,  chronic,  non malignant lymphoproliferation, although ALPS patients are 
susceptible  to  malignancy.  ALPS  is  associated  with  a  presence  of  peripheral  T  cell 27 
 
population bearing TCRαβ but lacking the expression of CD4 or CD8 molecules (105 
107). These cells are believed to originate from aging peripheral CD4
+ or CD8
+ T cells that 
lost the co receptor expression and can reach up to 40% of lymphocytes in ALPS patients 
(compared to 1% in healthy individuals) (105, 107). Other abnormalities include elevated 
levels  of  CD5
+  B  cells,  CD57
+  CD8
+  T  cells  and  TCRγδ  cells  and  a  decrease  in  the 
frequency of CD4
+ CD25
+ T cells (105). Most of the ALPS treatment strategies remain 
targeted at the disease manifestations (108).  
Systemic triggering of TNFR1 results in a massive inflammatory response, high 
levels of C reactive protein, IL 1, IL 6 and neutrophilia,  (2, 109). Mutations in the gene of 
TNFR1 can lead to TNF receptor associated periodic syndrome (TRAPS) characterized by 
prolonged  episodic  fevers  and  inflammation  which  can  affect  multiple  organs  with  an 
average duration of 21 days (109, 110). Autosomal dominant mutations leading to TRAPS 
occur predominantly in CRD1 and CRD2 while there are not any known TRAPS mutations 
in the transmembrane and intracellular domains of TNFR1. The mutations in CRD1 and 
CRD2  are  thought  to  render  the  receptor  constitutively  active,  increase  its  affinity  for 
TNFR1 or to impair cleavage of the receptor leading to reduced serum levels of soluble 
TNFR1. TRAPS is treated with etanercept and infliximab which neutralize TNF (109).  
Therapy for cancer should promote activity of T cells and antigen presenting cells. 
Ideally,  it  should  also  inhibit  generation  and  function  of  Tregs.  It  may  lead  to  the 
development of autoimmune diseases which is an inherent risk of this type of therapy. 
However,  the  benefits  can  probably  outweigh  the  risk  for  most  patients  with  tumours. 
Members of the TNFSF can be used in therapy of a wide range of tumours. There are three 
methods of using TNFSF members in anti tumour therapy. The first is administration of a 
TNFSF member known to enhance T cell response (e.g. OX40L, 4 1BBL or CD70), or to 
induce apoptosis of tumour cells (e.g. LIGHT). This method can be combined with a co 
administration of an immunostimulatory adjuvant, such as granulocyte macrophage colony 
stimulating factor (GM CSF). Another method is increasing the immunogenicity of tumour 
cells by transfecting them with cDNA encoding the appropriate TNFSF ligand. This can be 
achieved by in vivo injection of viral vectors into the tumour. The third method is injecting 
dendritic cells engineered to express the appropriate TNFSF ligand into the organism of a 
patient. A very effective method is also a combined approach (74). 28 
 
1.9.     TL1A (TNFSF15) 
 
1.9.1.  Structure and expression pattern of TL1A 
 
TL1A (TNF superfamily member 15, TNFSF15) is the most recently discovered 
member of the TNFSF, cloned for the first time in 2002. In humans, the gene of TL1A has 
the length of 17 kbp, contains 4 exons (111, 112) and is situated in the chromosome 9q32 
(111). In humans, there are three different isoforms of the protein generated from this gene 
as a result of alternative splicing – VEGI 174, VEGI 192 and the full length product – 
VEGI 251 (TL1A). They have the length of 174, 192 and 251 amino acids, respectively 
(112, 113) and share the same C terminal 151 amino acid long fragment (113). Migone et 
al. (111) have noticed that VEGI 174 cDNA completely matches a continous TL1A cDNA 
region that contains both exons and introns and therefore suggest that VEGI 174 might be 
a cloning artefact. 
The  main  receptor  for  VEGI 174  and  VEGI 192  has  not  been  identified  yet, 
although it is known that it is different than death receptor 3 – the main receptor for TL1A 
(111,  112).  Human  VEGI 174  and  VEGI 192  were  identified  as  endothelium derived 
factors that take part in regulation of angiogenesis by inducing apoptosis of proliferating 
endothelial  cells  or  growth  arrest  of  G0 G1  endothelial  cells  (111 115).  Mouse  and  rat 
TL1A have the length of 252 amino acids and show 63.7% and 66.1% sequence homology 
to  the  human  counterpart  respectively  (111).  TL1A  contains  a  predicted  hydrophobic 
transmembrane region near the N terminus (111) but exists either in a transmembrane (116, 
117) or soluble form (118, 119). Recombinant human soluble TL1A forms a homotrimer 
that resembles the trimeric structure other TNF superfamily members (120), however still 
little is known about the quaternary structure of the native form of TL1A.  
In humans, TL1A mRNA was detected in endothelial cells, kidney, prostate, liver, 
skeletal muscles and lungs (111, 113). Its expression is up regulated by TNF and IL 1α 
(111) and is dependent on NF κB which binds to the promoter region of the TL1A gene 
and activates its expression (121, 122). In human dendritic cells and monocytes, expression 
of  TL1A  mRNA  is  rapidly  (4 6  h)  and  transiently  up regulated  following  in  vitro 
stimulation  with  plate bound  immune  complexes  which  stimulate  Fcγ  receptors.  These 
cells start to secrete soluble TL1A after 6 12 h of in vitro stimulation with plate bound 
IgG, while expression of the transmembrane form of TL1A was detected only on human 
monocytes  stimulated  in  vitro  with  plate bound  IgG  for  16  h  (119).    In  murine  bone 29 
 
marrow derived dendritic cells, the level of TL1A mRNA peaks after 3 hours of in vitro 
stimulation  with  immune  complexes  or  toll like  receptor  (TLR)  ligands,  notably 
lipopolysacharide (LPS, ligand for TLR4) and soluble tachyzoite antigen (STAg, ligand for 
TLR11) (123). TL1A was detected also in chicken blood samples and spleens 2   4h after 
injection of LPS (124).  Shih et al. (121) identified several other TLR agonists as inducers 
of TL1A mRNA in human monocytes – synthetic bacterial lipoprotein Pam3CSK4 (ligand 
for  TLR2),  heat killed  Listeria  monocytogenes  (recognized  by  TLR2),  polyinosinic 
polycytidylic acid (poly(I:C), ligand for TLR3), lipopeptide FSL (ligand for TLR2), LPS, 
single stranded RNA (ligand for TLR7) and unmethylated CpG DNA sequence (ligand for 
TLR9).  Several  bacteria  strains,  including  both  Gram  negative  and  Gram  positive 
organisms, induce the expression of TL1A on human monocytes and monocyte derived 
dendritic cells. The level of TL1A mRNA in these cells peaks after 4h (monocytes) and 8h 
(monocyte derived dendritic cells) of in vitro stimulation with live bacteria. Furthermore, 
expression of TL1A mRNA induced by bacteria is higher than induced by single TLR 
ligands, suggesting that TLRs act synergistically to up regulate the expression of TL1A 
(121). Transient expression of TL1A, peaking after 24h, was detected also on in vitro 
activated CD4
+ and CD8
+ T cells (123, 125). Very little expression of TL1A was found on 
non activated cells of the immune system (111, 125). 
 
1.9.2.  Death receptor 3 (DR3) 
 
Death  receptor  3  (DR3)  is  the  main  receptor  for  TL1A,  it  is  a  death  domain 
containing receptor belonging to the TNFRSF. In humans there are at least 12 different 
splice variants of this receptor. The full length product contains both the death domain and 
the transmembrane domain, while the others are potentially secreted proteins (126, 127). 
Mouse gene of DR3 is situated in the chromosome 4E1, contains 10 exons and shows 55% 
homology to the human counterpart. At the protein level the homology is 63% with 94% 
homology  in  the  death  domain  and  52%  in  the  extracellular  domain.  There  are  three 
different splice variants of mouse DR3 –the full length transmembrane receptor, soluble 
receptor lacking the transmembrane domain and transmembrane receptor lacking one of 
the CRD regions in the extracellular domain (128).  
Signalling pathways for TNFR1, presented in the previous section, also function 
downstream of DR3. The death domain of DR3 shows 47% amino acid sequence similarity 30 
 
to  the  death  domain  of  TNFR1  (129).  Furthermore,  only  TNFR1  and  DR3  associate 
constitutively with SODD (75, 130). Several research groups showed that, like TNFR1, 
DR3 may induce both apoptosis and activation of NF κB (129, 131, 132). DR3 forms 
signalling complex comprising TRADD, TRAF2, RIP, FADD and caspase 8 (132, 133), 
although Wen et al.  (132) showed that FADD does not take part in signal transduction 
from DR3. This inconsistency can be explained by the fact that Wen and colleagues (132) 
were investigating DR3 signalling on erythroleukaemic TF 1 cells which naturally express 
DR3, while other researchers were using transient systems in which DR3 molecule was 
overexpressed (133). 
 Expression  of  DR3  was  detected  on  activated  human monocytes  (134),  resting 
mouse NKT cells, CD4
+ T cells and subpopulations of CD11c
+ and NK1.1
+ cells (125). 
DR3 mRNA present in resting human CD4
+ T
 cells and monocytes is strongly up regulated 
in activated CD4
+ and CD8
+ T cells (135). Expression of DR3 on human CD56
+ T cells 
and NK cells is slightly increased by in vitro stimulation with IL 12; this effect is more 
significant when the cells are treated with IL 18 alone (136). Since IL 12 up regulates the 
receptor  for  IL 18,  these  cytokines  act  in  synergy  to  increase  the  expression  of  DR3. 
Combination of both IL 12 and IL 18 up regulates expression of DR3 on human CCR9
+ 
CD4
+ T cells, CD56
+ T cells and NK cells, although it has minimal effect on other subsets 
of human T cells which do not constitutively express receptors for IL 12 and IL 18 (136, 
137). 
 
1.9.3.  Soluble decoy receptor 3 (DcR3) 
 
The  second  receptor  for  TL1A,  not  present  in  mice,  is  DcR3  (soluble  decoy 
receptor 3). It is a soluble receptor lacking the transmembrane domain; it belongs to the 
TNFRSF and acts as a decoy receptor also for FasL and LIGHT (118, 138).  
DcR3  blocks  the  interaction  between  its  ligands  and  their  membrane bound 
receptors and therefore can neutralize their biological effects (118). DcR3 is overexpressed 
by several tumours (139), notably malignant tumours arising from gastrointestinal tract, 
lungs  (138,  140)  and  virus associated  lymphomas  (118,  141).  Expression  of  DcR3  by 
tumour cells helps them to gain survival advantage by preventing Fas mediated apoptosis 
and by interfering with  LIGHT mediated T cell activation (139). DcR3 is also able to 
induce in vitro angiogenesis in human umbilical vein endothelial cells (HUVEC cells) by 
promoting  their  proliferation  and  migration.  These  effects  may  be  caused  by  the 31 
 
interference with biological activity of TL1A, since it has been shown that they can be 
mimicked by α TL1A and α DR3 antibodies. Furthermore, human aortic endothelial cells, 
which do not express TL1A, do not respond to DcR3 treatment (138). DcR3 treated DCs 
suppress  CD4
+  T  cell  proliferation  and  up regulate  IL 4  production  by  naïve  CD4
+ 
CD45RA
+ T cells (142). Solid phase (i.e. membrane  or plate bound) DcR3 can trigger 
reverse signalling of FasL or LIGHT which results in T cell costimulation (143). In this 
process, the signal is transduced by ligands which serve as receptors while receptors play 
roles of ligands. However, the question whether TL1A is capable of reverse signalling 
remains unanswered.  
 
1.9.4.  Function of TL1A/DR3 interactions in immune response 
 
The soluble form of TL1A exhibits growth inhibition of in vitro cultured HUVEC 
cells  and  overexpression  of  TL1A  by  tumour  cells  retards  the  tumour  growth  due  to 
inhibition of angiogenesis (113). In TF 1 cells, TL1A can induce apoptosis only in the 
presence of caspase inhibitors or cycloheximide (CHX) – an inhibitor of protein synthesis 
(111, 132) which prevents synthesis of proteins induced by NF κB and consequently only 
the signalling pathway leading to apoptosis remains active. Stimulation of activated T cells 
with TL1A does not lead to their apoptotic death even in the presence of CHX  (111) 
suggesting that TL1A plays a role in costimulation of T cells.  
In vitro studies show that the interaction between TL1A and DR3 in T cells triggers 
proliferative and costimulatory signals through activation of NF κB mediated pathways. 
TL1A increases proliferation of CD4
+ T cells which is the direct consequence of increased 
production of IL 2 (123). Furthermore, T cells up regulate the expression of IL 2 receptor 
in response to TL1A stimulation (111). The effect of increased proliferation of CD4
+ T 
cells in response to TL1A is most evident for CD45
low CD4
+ memory T cells while it is 
minimal for naïve CD45
high CD4
+ cells, which is the consequence of up regulation of DR3 
on  activated  T  cells  (144).  Pappu et  al.  (145)  showed  that  TL1A  selectively  enhances 
proliferation of activated Th17 cells but not Th1 cells. 
TL1A  also  induces  production  of  IL 6  from  CD4
+  T  cells  isolated  from  gut 
associated lymphoid tissue from mice with chronic colitis. This effect is less significant in 
CD4
+ T cells isolated from healthy mice (146), which is the consequence of much lower 
expression  of  DR3  on non activated  T  cells.  The  increase  of  IL 6  production  is  much 
higher when TL1A acts in synergy with IL 23 (146).  32 
 
TL1A  acts  as  a  polarizer  of  the  immune  response  by  regulating  secretion  of 
cytokines that skew the immune response towards Th1 (IFN γ), Th2 (IL 4, IL 10 and IL 
13) or Th17 (IL 17) type.  In vitro stimulation with TL1A enhances production of IL 4 and 
IFN γ from mouse CD4
+ T cells activated with anti CD3 and anti CD28 antibodies (123). 
On  the  other  hand,  splenocytes  from  mice  overexpressing  DcR3,  stimulated  with  an 
antigen show elevated production of IL 4 and IL 10 but downregulate the production of 
IFN γ.  Stimulation  of  these  cells  with  an  antigen  together  with  TL1A  but  not  LIGHT 
restored the production of IFN γ (142). CD4
+ T cells grown in the presence of DcR3 
treated dendritic cells show reduced proliferation and secretion of IFN γ while they up 
regulate the production of IL 4. Stimulation of the dendritic cells with Fas.Fc and LTβR.Fc 
does not result in a similar effect showing that it is the consequence of binding TL1A to 
DcR3 (142, 147). Prehn et al. (117) showed that TL1A slightly increases production of IL 
4 from human peripheral blood monocytes but does not up regulate production of IL 10 
from  these  cells.  Also  stimulation  of  DR3  on  activated  NK/NKT  cells  increases  the 
production of IL 4 and IL 13, but has no effect on the production of IFN γ (125). When 
TL1A is administered to mice intranasally together with an antigen, it strongly increases 
the level of serum IgG1 and the production of IL 4 and IL 5 from splenocytes (148).  
TL1A alone or in synergy with IL 23 enhances production of IL 17 from activated 
Th17 cells (145, 146, 149), however it has no effect on IFN γ production by Th1 cells 
which is the consequence of high level of DR3 expression on Th17 cells but not on other 
subsets of T helper cells (145).  In the absence of IL 2 signalling (which prevents Th17 
differentiation), TL1A enhances Th17 differentiation from naïve CD4
+ T cells (145). 
Taken  together,  the  results  of  different  research  groups  presented  above  vary 
depending on the conditions of a given experiment and show that the role of TL1A in 
polarization of the immune response towards Th1, Th2 or Th17 type is still not clear and 
requires careful investigation. 
Production of IFN γ by activated mouse CD4
+ T cells is enhanced by stimulation 
with  TL1A  alone  or  in  synergy  with  IL 12  (146).  TL1A  increases  production  of  this 
cytokine also from non activated mouse CD4
+ T cells in synergy with both IL 12 and IL 
18 (144) and from activated human peripheral blood mononuclear cells, lamina propria 
mononuclear cells and T cells independently of, but in synergy with IL 12 and IL 18 (111, 
117). A similar effect is observed in human peripheral blood NKT cells, NK cells and 
activated CD4
+ T cells stimulated with TL1A together with IL 12 and IL 18, although in 
NK cells this effect is due to stimulation of proliferation, not to increased IFN γ production 33 
 
per  cell  (136).  The  up regulation  of  IFN γ  production  in  response  to  stimulation  with 
TL1A  together  with  IL 12  and  IL 18  is  most  evident for  CCR9
+  CD4
+  T  cells  which 
represent 4% of peripheral blood T cells and are involved in small intestinal inflammatory 
process (137).  
TL1A has been shown to enhance IL 12 and IL 18 induced cytotoxicity (150) and 
proliferation of human NK cells (136) 
TL1A  affects  also  differentiation  and  maturation  of  dendritic  cells  which  show 
reduced expression of CD11c, CD40, CD54 and MHCII when are cultured in vitro in the 
absence of TL1A/DR3 signalling. These studies were conducted using DcR3, however the 
described effect is due to TL1A, because stimulation of the dendritic cells with Fas.Fc and 
LTβR.Fc (receptor for LIGHT) constructs did not give similar results.  (147, 151). 
Treatment  of  human  macrophage like  cells,  THP 1,  with  TL1A  in  combination 
with  IFN γ  induces  production  of  TNF,  macrophage  chemoattractant  MCP 1  and  IL 8 
which  is  a  pro inflammatory  cytokine  and  a  neutrophile  chemoattractant  (134).  TL1A 
induces production of IL 8 also in human peripheral blood macrophages (152). 
  
1.9.5.  Role of TL1A in autoimmune diseases 
 
TL1A  is  involved  in  pathogenesis  of  several  autoimmune  diseases  mediated  by 
Th1, Th2 or Th17 cells. TL1A protein and mRNA is up regulated in inflammatory bowel 
disease (IBD) and its production is localized to lamina propria macrophages, monocytes, 
dendritic cells, CD4
+ and CD8
+ T cells in patients with Th1  and Th17 mediated Crohn’s 
disease (146, 149, 153) as well as plasma cells isolated from patients with Th2 mediated 
ulcerative colitis (116). Furthermore, patients with IBD show a higher proportion of DR3 
expressing intestinal lamina propria T cells than healthy subjects (116, 117). The amount 
of TL1A protein and the number of TL1A positive cells correlates positively  with the 
severity  of  this  disease  (116)  and  administration  of  anti TL1A  antibodies  prevents 
development  of  experimental  bowel  inflammation  (134)  and  attenuates  chronic  colitis 
(146) in mice. 
Increased level of TL1A was detected also in blood and synovial fluids of patients 
with Th1 mediated rheumatoid arthritis (RA) (154, 155). High expression of TL1A was 
detected in atherosclerotic plaques in regions rich in macrophages and foam cells (134). In 
fact, TL1A has been shown to promote foam cell formation from human macrophages by 
regulating expression of several genes involved in low density lipoproteins uptake and 34 
 
cholesterol  efflux  (156).  TL1A  is  involved  in  this  disease  also  via  induction  of  pro 
inflammatory  cytokines  and  extracellular  matrix  degrading  enzymes,  such  as  matrix 
metalloproteinase 9 (134). Administration of monoclonal α TL1A antibodies protects mice 
from antigen induced arthritis (AIA), a mouse model of RA (102) while administration of 
TL1A increased penetration and clinical score of AIA in mice (155). DR3
 /  mice show 
reduction in histopathological hallmarks of AIA (102) and in clinical score of Th17 and 
Th1 mediated  experimental autoimmune encephalomyelitis, a mouse model of multiple 
sclerosis  (123).  TL1A/DR3  interactions  play  a  role  also  in  the  pathogenesis  of  Th2 
mediated lung inflammation (123, 125). 
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1.10.  Aims of the project 
  Members of the TNF and the TNFR superfamilies are important modulators of T 
cell mediated responses. The results published by several groups within the last four years 
showed that the interaction between TL1A and its receptor, DR3, enhances some aspects 
of T cell activation but full understanding of the role of TL1A in the immune system is 
currently incomplete. 
  The major aim of this project is to define the role of TL1A in T cell mediated 
immune responses. More specifically, this study aims to examine the expression pattern of 
TL1A on dendritic cells and T  cells, to investigate the influence exerted by TL1A on 
proliferation and effector functions of CD4
+ and CD8
+ T cells, to determine whether TL1A 
acts predominantly during the primary or the secondary immune response and finally to 
answer the question whether TL1A skews the immune response towards Th1, Th2 or Th17 
type. Some molecules belonging to the TNF or TNFR superfamily have been shown to 
inhibit the suppressive activity of regulatory T cells. Therefore, other aspect of this study is 
investigation whether TL1A exerts any effect on Tregs. Finally, another aim of this project 
was to examine the role of TL1A in inflammatory diseases, such as bowel inflammation, 
and in anti tumour immunity. 
  In this study, the role of TL1A was examined carefully both in vitro and in vivo 
using  soluble  recombinant  TL1A  and  transgenic  mice  overexpressing  TL1A  under  the 
control of either CD11c or CD2 promoter.  
  Detailed investigation of the role of TL1A in the immune system will have impact 
on  understanding  the  processes  of  immune  pathology  in  inflammatory  diseases  and 








MATERIALS AND METHODS 
 
2.1.  Reagents, cells and antibodies 
 
2.1.1.  Reagents 
 
Ovalbumin peptide 257 264 (OVA257 264; SIINFEKL) was purchased from Peptide Protein 
Research  Ltd.  The  lyophilised  peptide  was  (>95%  purity)  was  dissolved  in  phosphate 
buffered saline (PBS; 120 nM NaCl / 24 mM Na2HPO4 / 5.8 mM KH2PO4) and stored at  
20
oC. LPS from Salmonella minnesota was purchased from Sigma; it was dissolved in 
water (1 mg/ml), aliquoted and stored at  20
oC. PE labelled H 2K
b SIINFEKL tetramer 
was  obtained  from  the  University  of  Southampton,  Cancer  Sciences  Division  protein 
expression  facility.  DR3.Fc  and  TL1A.Fc  constructs  were  produced  in house. 
Polyinosinic polycytidylic acid (poly(I:C); Sigma) was dissolved in water (10 mg/ml) and 
stored at  20
oC. α Galactosylceramide (α GalCer; gift from Dr. Bruno Linclau, School of 
Chemistry, University of Southampton, UK) was dissolved in DMSO (1 mg/ml), aliquoted 
and stored at  20
oC. Unmethylated CpG DNA (Invitrogen) was dissolved in water and 
stored at  20
oC. Synthetic bacterial lipoprotein, Pam3CSK4 (InvivoGen), was dissolved in 
water (1 mg/ml) and stored at +4
oC. TAPI 0 (Calbiochem) was dissolved in DMSO (20 
mM) and stored at  20
oC. Allophycocyanin (APC) conjugated streptavidin was purchased 
from  BD  Pharmingen.  Phycoerythrin  (PE) conjugated  streptavidin  and  horseradish 
peroxidise (HRP) conjugated streptavidin were purchased from Sigma Aldrich. 
 
2.1.2  Antibodies 
 
The  following  monoclonal  antibodies  were  produced  and  purified  in house  from 
hybridoma lines: anti rat CD4 domains 3 and 4 (OX68), anti IFN γ (HB170), anti CD86 
(GL 1), anti Bcl1 idiotype (Mc39 16), anti CD3 (145.2C11), anti TL1A (TAN2 2), anti 
CD4 (YTA3.2.1.), anti CD8 (YTS169), anti MHC class II (N22), anti CD25 (PC61), anti 
IL 2 (S4B6), anti CD80 (106A1), anti FcRII and III (2.4G2). Monoclonal antibodies listed 
above, used for flow cytometry, were fluorescein (FITC), PE or APC conjugated in house. 
APC conjugated  anti CD11c  (HL3),  FITC conjugated  anti CD49b  (DX5)  ,  FITC   and 37 
 
APC conjugated  anti CD25  (7D4),  PE conjugated  anti Vα2  chain  (B20.1),  FITC 
conjugated anti Vβ5 chain (MR9 4), APC conjugated anti KLRG 1 (2F1), FITC  and PE 
conjugated  anti CD62L  (MEL14),  PE conjugated  anti CD44  (IM7),  anti IL 4    and 
biotinylated  anti IL 4  (11B11)  monoclonal  antibodies  were  purchased  from  BD 
Pharmingen.  APC conjugated  anti CD4  (GK1.5),  APC conjugated  anti CD8a  (53 6.7), 
PE conjugated anti IFN γ (AN 18)  and APC  and PE conjugated anti FoxP3 (FJK 16s) 
monoclonal antibodies were purchased from eBiosciences. Polyclonal biotin conjugated 
anti DR3  antibody  was  purchased  from  R&D  Systems.  Anti asialo  GM1  antibody  was 
purchased  from  Wako.  Biotinylated  anti IFN γ  (R4 6A2)  monoclonal  antibody  was 
purchased from AbD Serotec. Polyclonal PE conjugated anti human IgG and anti rat IgG 
antibodies were purchased from Sigma Aldrich. Human IgG and biotin conjugated goat 
IgG were purchased from Sigma Aldrich. 
 
2.1.3.  Cell lines and cell culture 
  
HEK293T (a human embryonic kidney cell line) and J558L (a mouse plasmacytoma cell 
line) cells were cultured in vitro in DMEM (Invitrogen) medium supplemented with 10% 
(v/v)  foetal  calf  serum  (FCS;  Invitrogen),  100  U/ml  penicillin  (Invitrogen),  100   g/ml 
streptomycin (Invitrogen), 2 mM glutamine (Invitrogen) and 1 mM pyruvate (Invitrogen). 
J558L cells stably transfected with BALB/c mouse TL1A cDNA which had been cloned 
into  pEF1/V5 HisA  vector  (Invitrogen)  containing  also  the  neomycin  resistance  gene 
(J558L TL1A)  and  J558L  cells  stably  transfected  with  empty  pEF1/V5 HisA  vector 
(J558L PEF) were cultured in vitro in DMEM medium containing the supplements listed 
above and 800  g/ml of geneticin (Invitrogen). EG.7 (a mouse thymoma cell line) and 
mouse  spleen  cells  were  cultured  in  vitro  in  RPMI  1640  medium  (Invitrogen) 
supplemented  with  10%  (v/v)  FCS  (Invitrogen),  100  U/ml  penicillin  (Invitrogen),  100 
 g/ml  streptomycin  (Invitrogen),  2  mM  glutamine  (Invitrogen),  1  mM  pyruvate 
(Invitrogen) and 50  M 2 mercaptoethanol. Untransfected CHO.K1 (a Chinese hamster 
ovary  cell  line)  cells  were  cultured  in  RPMI  1640  medium  containing  all  of  the 
supplements listed above, except for 2 mercaptoethanol. All cell lines were re cultured 
every 2 3 days and maintained at 37
oC in a 5% CO2 humidified incubator. Adherent cells 
(HEK293T and CHO.K1) were detached from culture flasks by incubation with Trypsin 
EDTA (Invitrogen) for 5 min in the tissue culture incubator.  
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2.1.4.  Cell quantitation 
 
Cells were counted using a Coulter Industrial D Cell Counter (Coulter Electronics) or by 
manual counting using a haemocytometer by dilution 1:1 with trypan blue dye (Sigma) and 
observation of dye exclusion from viable cells. 
 
2.1.5.  LPS testing 
 
Antibodies and sTL1A construct used for in vivo experiments were tested for endotoxin 
contamination  using  the  Endosafe® PTS
TM  system  (Charles  River)  according  to  the 
manufacturer’s instructions. Typically, the contamination with endotoxin has never been 
higher than 0.9 ng of LPS / 1 mg of protein. 
 
2.1.6.  Biotinylation of antibodies 
 
Biotinylation  of  antibodies  was  conducted  using  EZ Link  Sulfo NHS Biotinylation  Kit 
(ThermoScientific)  according  to  the  manufacturer’s  instructions.  Briefly,  2 5  mg  of  an 
antibody was incubated with 20 fold molar excess of Sulfo NHS Biotin in 1 ml of PBS at 
room temperature for 30 min. The antibodies were then dialysed overnight against 5 L of 
PBS and their concentration was measured using Nanodrop ND 1000 spectrophotometer 
(ThermoScientific). 
 
2.2.  Molecular biology 
 
2.2.1  Bacterial transformation and amplification 
 
2 ng of DNA were mixed with DH5α or TOP10 competent cells (Invitrogen) and incubated 
on ice for 30 min before heat shocking at 42
oC for 1 min. The cells were then incubated on 
ice for 2 min before addition of 300  l of SOC medium (10% (w/v) bacto tryptone, 2.5% 
(w/v) yeast extract, 0.29% (w/v) NaCl, 0.093% (w/v) KCl; Invitrogen) and incubation for 
1h in an orbital incubator at 37
oC. 150  l of the bacterial culture was spread on agarose 
plates  (1.5%  (w/v)  Bacto Agar  (Difco),  10%  (w/v)  tryptone  (Sigma),  5%  (w/v)  NaCl) 
containing  the  appropriate  selection  agent  (100   g/ml  of  ampicilin  or  50   g/ml  of 
kanamycin)  and  incubated  overnight  at  37
oC.  Individual  colonies  were  amplified  by 39 
 
overnight  culture  in  10  ml  Luria  Broth  (10%  (w/v)  tryptone  (Sigma),  5%  (w/v)  yeast 
extract (Sigma), 5% (w/v) NaCl) containing the appropriate selection agent. Plasmid DNA 
was subsequently isolated and analysed by sequencing and/or restriction digest analysis. 
300  l of the culture were then added to 150 ml of Luria Broth and again grown overnight 
to amplify the plasmid DNA. 
  
2.2.2.  Isolation of plasmid DNA from bacterial cultures 
 
Plasmid DNA was isolated from bacterial cultures using QIAprep Spin Miniprep Kit (10 
ml culture; Qiagen) or HiSpeed Maxi Plasmid Kit (150 ml culture; Qiagen) according to 
the manufacturer’s instructions. Briefly, the bacteria were lysed under alkaline conditions, 
the  lysate  was  subsequently  neutralized  and  adjusted  to  high salt  binding  conditions. 
Following the clearing of the lysate, the plasmid DNA was bound to the silica membrane 
and eluted with water.  
 
2.2.3.  Isolation of mouse genomic DNA 
 
Mouse ear or tail tip was added to 100  l of complete isolation buffer (50 mM tris, 12.5 
mM  MgCl2, 0.5% (v/v) Tween 20, 0.5 mg/ml proteinase K, pH=8.9; proteinase K was 
added just before the isolation of DNA) and incubated overnight at 55
oC in a thermocycler 
with a heated lid (PTC 100; MJ Research, Inc.). The mixture was centrifuged for 5 min at 




2.2.4.  Restriction enzyme digests 
 
Restriction enzyme digests were performed by incubation of DNA for 2 h at 37
oC with the 
required restriction enzyme (Promega) at 3 U/ g of DNA in the presence of the relevant 







2.2.5.  DNA ligation 
 
Vector and insert DNA fragments were ligated at 1:1 or 1:3 molar ratios in the presence of 
1.5 U of T4 DNA Ligase (Promega) and 1x T4 Ligase Buffer (Promega) for 3 h at room 
temperature. The total volume of the reaction mixture was 10  l. 
 
2.2.6.  Agarose electrophoresis of DNA fragments 
 
DNA electrophoresis was performed in 0.7 – 1% agarose gels made in TBE (89 mM tris, 
89 mM boric acid, 2 mM EDTA) containing 20  g/ml of ethidium bromide. DNA samples 
were mixed 10:1 with loading buffer (20% (w/v) Ficoll 400, 0.1 M EDTA, 0.25% (w/v) 
bromophenol blue) and loaded on the gel. Gels were run in TBE buffer at 70 mA in a 
BioRad electrophoresis tanks and visualized on a UV transilluminator (BioRad). 
 
2.2.7.  DNA sequencing 
  
DNA sequencing was performed using BigDye Terminator v3.1 Cycle Sequencing Kit 
(Applied Biosystems). 5  l of template DNA at the concentration of 0.1  g/ l was added to 
the reaction mixture containing 2  l of 5x sequencing buffer, 2  l of BigDye reaction mix 
and 1  l of the desired primer at the concentration of 1.6 pmol/ l. The reaction was run in 
GeneAmp 9700 thermocycler (Applied Biosystems) for 25 cycles of: 96
oC 10 s, 50
oC 5s, 
60
oC  2  min.  Afetr  the  PCR  reaction,  DNA  was  precipitated  with  ethanol  and  sodium 
acetate. 10  l of the PCR reaction mixture was added to 67  l of ethanol/sodium acetate 
stock solution (550  l of 100% ethanol, 40  l of 3 M sodium acetate) in an Eppendorf tube. 
The mixture was incubated for 15 min at room temperature to allow precipitation of DNA. 
Subsequently,  it  was  spun  for  20  min  at  13000  rpm  in  a  bench top  centrifuge.  The 
supernatant was removed with a pipette and the DNA pellet was washed in 150  l of 75% 
ethanol. Following 15 min spin at 13000 rpm, the supernatant was removed and the DNA 
pellet was resuspended in 10  l of formamide. The samples were run on a polyacrylamide 
gel on the ABI PRISM 300 sequencer (Applied Biosystems) and the data were analysed 





2.2.8.  Isolation of RNA 
 
Total RNA was isolated from the cells using RNeasy Mini Kit (Qiagen) or RNeasy Micro 
Kit (Qiagen) according to the manufacturer’s instructions. Briefly, 1x10
7 of bone marrow 
derived dendritic cells (RNeasy Mini Kit) or 5x10
5 of cells isolated from the mesenteric 
lymph  nodes  (RNeasy  Micro  Kit)  were  disrupted  in  a  buffer  containing  guanidine 
isothiocyanite and homogenized using QIAShredder Spin Column (Qiagen). Alternatively, 
30 mg of the spleen or the gut tissue (RNeasy Mini Kit) was homogenized in the same 
buffer using TissueRuptor homogenizer (Qiagen). Ethanol was added to the cell lysate to 
create conditions that promote binding of RNA to silica gel membrane. The sample was 
applied to RNeasy spin column and total RNA was bound to the membrane. Contaminants 
were washed away and RNA was eluted into 40  l (RNeasy Mini Kit) or 14  l (RNeasy 
Micro Kit) of RNase free water. When it was required, genomic DNA was digested using 
DNA free  kit  (Ambion)  according  to  the  manufacturer’s  instructions.  Briefly,  1   l  of 
DNase I and 5  l of 10x DNase I Buffer were added to 50  l of RNA solution in water (0.2 
 g/ l). The reaction mixture was incubated at 37
oC for 30 min. Following that time, DNase 
was inactivated by addition of 5  l of DNase Inactivation Reagent and incubation at room 
temperature for 2 min. Subsequently, the reaction mixture was spun at 10000 rpm and the 
supernatant containing RNA free from genomic DNA contamination was collected and 
stored  at   80
oC.  RNA  concentration  was  measured  using  Nanodrop  ND 1000 
spectrophotometer (ThermoScientific).  
 
2.2.9.  Reverse transcription of RNA 
 
First strand  cDNA  was  reverse  transcribed  from  RNA  templates  using  SuperScript  III 
First Strand  Synthesis  Super  Mix  for  qRT PCR  (Invitrogen)  according  to  the 
manufaturer’s  instructions.  Briefly,  1 2   g  of  total  RNA  were  added  to  10   l  of  2x 
Reaction Mix (containing 2.5 ng/ l of random hexamers, 10 mM MgCl2 and dNTPs), 2  l 
of Reverse Transcriptase Enzyme Mix and DEPC treated water to 20   l. The reaction 
mixture was incubated at room temperature for 10 min and transferred to 50
oC for 30 min. 
The  reaction  was  stopped  by  incubation  at  85
oC  for  5  min.  The  reaction  mixture  was 
chilled on ice, 2 U (1  l) of RNase H were added and the mixture was incubated for 20 min 
at 37
oC to digest the remaining RNA. 
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2.2.10. Quantitative real time PCR (qPCR) 
 
Quantitative real time PCR was used to determine the level of expression of TL1A, IL 
17A,  IL 13,  IL 4,  IL 2  and  IFN γ.  The  reactions  were  run  in  iCycler  thermocycler 
(BioRad)  using  cDNA specific  TaqMan  gene  expression  assays  (TL1A  – 
Mm00770031_m1,  IL 17A  –  Mm00439619_m1,  IL 13  –  Mm99999190_m1,  IL 4  – 
Mm00445260_m1,  IL 2  –  Mm00439861_m1,  IFN γ  –  Mm00801778_m1;  Applied 
Biosystems). Fold expression of TL1A mRNA was calculated using   CT method and 
HPRT (TaqMan assay Mm00446869_m1; Applied Biosystems) as a reference gene. For 
relative expression of cytokine genes (Figures 5.10. and 5.11.), the measurement was first 
normalized to expression of the reference gene, HPRT, ( CT) and then 2
  C
T was used to 
obtain relative gene expression levels. Gene expression levels were then normalized to the 
average gene expression on control mice.  
 
2.2.11. Generation of pcDNA3.1/Zeo( ).TL1A plasmid 
 
A C57BL/6 mouse was injected i.v. with 40  g of LPS. 4 hours later, total RNA was 
isolated from the spleen cells of the mouse and reverse transcribed to obtain cDNA. TL1A 
cDNA was amplified from the total cDNA by nested PCR. The PCR consisted of two 
separate  reactions  –  1
st  with  external  primers  (forward  –  
5’ AGAAGGGATCAGAAGTCTCTC 3’  and  reverse  –  
5’ GGAAATTGGAAAGTAGGAGGCAG 3’)  and  2
nd  with  internal  primers  (forward  –  
5’ GAAGGATGGCAGAGGAGCTG 3’  and  reverse  –  
5’ CCTCCTTATAGCAAGAAAGCT 3’). The PCR mixture after the first reaction was 
used as a template in the second reaction. Each reaction contained 1.25 µl of 10 mM 
dNTPs (Promega), 5 µl of the respective 5 µM forward and reverse primer (Invitrogen), 2 
µl of the template, 5 µl of 10x Pfu polymerase reaction buffer (Promega), 30.75 µl of water 
and 3 U (1 µl) of Pfu polymerase (Promega) which was added after the initial denaturing 
step in order to reduce non specific  amplification. The reactions were  run in PTC 100 
thermocycler  (MJ Research,  Inc.)  under  the  following  conditions:  95
oC  for  7  min,  25 
cycles of 94
oC for 4 min, 58
oC for 1 min, 72
oC for 2 min followed by the final extension 
step at 72
oC for 20 min. The PCR product (742 bp) was isolated from the agarose gel and 
ligated with pCR Blunt II TOPO vector (Invitrogen) using Zero Blunt TOPO Cloning Kit 
(Invitrogen) according to the manufacturer’s instructions. Briefly, 4 µl of the PCR product 43 
 
were mixed with 1 µl of salt solution (1.2 M NaCl / 0.06 M MgCl2), 1 µl (10 ng) of pCR 
Blunt  II TOPO  vector  and  incubated  for  5  min  at  room  temperature.  The  obtained 
construct was sequenced to verify the orientation and sequence of the cloned TL1A cDNA. 
The sequencing was conducted in two separate reactions, using two different primers: (1) 
5’ GAAGGATGGCAGAGGAGCTG 3’  and  (2)  5’ CCTCCTTATAGCAAGAAAGCT 
3’. The insert was subsequently excised from pCR Blunt II TOPO vector using BamHI and 
XbaI restriction enzymes and cloned into pcDNA3.1/Zeo( ) vector (Invitrogen) using the 
same restriction sites. 
 
Figure 2.1.   Map of pCR Blunt II TOPO vector  
(Invitrogen; http://tools.invitrogen.com/content/sfs/vectors/pcrbluntiitopo_map.pdf 44 
 
 
Figure 2.2.  Map of pcDNA3.1/Zeo( ) vector  









2.2.12. Generation of soluble recombinant TL1A  
 
The cDNA sequence encoding the extracellular part of TL1A, with added EcoRI restriction 
site  at  the  5’  end,  was  amplified  by  PCR  from  pcDNA3.1/Zeo( )  vector  (Invitrogen) 
containing TL1A cDNA cloned between BamHI and XbaI restriction sites (see section 
2.2.11.),  using  the  following  primers  –  forward:  5’ 
CGAATTCCACAGAAGAGAGATCTGAGCCT 3’  (EcoRI  site  is  shown  in  bold)  and 
reverse:  5’ CCTCCTTATAGCAAGAAAGCT 3’.  The  PCR  reaction  mixture  contained 
1.25  l of 10 mM dNTPs (Promega), 5  l of 5 M forward and reverse primer, 5 µl of 10x 
Pfu  polymerase  reaction  buffer  (Promega),  30.75  µl  of  water  and  3  U  (1  µl)  of  Pfu 
polymerase (Promega) which was added after the initial denaturing step in order to reduce 
non specific amplification. The reaction was run in PTC 100 thermocycler (MJ Research, 
Inc.) under the following conditions: 95
oC for 5 min, 25 cycles of 94
oC for 1 min, 57
oC for 
1 min, 72
oC for 2 min followed by an extension step at 72
oC for 10 min. The obtained 
fragment (540 bp) was isolated from the agarose gel and ligated with pCR Blunt II TOPO 
vector  (Invitrogen)  using  Zero  Blunt  TOPO  Cloning  Kit  (Invitrogen)  according  to  the 
manufacturer’s  instructions  as  described  in  the  section  2.2.11.  The  construct  was 
sequenced  to  verify  the  orientation  and  the  sequence  of  the  cloned  insert,  using  the 
following primer 5’ CCTCCTTATAGCAAGAAAGCT 3’. Subsequently, the insert was 
excised from pCR Blunt II TOPO vector using EcoRI restriction enzyme and cloned into 
pEE14.CD4(d3+4) vector (containing the sequence of rat CD4 domains 3 and 4, cloned 
between the restriction sites XbaI ￿ EcoRI) using the same restriction site. The sequence 
and the orientation of the obtained construct were verified by DNA sequencing, using the 
following primer 5’ CCTCCTTATAGCAAGAAAGCT 3’. As a result, cDNA encoding 
domains 3 and 4 of rat CD4 (rCD4 d3+4) was added to the 5’ end of the cDNA encoding 
the extracellular part of TL1A. Rat CD4(d3+4) tag is recognized by mouse monoclonal 
OX68 antibody which allowed to purify the recombinant protein. The obtained vector was 
transfected into CHO.K1 cells using calcium phosphate precipitate method. The cells were 
grown in DMEM medium (Safc) supplemented with 100 U/ml penicillin (Invitrogen), 100 
 g/ml  streptomycin  (Invitrogen),  5%  dialysed  foetal  calf  serum  (First  Link,  Ltd.),  GS 
supplements (containing alanine, asparagine, aspartic acid, glutamic acid, proline, serine, 
adenosine, thymidine, uridine and cytidine; Sigma) and 20  M methionine sulfoximine 
(MSX;  Sigma).  The  clone  secreting  the  highest  amount  of  the  recombinant 46 
 
TL1A.rCD4(d3+4)  protein  was  selected  by  ELISA  screening,  expanded  and  the 
recombinant  protein  was  purified  on  an  OX68  antibody  column.  TL1A.CD4(d3+4) 








TFFGAFLL; rat CD4(d3+4) sequence is shown in bold). Extinction coefficient is 0.95, as 
determined by ProtParam online database (www.expasy.ch/cgi bin/protparam). Each batch 
of sTL1A was tested for LPS contamination which varied between 0.5 – 0.7 ng of LPS per 
1 mg of sTL1A. 
 
 








2.3.  Cellular assays, cell transfection and flow cytometry 
 
2.3.1.  Isolation of murine spleen cells 
 
Spleens were aseptically removed from mice and a single cell suspension was prepared by 
passing the spleens through a cell strainer. The cells were centrifuged (5 min, 400 g) and 
resuspended in 5 ml of red cell lysis buffer (0.83% (w/v) NH4Cl, 0.1% KHCO3 in water) 
and incubated for 5 min at room temperature. Subsequently, the cells were washed twice in 
PBS and resuspended in growth medium (see section 2.1.3.).  
 
2.3.2.  Enrichment of splenic dendritic cells 
 
3 ml of RPMI 1640 medium (Invitrogen) containing collagenase (1 mg/ml) and DNase (50 
 g/ml) were added to the appropriate number of wells in a 6 well plate containing a spleen 
isolated from a C57BL/6 mouse. The medium was injected into the spleens which were 
then cut into small pieces and incubated for 45 min at 37
oC to allow digestion of collagen 
and the release of dendritic cells. After that time, EDTA was added to each well to the final 
concentration of 10 mM and incubated for 10 min at room temperature. Subsequently, a 
single cell suspension was prepared from the cells using a cell strainer. The cell suspension 
was  transferred  into  15  ml  tubes  and  centrifuged  (5  min,  400  g).  The  cell  pellet  was 
resuspended in 5 ml of red cell lysis buffer (0.83% (w/v) NH4Cl, 0.1% KHCO3 in water) 
and incubated for 10 min at room temperature. The cells were washed with RPMI 1640 
(Invitrogen) supplemented with 10% (v/v) Foetal Calf Serum (FCS; Invitrogen), 10 mM 
EDTA and 20 mM Hepes (Sigma)  and resuspended in 2 ml of this medium. The cell 
suspension was loaded onto 2 ml of 14.5% Nycodenz (Axis Shield) gradient in RPMI 1640 
supplemented with 10% FCS, 10 mM EDTA and 20 mM Hepes and centrifuged for 20 min 
at 530 g at room temperature. The interface containing the enriched dendritic cells was 
collected and washed in RPMI 1640 supplemented with 10% (v/v) FCS, 10 mM EDTA 
and  20  mM  Hepes.  The  percentage  of  CD11c
+  CD11b
+  cells  was  measured  by  flow 
cytometry. Before the centrifugation of Nycodenz gradient, CD11c
+ CD11b
+ represented 
typically 2.0 2.5% of total cell population; after the enrichment they represented typically 





2.3.3.  Generation of bone marrow derived dendritic cells 
 
Bone marrow was isolated from mouse femurs and tibias. The cell suspension was filtered 
through a cell strainer to remove particles and obtain a single cell suspension. The cells 
were centrifuged for 10 min at 280 g and resuspended in 5 ml of red cell lysis buffer 
(0.83% (w/v) NH4Cl, 0.1% (w/v) KHCO3 in water). Following 5 min of incubation at room 
temperature,  the  cells  were  centrifuged  as  before  and  washed  twice  with  RPMI  1640 
(Invitrogen), each time by centrifuging for 10 min at 280 g. The cell concentration was 
adjusted to 1x10
6 cells/ml in RPMI 1640 (Invitrogen) supplemented with 5% (v/v) FCS 
(Invitrogen), 100 U/ml of penicillin (Invitrogen), 100  g/ml of streptomycin (Invitrogen), 1 
mM pyruvate (Invitrogen) and 20 ng/ml of GM CSF (PeproTec). The cell suspension was 
plated out at 1 ml/well in a 24 well plate. The cells were washed and fed every two days, 
each  time  by  removing  the  old  medium,  gently  washing  with  plain  RPMI  1640  and 
replacing the old medium with 1 ml of RPMI  1640 supplemented with 5% (v/v) FCS 
(Invitrogen), 100 U/ml of penicillin (Invitrogen), 100  g/ml of streptomycin (Invitrogen), 1 
mM pyruvate (Invitrogen) and 20 ng/ml of GM CSF (PeproTec). The cells were used for 
experiments after 7 days of culture which allowed optimal differentiation of bone marrow 
derived dendritic cells. The level of CD11c
+ after that time has always been >85%, as 
determined by flow cytometry analysis. 
 
2.3.4.  Isolation of cells from the peritoneal cavity 
 
Mice were sacrificed, their skin was cut and pulled back to expose the inner skin lining of 
the peritoneal cavity. 5 ml of ice cold PBS was injected into the peritoneal cavity using a 
27 G needle. The peritoneal cavity was gently massaged to dislodge any attached cells into 
PBS. PBS containing the cells was removed from the peritoneal cavity using the same 
syringe and needle.  
 
2.3.5. 
 3H thymidine incorporation assay 
 
Methyl 
3H thymidine (0.5  Ci/well in a 96 well plate; Amersham) was added to the cell 
cultures for the last 16 h of a 72 h culture. After that time, the cells were harvested onto 
glass  fibres  (Unifilter  GF/B;  Perkin  Elmer)  using  an  automated  harvester  (Filtermate; 49 
 
Packard). The glass fibres were dried for 1 h at 37
oC and the incorporation of 
3H thymidine 
was measured via liquid scintillation counting. 
 
2.3.6.  Flow cytometry 
 
The cells were stained for 30 min at 4
oC in darkness with fluorophore conjugated (direct) 
or unlabelled (indirect) antibodies or protein constructs (unless stated otherwise, the final 
concentration  was  10   g/ml)  in  PBS/BSA  buffer  (0.2%  (w/v)  Bovine  Serum  Albumin 
fraction V (BSA; First Link, Ltd.) in PBS) in transparent FACS tubes (Becton Dickinson). 
The  cells  were  washed  twice  in  PBS/BSA  buffer  and  resuspended.  For  indirect 
immunofluorescence, the cells were further incubated for 30 min at 4
oC in darkness with 
fluorophore conjugated  secondary  antibodies  directed  against  the  primary  antibodies  or 
protein constructs, washed twice and resuspended in PBS/BSA buffer and subsequently 
analysed on FACSCalibur (Becton Dickinson) or FACS Canto II (Becton Dickinson) flow 
cytometers. Forward scatter versus side scatter analysis was used to gate viable cells or 
lymphocyte  population.  Ten  thousand  viable  cells  were  typically  collected  per  sample. 
Bone marrow derived dendritic cells, blood cells, splenic dendritic cells and spleen cells 
were pre incubated for 15 min at 4
oC with 10  g/ml of anti FcR II and III antibody (2.4G2) 
prior to staining with primary antibodies to prevent their binding to Fc receptors. Blood 
samples  (~100   l)  were  directly  stained  in  FACS  tubes  with  antibodies  or  protein 
constructs,  washed  once  with  red  cell  lysis  buffer  and  once  with  PBS/BSA  buffer, 
resuspended and analysed on a flow cytometer. The data were analysed using CellQuest or 
WinMDI software. 
 
2.3.7.  Intracellular staining for the presence of IFN γ and FoxP3 
 
Intracellular staining for the presence of IFN γ was performed using Cytofix/Cytoperm Kit 
(BD  Biosciences)  according  to  the  manufacturer’s  instructions.  1   l/ml  of  GolgiPlug 
(containing brefeldin A; BD Biosciences) was added to the cell culture for the last 6 h of 
culture. The cells were pre incubated with 2.4G2 antibody in the staining buffer (PBS/BSA 
containing 1  l/ml of GolgiPlug) as described above and surface antigens were stained 
with fluorophore conjugated antibodies in the staining buffer as described above. The cells 
were washed twice with staining buffer and fixed in Cytofix/Cytoperm buffer (1 ml/tube) 
for  20  min  at  4
oC.  The  cells  were  vortexed,  resuspended  in  Fixation/Permeabilization 50 
 
solution (250  l/tube) and incubated for 20 min at 4
oC. The cells were washed twice in 1x 
Perm/Wash buffer (containing foetal bovine serum and saponin; 1 ml/tube). Subsequently, 
the  cells  were  resuspended  in  50   l  of  1x  Perm/Wash  buffer  containing  fluorophore 
labelled anti IFN γ antibody (10  g/ml). Finally, the cells were again washed twice in 1x 
Perm/Wash buffer, resuspended in the staining buffer and analysed by flow cytometry. 
Intracellular  staining  for  the  presence  of  FoxP3  was  performed  using  FoxP3  Staining 
Buffer Set (eBiosciences) in a similar way as described above. 
 
2.3.8.  CFSE dilution assay 
 
5x10
7 cells/ml were incubated for 10 min at 37
oC with 5  M or indicated concentrations of 
carboxyfluoresceine  diacetate  succinimidyl  ester  (CFSE;  Molecular  Probes)  in  PBS 
containing 0.1% (w/v) bovine serum albumin. Labelled cells were then washed twice with 
RPMI 1640 containing 10% FCS. The level of labelling was checked by flow cytometry 
analysis. 
 
2.3.9.  Depletion of CD4
+ T cells for in vitro cellular assays 
 
Depletion  of  CD4
+  T  cells  was  performed  using  CD4  (L3T4)  MicroBeads  (Miltenyi 
Biotec) according to the manufacturer’s instructions. First, CD4
+ T cells were stained with 
magnetically labelled anti CD4 (L3T4) antibodies (Mitenyi Biotec) and the cell suspension 
(8x10
7 cells) was loaded on MACS LD column (Miltenyi Biotec) which was then placed in 
the magnetic field. The magnetically labelled CD4
+ T cells were retained on the column 
while the unlabelled cells run through it and were used for cellular assays. The depletion of 
CD4
+ T cells was confirmed by flow  cytometry. Usually ~90% of CD4
+ T cells were 
removed from the total population of spleen cells. 
 
2.3.10. Isolation of CD49b
+ cells for in vitro cellular assays 
 
CD49b
+  cells  were  isolated  from  spleens  of  SCID  BALB/c  mice  using  DC49b  (DX5) 
MicroBeads (Miltenyi Biotec) according to the manufacturer’s instructions. Briefly, DX5
+ 
cells  were  stained  with  magnetically  labelled  anti CD49b  antibodies  and  the  cell 
suspension (15x10
7 cells) was loaded onto a MACS LS column (Miltenyi Biotec) which 
was then placed in a magnetic field. The magnetically labelled CD49b
+ cells were retained 51 
 
on the column, while the non labelled cells run through the column. CD49b
+ cells were 
eluted from the column after it had been removed from the magnetic field. 
 
2.3.11. Stable transfection of CHO.K1 cells by calcium phosphate precipitate 
 
Mammalian  expression  vector  pEE14.rCD4(d3+4).TL1A  vector,  containing  cDNA 
encoding the extracellular part of TL1A fused to rat CD4 domains 3 and 4 was stably 
transfected into CHO.K1 cells via calcium phosphate precipitate method. Cell clones that 
stably  expressed  soluble  TL1A  were  selected  using  glutamate  synthetase  system. 
Glutamine is a metabolite synthesised from glutamate and ammonia in a reaction catalysed 
by glutamine synthetase. Inhibition of this enzyme using methionine sulfoximine (MSX), 
in the absence of exogenous glutamine, will cause death of the cell.  However, pEE14 
vector  contains  a  glutamine  synthetase  minigene,  therefore  cells  transfected  with  this 
vector  become  resistant  to  sub optimal  concentrations  of  MSX  because  of  elevated 
expression of the enzyme.  
The day before the transfection, CHO.K1 cells were seeded at 1x10
6 cells per 80 cm
2 flask 
in  DMEM  media  (Safc)  supplemented  with10%  (v/v)  FCS  (Invitrogen),  100  U/ml 
penicillin (Invitrogen), 100  g/ml streptomycin (Invitrogen), 1 mM pyruvate (Invitrogen), 
2  mM  L glutamine  (Invitrogen)  and  GS  supplements  (containing  alanine,  asparagines, 
aspartic acid, glutamic acid, proline, serine, adenosine, guanosine, cytidine, uridine and 
thymidine; Sigma). A sterile solution containing 15  g of pEE14.rCD4(d3+4).TL1A vector 
and 186  l of 1M CaCl2 in a total volume of 750  l was added dropwise with agitation to 
750   l  of  2x  HBS,  pH=7.05  (1.636%  (w/v)  NaCl,  1.188%  (w/v)  Hepes,  0.04%  (w/v) 
Na2HPO4)  and  incubated  for  10  min  at  room  temperature  to  allow  the  DNA calcium 
phosphate to form. The precipitate was added to the CHO.K1 cells in 20 ml of the media 
and the cells were incubated for 5 h in a tissue culture incubator. After that time, the cells 
were washed twice with plain DMEM (Safc) media and incubate with 2 ml of 15% (v/v) 
glycerol  in  1x  HBS  for  2  min.  The  cells  were  subsequently  washed  twice  with  plain 
DMEM media (Safc) and cultured overnight in DMEM (Safc) supplemented with 10% 
(v/v)  FCS  (Invitrogen),  100  U/ml  penicillin  (Invitrogen),  100   g/ml  streptomycin 
(Invitrogen) and GS supplements (Sigma). The transfected CHO.K1 cells were plated over 
96 well flat bottomed plates (5x10
4 cells/ml) at 200  l/well. The plates were demi fed after 
7 daysand screened by ELISA. After the expansion into 24 well plates, the clones were re 52 
 
screened  by  ELISA  to  confirm  stable  expression  of  sTL1A.  Clones  that  expressed  the 
highest amounts of sTL1A were further expanded and used for the production of sTL1A. 
 
2.3.12. Transient transfection of HEK293T cells with pcDNA3.1/Zeo( ).TL1A vector 
 
Transient  transfection  of  HEK293T  cells  with  pcDNA3.1/Zeo( ).TL1A  vector  was 
performed using Effectene Transfection Reagent (Qiagen) according to the manufacturer’s 
instructions. Briefly, the day before the transfection, the 8x10
5 cells were seeded on a 60 
mm dish in DMEM (Invitrogen) medium supplemented with 10% (v/v) foetal calf serum 
(FCS; Invitrogen), 100 U/ml penicillin (Invitrogen), 100  g/ml streptomycin (Invitrogen), 
2 mM L glutamine (Invitrogen) and 1 mM pyruvate (Invitrogen). The dishes were 80% 
confluent on the day of the transfection. 1  g of the DNA construct in 10  l of TE buffer 
(10 mM tris, 1 mM EDTA, pH=7.5) was added to 140  l of DNA condesation buffer (EC 
buffer). Then, 8  l of Enhancer buffer was added; the mixture was briefly vortexed and 
incubated for 5 min at room temperature. After that time, 25  l of Effectene Transfection 
Reagent (containing liposomes) was added to the mixture which was then incubated for 
another 10 min at room temperature. Next, 1 ml of growth medium was added to the 
DNA/liposomes solution and was added dropwise to the cells. The transfected cells were 
used for experiments 48 h after the transfection. 
 
2.4.  Protein analysis and purification 
 
2.4.1.  SDS polyacrylamide gel electrophoresis (SDS PAGE) 
 
SDS PAGE was performed using a mini gel system (BioRad). The stacking gel consisted 
of 4% (v/v) acrylamide/bisacrylamide (National Diagnostics), 0.4% (w/v) sodium dodecyl 
sulphate (SDS), 0.005%  (w/v) N N N’ N’ tetramethylethylene (TEMED) in 0.125 M tris, 
pH=6.8. The resolving gel consisted of 12% (v/v) acrylamide/bisacrylamide, 0.4% (w/v) 
SDS,  0.01%  (w/v)  TEMED  in  0.375  M  tris,  pH=8.8.  Polymerization  of  the  gels  was 
initiated with a fresh 10% (w/v in water) solution of ammonium persulfate, added at the 
final concentration of 1% in stacking gels and 0.5% in resolving gels. 10  g of protein per 
lane was analysed. Non reduced samples were diluted 1:1 in 2x loading buffer (40% (w/v) 
urea, 1.6% (v/v) SDS, 0.16 M tris HCl, 0.08% (w/v) bromophenol blue, pH=8.0). Reduced 
samples were diluted 1:1 in 2x loading buffer containing also 50 mM DTT. Samples were 53 
 
denatured by heating at 95
oC for 5 min and immediately loaded on the gel. Gels were run 
at 150 V in running buffer (0.0125 M tris HCl, 0.096 M glycine, 0.1% (w/v) SDS). Gels 
were fixed by submerging in 25% isopropanol, 10% acetic acid for 30 min and protein was 
detected using coomassie brilliant blue stain (0.006% (w/v) coomassie brilliant blue in 5% 
(v/v) acetic acid). Gels were destained to the desired extent with 10% (v/v) acetic acid. 
 
2.4.2.  TL1A, IFN γ and IL 4 ELISA 
 
96 well  microtiter  plates  were  coated  overnight  at  4
oC  with  10   g/ml  of  anti TL1A 
(TAN2 2),  4   g/ml  of  anti IFN γ  (HB170)  or  1.25   g/ml  of  anti IL 4  monoclonal 
antibodies in 50 mM bicarbonate buffer (1.59 g Na2CO3, 2.93 g NaHCO3 in 1 L of water). 
The  plates  were  blocked  with  PBS/1%  (w/v)  bovine  serum  albumin  for  2  h  at  room 
temperature and washed 3 times with PBS / 0.05% (v/v) Tween 20. Diluted standards of 
mouse soluble recombinant TL1A (TL1A.Fc), IFN γ or IL 4 and supernatants from the cell 
cultures were added to the plates which were then incubated for 2 h at 37
oC. The plates 
were washed 5 times with PBS/0.05% (v/v) Tween 20. Biotinylated anti TL1A (TAN2 2; 
5  g/ml), anti IFN γ (0.5  g/ml) or anti IL 4 (0.125  g/ml) were added to the wells and 
incubated for 1.5 h at 37
oC. The plates were washed 5 times with PBS/0.05% (v/v) Tween 
20 and 1:1000 dilution of streptavidin HRP in PBS/1% (w/v) bovine serum albumin. The 
plates were incubated for 30 min at room temperature, washed 5 times with PBS/0.05% 
(v/v) Tween 20 and OPD (o phenylene dihydrochloride; Sigma) substrate for colorimetric 
detection of HRP was added. The plates were incubated for 10 min at room temperature in 
darkness. After that time, 50  l/ml of 2.5M H2SO4 was added. The plate was read at 460 
nm on Dynatech MR4000 plate reader. 
 
2.4.3.  Purification of soluble recombinant TL1A (sTL1A) 
 
The clone of CHO.K1 cells stably transfected with pEE14.rCD4(d3+4).TL1A construct, 
showing the highest level of expression of sTL1A (extracellular region of TL1A fused to 
rat CD4 domains 3 and 4) was cultured in 175 cm
2 triple layer culture flasks (Nunc) in 150 
ml of DMEM medium (Safc) supplemented with 100 U/ml penicillin (Invitrogen), 100 
 g/ml  streptomycin  (Invitrogen),  5%  dialysed  foetal  calf  serum  (First  Link,  Ltd.),  GS 
supplements (containing alanine, asparagine, aspartic acid, glutamic acid, proline, serine, 
adenosine, thymidine, uridine and cytidine; Sigma) and 20  M methionine sulfoximine 54 
 
(MSX; Sigma). 5 L of supernatant collected from the cell culture was filterded through 
Whatman  paper  and  concentrated  to  1  L  using  Dicea  150  Dialyzer  (Baxter).  A  15  ml 
column containing anti rat CD4 (OX68) antibody conjugated sepharose beads was washed 
10 times with 200 ml of low tris buffer (1:7 dilution of stock tris buffer (200 mM tris, 1 M 
NaCl, 10 mM EDTA, pH=8.0 in water) and 10 times with 200 ml of high tris buffer (1:2 
dilution  of  stock  tris  buffer  in  water).  1  L  of  the  concentrated  CHO.K1  cell  culture 
supernatant was run through the column (~200  l/sec). The column was washed 10 times 
with 200 ml of low tris buffer and the protein was eluted with 0.1 M glycine HCl, pH=2.5. 
The whole process of elution was then repeated, so that 2 batches of protein were collected 
from 1 L of the concentrated supernatant. Usually, 5 mg of sTL1A were collected from 5 L 
of non concentrated cell culture supernatant.   
 
2.4.4.  Conjugation of anti rat CD4 (OX68) antibody to sepharose beads 
 
30 mg of antibody was dialysed against 5 L of citrate buffer (0.2 M citric acid, 0.58 M 
NaOH, pH=6.5). The antibody was then diluted to a final concentration of 2 mg/ml. 200 ml 
of 10 mM HCl was added to 1.2 g of CNBr activated sepharose 4B beads (Amersham 
Biosciences)  and  left  at  room  temperature  for  20  min.  The  beads  were  poured  over  a 
sintered glass filter and washed with 500 ml of 10 mM HCl, followed by 500 ml of the 
citrate buffer. The beads were placed into a universal tube and 26 mg of OX68 antibody 
was  added.  The  beads  together  with  antibody  were  left  for  4  h  at  room  temperature, 
rotating. Antibody binding to the beads was confirmed by spectrophotometry at 280 nm of 
the residual citrate buffer. The beads were then incubated with 20 ml of 1 M ethanolamine 
HCl, pH=9.5 for 1 h, rotating. The beads were again poured onto a sintered glass filter and 
washed  with  1  L  of  0.1M  tris,  0.5  M  NaCl,  5  mM  EDTA,  followed  by  ammonium 
thiocyanate (1 M KSCn, 0.7 M ammonium), followed by a second  wash with 0.1 M tris, 
0.5 M NaCl, 5 mM EDTA. Conjugated beads were then packed over glass wool in a 30 ml 








2.5.  Mice and in vivo experiments 
 
2.5.1.  OT I, OT II transgenic mice, wild type C57BL/6 and BALB/c mice 
 
OT I  and  OT II  C57BL/6  mice  were  bred  in  the  in house  animal  facility  (Tenovus 
Research Laboratory). Wild type C57BL/6 and BALB/c mice were purchased from Harlan 
and bred in the in house animal facility (Tenovus Research Laboratory). C3H/HeN and 
C3H/HeJ mice were purchased from Jackson  Laboratory. The mice were used at 8 12 
weeks of age. All animal experiments described in this thesis were carried out according to 
the  UK  Home  Office  licence  guidelines  and  were  approved  by  the  University  of 
Southampton’s ethical committee.  
 
2.5.2.  CD11c TL1A transgenic mice 
 
CD11c TL1A transgenic mice were generated in house by injection of a DNA construct 
containing the coding sequence of TL1A under the control of CD11c promoter into the 
male pronuclei of FVB/N zygotes. The transgenic progeny was then backcrossed to the 
C57BL/6 strain for 5 6 generations. Transgenic mice and age matched control littermates 
were used at 6 24 weeks of age. CD11c TL1A transgenic mice were identified by PCR 
using the following primers: forward – 5’ CTCACCTCCCAGAGGCAAG 3’ and reverse 
– 5’ GGAGTCTGGCTTGTTTGGTCG 3’. The following reaction mixture was used: 0.5 
 l of 10 mM dNTPs, 1  l of the forward and reverse primer at the concentration of 100 
ng/ml, 5  l of 5x Green GoTaq Polymerase Buffer (Promega), 1  l of mouse genomic 
DNA, 0.5  l (0.5 U) of GoTaq Polymerase (Promega) and 16  l of water. The reaction was 
run under the following conditions: 95
oC 5 min, 25 cycles of 95
oC 1 min, 60.5
oC 1 min, 
72
oC 2 min, followed by the final extension step 72
oC 10 min. The reaction was run in 
PTC 100 thermocycler (MJ Research, Inc.). The primers used for this PCR can amplify 
both cDNA and the whole genomic sequence of TL1A, giving products of 720 bp and 
5500 bp, respectively. However, the extension step used in this reaction is too short to 






2.5.3.  CD2 TL1A transgenic mice 
 
CD2 TL1A transgenic mice were generated at Cancer Research UK using the prepared in 
house DNA construct containing the coding sequence of TL1A under the control of CD2 
promoter.  The  DNA  construct  was  injected  into  male  pronuclei  of  CBN  zygotes.  The 
transgenic progeny was then backcrossed to the C57BL/6 strain for 4 5 generations. The 
transgenic mice and age matched control littermates were used at 8 20 weeks of age. CD2 
TL1A transgenic mice were identified by PCR, as described in the previous section.  
 
2.5.4.  Adoptive transfer of OT I and OT II T cells 
 
For  adoptive  transfer  of  OT I  and  OT II  to  naive  C57BL/6  recipients,  a  single  cell 
suspension  of  lymph  node  (inguinal,  brachial  and  mesenteric)  and  spleen  cells  was 
prepared from OT I or OT II transgenic C57BL/6 mice. The proportion of OT I T cells 
was determined by H 2K
b SIINFEKL tetramer and anti CD8 antibody staining and flow 
cytometry analysis. The proportion of OT II T cells was determined by staining the cells 
with anti CD4, anti Vα2 and anti Vβ5 antibodies and analysis by  flow cytometry. The 
cells  were  then  injected  i.v.  into  sex matched  C57BL/6  recipients.  The  number  of 
transferred cells is indicated in the figure legends.  
 
2.5.5.  In vivo depletion of CD4
+, CD8




+ T cell depletion was carried out by i.p. injection of anti CD4 (YTA3.1.2.; 
1 mg) or anti CD8 (YTS169; 0.5 mg) monoclonal antibodies, respectively on days  3,  1 
and 3. NK cell depletion was carried out by i.v. injection of 25  g of anti asialo GM1 
antibody on days  3,  2 and  1, where day 0 was the day of tumour challenge. 
 
2.6.   Histology 
 
Tissue  was  fixed  in  10%  neutral  buffered  formalin  (Sigma).  Samples  were  embedded, 
sectioned and stained with H&E. The histology analysis was conducted by University of 




2.7.  Statistical analysis 
 
Statistical analyses were performed with GraphPad Prism 5 software and involved the use 
of  two tailed  Student  t  test,  except  for  comparing  survival  curves  where  the  log rank 

































   
EXPRESSION OF TL1A ON DENDRITIC CELLS AND T CELLS 
 
3.1.  Introduction 
 
  There are several reports showing that TL1A acts as a co stimulatory molecule for 
T cells (116, 123, 145, 146). Expression of co stimulatory molecules is usually localized to 
antigen presenting cells and T cells and is up regulated following their activation (59). This 
chapter  shows  that  expression  of  transmembrane  TL1A  is  transiently  up regulated  on 
activated  T  cells,  bone  marrow derived  dendritic  cells  and  splenocytes  stimulated  with 
ligands for Toll like receptor (TLR) 3 and TLR4.  
  Dendritic cells undergo activation and maturation following the interaction with 
pathogen associated molecular patterns (PAMPs) or ligation of certain receptors present on 
their surface (e.g. CD40). Therefore, expression of  TL1A was investigated in T cells, bone 
marrow derived dendritic cells and total population of splenocytes activated both in vitro 
and in vivo with several PAMPs recognized by TLRs and dectin 1 and other factors that 
activate antigen presenting cells or T cells either directly or indirectly.  
  PAMPs are recognized by pattern recognition receptors (PRRs), such as Toll like 
receptors  (TLRs)  which  are  the  best  characterized  class  of  PRRs.  There  are  10  to  15 
different TLRs in mammals. They are key components of the innate immune system that 
detect  microbial  infection  and  trigger  antimicrobial  host  defence  responses.  TLRs  are 
expressed on epithelial cells and on a variety of cells of the immune system, including 
dendritic cells, and detect multiple PAMPs including lipopolysaccharide (LPS), flagellin, 
unmethylated CpG DNA and double stranded viral RNA (157). TLRs use four adaptor 
proteins (MyD88, TIRAP, TRIF and TRAM) to transduce signals leading to activation of 
several  transcription  factors  –  NF κB,  AP 1,  IRF 3,  IRF 5  and  IRF 7.  IRFs  induce 
expression of type I interferons which, in turn, activate transcription of interferon induced 
genes (158). 
  Another PRR is dectin 1. It is a C type lectin receptor recognizing β 1,3 glucan 
which is a component of yeast cell wall. Dectin 1 expressed in high levels on dendritic 
cells, monocytes, macrophages and neutrophiles and its stimulation results in activation of 
these cells. Dectin 1 signalling, via Src and Syk tyrosine kinases and an adaptor protein 
Card9, leads to activation of NF κB. It also synergizes with TLR2 to augument secretion of 59 
 
pro inflammatory cytokines. It is known that dectin 1/Syk and Dectin 1/TLR2 pathways 
act independently (159, 160). 
  The other issue described in this chapter is the specificity of binding of TAN2 2 (α 
TL1A)  antibody  and  DR3.Fc  construct  to  transmembrane  TL1A  expressed  on  cells 
transfected with TL1A cDNA and cells naturally expressing TL1A. This part the research 
led to a hypothesis that TL1A exists in two forms – homo  and heterotrimeric. 60 
 
3.2.  Results 
 
3.2.1.  Expression of TL1A on activated splenocytes, bone marrow derived dendritic cells 
and T lymphocytes   
 
  Expression  of  TL1A  mRNA  in  bone  marrow derived  dendritic  cells  (BMDCs) 
stimulated in vitro with 100 ng/ml of lipopolysaccharide (LPS; ligand for TLR4) or 50 
 g/ml  of  polyinosinic polycytidylic  acid  (poly(I:C);  ligand  for  TLR3)  for  4  h  was 
determined by quantitative PCR (qPCR). LPS induced an average 442 fold increase of 
TL1A mRNA level compared to non stimulated cells, while poly(I:C) induced an average 
177 fold increase of TL1A mRNA level compared to non stimulated cells (Figure 3.1.).  
 








Figure 3.1. Expression of TL1A mRNA in bone marrow derived dendritic cells stimulated with LPS or 
poly(I:C). The cells were stimulated in vitro with 100 ng/ml of LPS or 50  g/ml of poly(I:C). After 4 h of 
stimulation, total RNA was extracted from the cells, genomic DNA in the RNA samples was digested, RNA 
was reverse transcribed and TL1A transcript was quantified by qPCR. The graph represents mean values 
from three separate experiments ±SE. In each experiment the fold change was calculated using triplicate 
qPCR samples. 
 
  Expression  of  the  transmembrane  form  of  TL1A  was  detected  on  CD11c
high 
fraction of BMDCs by flow cytometry after 4 h and 24 h of in vitro stimulation with 100 
ng/ml of LPS. The level of activation of BMDCs was estimated by the expression of the 
CD86 molecule which increased following stimulation with LPS (Figure 3.2.). The cells 
were grown also in the presence of both LPS and 20  M TAPI 0 which is an inhibitor of 
the  TNF  convertase  (TACE),  belonging  to  the  family  of  matrix  metalloproteinases 
(MMPs), responsible for shedding of TNF from the cell surface. Taking into account the 







































members, it is possible that the same MMPs which induce the release of soluble TNF are 
also involved in shedding of TL1A. However, BMDCs grown in the presence of TAPI 0 
did  not  show  higher  expression  of  TL1A  than  the  control  cells  (Figure  3.2.A).  This 
experiment indicates that TL1A is not shed from the surface of BMDCs in these conditions 
or enzymes other than TACE are responsible for shedding of this molecule, since others 
have reported the release of soluble TL1A from human dendritic cells and monocytes in 







Figure 3.2. Expression of TL1A and CD86 on bone marrow derived dendritic cells (BMDCs) stimulated 
with LPS. (A) BMDCs from a WT C57BL/6 mouse were stimulated in vitro with 100 ng/ml of LPS in the 
presence (blue line) or absence (black line) of 20  M TAPI 0 and stained for the presence of TL1A with 
DR3.Fc construct and PE conjugated goat anti human IgG antibody. Grey histograms represent staining with 
the isotype control for DR3.Fc (human IgG). (B) BMDCs were stimulated as above and stained for the 
presence  of  CD86  with  FITC conjugated  GL1  antibody.  Black  line  –  naive  cells,  blue  line  –  4h  of 
stimulation, red line – 24h of stimulation, grey histogram – staining with the isotype control antibody for 
GL1  (FITC conjugated  Mc39 16  antibody).  The  cells  presented  on  the  histograms  were  gated  on  both 
CD11c





































































  TL1A expression was examined by flow cytometry also on mouse T cells activated 
with 10  g/ml of anti
receptor, therefore stimulation of this co
other  cells,  present  in  the  population  of  splenocytes.  Activated  T  cells  transiently  up
regulate the expression of transmembrane T
antibody (Figure 3.3.).
 
Figure 3.3. Expression of TL1A on activated T cells. Splenocytes isolated from a WT C57BL/6 mouse were 
stimulated in vitro with 10 
presence of TL1A with DR3.Fc construct and PE




  Expression of TL1A mRNA was investigated also in splenocytes of C57BL/6 mice 
injected i.v. with 40  
LPS; ligand for TLR4), 50 
for TLR3), 50  g of unmethylated CpG sequences (CpG; ligand for TLR9), 50 
synthetic  lipopeptide 
Ser (S) Lys4 OH  trihydrochloride  (Pam3CSK4;  ligand  for  TLR2),  2 
galactosylceramide  (α
dectin 1), or 500  g of 
h and 24 h of stimulation. The most potent inducers of TL1A mRNA were poly(I:C) which 
induced an average 18
animals, Lipid A (average 19
3.4.). TL1A mRNA level peaked after 4h of stimulation with LPS and Lipid A, and after 
6h of stimulation with poly(I:C). It returned to the level of naive cells after 24 h. The other 
tested factors did not significantly change the level of TL1A mRNA expression. 
TL1A expression was examined by flow cytometry also on mouse T cells activated 
g/ml of anti CD3 antibody. CD3 takes part in signal transduction from T cell 
receptor, therefore stimulation of this co receptor results in activation of T cells, but not 
other  cells,  present  in  the  population  of  splenocytes.  Activated  T  cells  transiently  up
regulate the expression of transmembrane TL1A after 24 h of stimulation with anti
antibody (Figure 3.3.). 
Expression of TL1A on activated T cells. Splenocytes isolated from a WT C57BL/6 mouse were 
with 10  g/ml of anti CD3 antibody for 24 h and 48 h. The cells
presence of TL1A with DR3.Fc construct and PE conjugated goat anti human IgG antibody (black line). 
Grey histograms represent staining with the isotype control for DR3.Fc (human IgG). The cells presented on 
histograms were electronically gated on viable population. The presented results are representative 
Expression of TL1A mRNA was investigated also in splenocytes of C57BL/6 mice 
 g of LPS (ligand for TLR4), 40  g of Lipid A (lipid
LPS; ligand for TLR4), 50  g of poly(I:C) mimicking double stranded viral RNA (ligand 
g of unmethylated CpG sequences (CpG; ligand for TLR9), 50 
synthetic  lipopeptide  (S) (2,3 bis(polmitoyloxy) (2RS) propyl) N
OH  trihydrochloride  (Pam3CSK4;  ligand  for  TLR2),  2 
α GalCer),  or  i.p.  with  5  mg  of  curdlan  (
g of α CD40. TL1A transcript was quantified by qPCR following 4 h, 6 
h and 24 h of stimulation. The most potent inducers of TL1A mRNA were poly(I:C) which 
induced an average 18 fold increase of TL1A mRNA expression in comparison to naive 
animals, Lipid A (average 19 fold increase) and LPS (average 12
3.4.). TL1A mRNA level peaked after 4h of stimulation with LPS and Lipid A, and after 
6h of stimulation with poly(I:C). It returned to the level of naive cells after 24 h. The other 
not significantly change the level of TL1A mRNA expression. 
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TL1A expression was examined by flow cytometry also on mouse T cells activated 
signal transduction from T cell 
receptor results in activation of T cells, but not 
other  cells,  present  in  the  population  of  splenocytes.  Activated  T  cells  transiently  up 
L1A after 24 h of stimulation with anti CD3 
Expression of TL1A on activated T cells. Splenocytes isolated from a WT C57BL/6 mouse were 
CD3 antibody for 24 h and 48 h. The cells were stained for the 
human IgG antibody (black line). 
Grey histograms represent staining with the isotype control for DR3.Fc (human IgG). The cells presented on 
lly gated on viable population. The presented results are representative of five 
Expression of TL1A mRNA was investigated also in splenocytes of C57BL/6 mice 
g of Lipid A (lipid component of 
stranded viral RNA (ligand 
g of unmethylated CpG sequences (CpG; ligand for TLR9), 50  g of 
N palmitoyl (R) Cys (S) 
OH  trihydrochloride  (Pam3CSK4;  ligand  for  TLR2),  2   g  of  α 
with  5  mg  of  curdlan  (β 1,3 glucan;  ligand  for 
L1A transcript was quantified by qPCR following 4 h, 6 
h and 24 h of stimulation. The most potent inducers of TL1A mRNA were poly(I:C) which 
fold increase of TL1A mRNA expression in comparison to naive 
d increase) and LPS (average 12 fold increase) (Figure 
3.4.). TL1A mRNA level peaked after 4h of stimulation with LPS and Lipid A, and after 
6h of stimulation with poly(I:C). It returned to the level of naive cells after 24 h. The other 





   
 
 





Figure 3.4. Expression of TL1A mRNA in mouse splenocytes. WT C57BL/6 mice (n=4 mice per time point) 
were injected i.v.  with 40  g of  LPS, 40  g of  Lipid  A, 50  g of poly(I:C), 50  g  of CpG, 50  g of 
Pam3CSK4, 2  g of α GalCer, or i.p. with 5 mg of curdlan or 500  g of α CD40 antibody. Following 4 h, 6 
h or 24 h of stimulation, total RNA was isolated from splenocytes, genomic DNA in the RNA samples was 
digested, RNA was reverse transcribed and the amount of TL1A transcript was quantified by qPCR. In each 
experiment the fold change was calculated using triplicate qPCR samples. 
   











Figure 3.5. Expression of TL1A on splenocytes stimulated with LPS in vivo. A C57BL/6 mouse was injected 
i.v. with 40  g of LPS. After 24 h of stimulation, splenocytes were stained for the presence of TL1A with 
DR3.Fc construct and PE conjugated goat anti human IgG antibody (black line). Grey histograms represent 
staining with the isotype control for DR3.Fc (human IgG). The cells presented on the histograms were gated 




















































Expression of the transmembrane form of T1A was detected on splenocytes of C57BL/6 
mice 24h  after the i.v. injection of 40  g of  LPS (Figure 3.5.),  although it  was much 
smaller than the level of up regulation of TL1A mRNA following stimulation with LPS. 
No expression of transmembrane TL1A was detected at the earlier time point (12 h). 
To determine whether TLR4 is the receptor responsible for up regulation of TL1A 
in splenocytes, C3H/HeJ mice (bearing an inactivating mutation in TLR4 (161)) and wild 
type C3H/HeN control mice were injected i.v. with 40  g of LPS and the amount of TL1A 
transcript  in  their  splenocytes  was  quantified  after  4h  of  stimulation.  C3H/HeN  mice 
showed  8 fold  higher  expression  of  TL1A  mRNA  than  non stimulated  mice  while 
C3H/HeJ  mice  showed  only  1.5 fold  increase  in  the  expression  of  TL1A  transcript 
compared  to  non stimulated  C3H/HeN  mice  (Figure  3.6.).  This  clearly  shows  that  up 












Figure 3.6. Expression of TL1A mRNA in splenocytes of C3H/HeN and C3H/HeJ mice (n=3 mice of each 
strain) stimulated with LPS. The mice were injected i.v. with 40  g of LPS. 4 h later, total RNA was isolated 
from splenocytes, genomic DNA in the RNA samples was digested, RNA was reverse transcribed and the 
amount of TL1A transcript was quantified by qPCR.  
 
3.2.2.  Specificity of TAN2 2 and DR3.Fc binding 
 
  Two reagents were used for detection of TL1A by flow cytometry – a monoclonal 
antibody (TAN2 2) and a soluble receptor (DR3.Fc). TAN2 2 antibody was raised in rats 
against the mouse homotrimeric form of TL1A. DR3.Fc is a fusion protein consisting of 







































  To check the binding specificity of these reagents, J558L cells stably transfected 
with  a  plasmid  vector  carrying  TL1A  cDNA  (J558L TL1A)  and  J558L  cells  stably 
transfected  with  an  empty  control  vector  (J558L PEF)  were  stained  with  TAN2 2  and 
DR3.Fc. Both TAN2 2 and DR3.Fc showed binding to J558L TL1A cells but none of the 
reagents bound to J558L PEF cells (Figure 3.7.A and B). Both reagents showed binding 
also  to  EG.7  cells     mouse  thymoma  cells,  naturally  expressing  transmembrane  TL1A 
(Figure 3.7.C). Interestingly, TAN2 2 bound more strongly to J558L TL1A cells than to 
EG.7 cells, whereas DR3.Fc appeared to bind equally well to both J558L TL1A and EG.7 
cells (Figure 3.7.B and C). Unlike DR3.Fc, TAN2 2 did not show any binding to T cells 
activated  in  vitro  with  10   g/ml  of  anti CD3  antibody  (Figure  3.7.E),  whereas  neither 
TAN2 2 nor DR3.Fc bound to non activated T cells (Figure 3.7.D). 
  TAN2 2 and DR3.Fc were used also for staining of HEK293T TL1A cells which 
were transiently transfected with pcDNA3.1/Zeo( ).TL1A vector carrying TL1A  cDNA 
and non transfected HEK293T cells. Both TAN2 2 and DR3.Fc showed higher binding to 
the transfected cells, although there was also some low level binding of DR3.Fc to the non 
transfected cells (Figure 3.8.). Titration of DR3.Fc binding to HEK293T cells showed that 
above a certain point (10
2 on logarithmic scale) this binding is saturable and specific on 
HEK293T TL1A cells (Figure 3.9.). Also, pre incubation of HEK293T TL1A cells with 
TAN2 2 but not with isotype control Mc39 16 antibody reduced the binding of DR3.Fc to 
the cells (Figure 3.10.A). Pre incubation with TAN2 2, however, did not block binding of 













Figure 3.7. Binding of TAN2
(D) and activated T cells (E). The cells were stained for the presence of TL1A with TAN2
PE conjugated  goat  anti 
antibody (black lines). Grey  histograms represent staining  with isotype controls  for TAN2
(MC39 16  and  human  IgG,  respectively).  The  cells  were  electronically 







Binding of TAN2 2 and DR3.Fc to J558L PEF (A), J558L TL1A (B), EG.7 (C) non
(D) and activated T cells (E). The cells were stained for the presence of TL1A with TAN2
 rat  IgG  antibody  or  DR3.Fc  construct  and  PE conjugated  goat  anti
antibody (black lines). Grey  histograms represent staining  with isotype controls  for TAN2
16  and  human  IgG,  respectively).  The  cells  were  electronically  gated  on  viable  population.  The 









TL1A (B), EG.7 (C) non activated 
(D) and activated T cells (E). The cells were stained for the presence of TL1A with TAN2 2 antibody and 
conjugated  goat  anti human  IgG 
antibody (black lines). Grey  histograms represent staining  with isotype controls  for TAN2 2 or DR3.Fc 




Figure 3.8. Binding of TAN2
transfected  with  a  plasmid  encoding  TL1A.  The  cells  were  stained  with 
conjugated goat anti rat IgG antibodies or 
IgG PE antibody (black lines). Grey histograms represent staining with the isotype controls for TAN2
DR3.Fc (Mc39 16 and human IgG, respectively). The cells were electronically gated on viable population. 









Figure 3.9. Titration of DR3.Fc binding to HEK293T cells transfected with a 
























Binding of TAN2 2 and DR3.Fc to non transfected HEK293T cells (A) and HEK 293T cells 
transfected  with  a  plasmid  encoding  TL1A.  The  cells  were  stained  with  10   g/ml
rat IgG antibodies or 10  g/ml of DR3.Fc construct and PE
PE antibody (black lines). Grey histograms represent staining with the isotype controls for TAN2
16 and human IgG, respectively). The cells were electronically gated on viable population. 
results are representative of four separate experiments. 





























transfected HEK293T cells (A) and HEK 293T cells 
10   g/ml  of  TAN2 2  and  PE 
PE conjugated goat anti human 
PE antibody (black lines). Grey histograms represent staining with the isotype controls for TAN2 2 and 
16 and human IgG, respectively). The cells were electronically gated on viable population. 
plasmid vector encoding TL1A 
TL1A-transfected HEK293T (above 10^2)















Figure 3.10. Binding of DR3.Fc to HEK293T cells transfected with a plasmid vector encoding TL1A (A) 
and T cells activated in vitro
with 20  g/ml of TAN2 2 antibody or its isotype control (Mc39
with DR3.Fc and PE conjugated goat anti
the negative control for DR3.Fc (human IgG). The cells were electronically gated on viable population. The 











Binding of DR3.Fc to HEK293T cells transfected with a plasmid vector encoding TL1A (A) 
in vitro with 10  g/ml of anti CD3 antibody (B). The cells were pre
2 antibody or its isotype control (Mc39 16) and stained for the presence of TL1A 
conjugated goat anti human IgG (black lines). Grey histograms repre
the negative control for DR3.Fc (human IgG). The cells were electronically gated on viable population. The 




Binding of DR3.Fc to HEK293T cells transfected with a plasmid vector encoding TL1A (A) 
CD3 antibody (B). The cells were pre incubated on ice 
16) and stained for the presence of TL1A 
human IgG (black lines). Grey histograms represent staining with 
the negative control for DR3.Fc (human IgG). The cells were electronically gated on viable population. The 69 
 
3.3.  Discussion 
 
  The  most  potent  inducers  of  TL1A  expression  were  LPS,  Lipid  A  (ligands  for 
TLR4) and poly(I:C) (ligand for TLR3) which very rapidly up regulated the expression of 
TL1A transcript. It is consistent with the results obtained by other research groups (121, 
123, 124) which were published after the completion of this part of research. In contrast to 
the data published by Shih et al. (121), no up regulation of TL1A expression was detected 
following stimulation of TLR2 and TLR9. In contrast to the research presented in this 
thesis, Shih et al. (121) investigated the expression of TL1A in human monocytes where 
TL1A expression may be regulated in a different way than in murine cells. Rapid (4–6 h) 
up regulation  of  TL1A  transcript  in  activated  bone  marrow derived  dendritic  cells  and 
splenocytes and lack of its expression on naive cells of the immune system indicates that 
this molecule is involved in co stimulation of T cells. Furthermore, up regulation of TL1A 
in response to stimulation with pathogen associated molecular patterns, such as LPS or 
poly(I:C), suggests that TL1A is involved in immune response directed against pathogen 
infection, although there are no published reports concerning the role of TL1A in host 
defence. 
The  increase  of  the  expression  of  the  transmembrane  form  of  TL1A  on  bone 
marrow derived dendritic cells and splenocytes stimulated in vitro or in vivo with LPS is 
much smaller than the increase of the expression of TL1A mRNA in these cells. However, 
the expression of transmembrane TL1A was much higher on activated T cells than on bone 
marrow derived dendritic cells which is consistent with the finding of Meylan et al. (123) 
who found that TL1A can be cleaved off the plasma membrane in endothelial and dendritic 
cells but not in T cells. Other report shows that TL1A is released from monocytes and 
dendritic cells stimulated with immune complexes in vitro and the level of soluble TL1A 
detected in the culture supernatants correlates with peak TL1A mRNA levels. However, 
high expression of TL1A was detected only on the surface of monocytes, whereas dendritic 
cells show only a modest induction of transmembrane TL1A on their surface following 
stimulation  with  immune  complexes.  Furthermore,  supernatant  of  dendritic  cell  culture 
contained  higher  concentration  of  soluble  TL1A  than  the  monocyte  supernatant  which 
suggests that there is a difference in the protease activity in dendritic cells and monocytes, 
although the enzyme involved in shedding of TL1A remains unidentified (119). Therefore 
it is highly possible that TL1A produced by bone marrow derived dendritic cells exists 70 
 
primarily in a soluble form, although the relatively low expression of the transmembrane 
form of TL1A may also be biologically significant.   
  Transient  up regulation  of  TL1A  on  activated  T  cells  suggests  that  it  plays  an 
important role during clonal expansion phase of the immune response where T cells can be 
co stimulated  by  other  T  cells  expressing  TL1A  in  an  autocrine  or  paracrine  manner. 
Similar  occurrence  was  observed  in  an  in  vitro  system  where  expansion  and  cytolytic 
function of cytotoxic T cells was enhanced by CD4
+ T cells which provided co stimulatory 
signals mediated by cell surface molecules (162).  
  The data presented in this chapter show that the only receptors which stimulation 
induces expression of TL1A are TLR3 and TLR4, although they up regulate TL1A with 
different kinetics. IRF 3 is the only transcription factor activated by both TLR3 and TLR4 
(via  adaptor  proteins  TRIF  and  TRAM)  but  not  other  TLRs  or  dectin 1  (158,  163). 
Furthermore, triggering of TLR4 by LipidA induces only the TRIF mediated signalling 
pathway, but not the MyD88 pathway, which results in activation of IRF3 (164). IRF3 is 
constitutively expressed in cells as a monomer and undergoes dimerization and nuclear 
translocation following the phosphorylation which leads to its activation. IRF3 binds to 
target DNA sequences but does not have an intrinsic transcriptional activity; it activates 
transcription  of  target  genes  by  recruiting  co activators  p300  and  cAMP responsive 
element binding protein (CREB) binding protein (CBP) (158, 165). Some reports suggest 
that IRF3 is activated by two different signalling pathways – one is triggered as a result of 
stimulation of TLR3 and the other as a result of stimulation of TLR4 (166). On the other 
hand,  others  speculate  that  TLR3   and  TLR4 mediated  induction  of  IRF 3  differs 
quantitatively rather than qualitatively (158). Finally, TLR3 and TLR4 may have different 
expression patterns on the investigated cells. These are possible explanations as to why 
stimulation  of  TLR3  up regulates  TL1A  expression  with  slightly  delayed  kinetics  in 
comparison to TLR4 mediated up regulation of TL1A. An interesting question is whether 
IRF3  activated  the  transcription  of  TL1A  gene  directly  or  via  other  proteins.  IRF3  is 
known to induce expression of type I interferons, which in turn activate the expression of 
interferon inducible genes via JAK/STAT signalling pathway (158), therefore it is possible 
that expression of TL1A is induced indirectly via type I interferon.  
  Very little is known about the quaternary structure of TL1A. Members of the TNF 
superfamily are trimeric proteins, therefore the difference in binding specificity of TAN2 2 
and DR3.Fc led to the hypothesis that TL1A naturally exists in two biologically active 
forms – homo  and heterotrimeric, although it remains unknown which molecule forms the 71 
 
heterotrimer together with a monomer (or two monomers) of TL1A. We hypothesize that 
DR3.Fc  binds  to  both  homo   and  heterotrimeric  form  of  TL1A  while  TAN2 2  (raised 
against the homotrimeric form of TL1A) binds only to the homotrimeric form. TAN2 2 
antibody as well as DR3.Fc construct showed binding to both J558L TL1A and HEK293T 
TL1A cells transfected with TL1A cDNA, therefore these cells probably express only the 
homotrimeric form of TL1A. In contrast to DR3.Fc, TAN2 2 does not bind to activated T 
cells which are expected to express the heterotrimeric form of TL1A. EG.7 cells probably 
express express both forms of TL1A, although the heterotrimeric form predominates, as 
DR3.Fc  shows  higher  binding  to  these  cells  than  TAN2 2.  The  epitope  recognised  by 
TAN2 2  is  most  probably  located  on  the  border  between  two  monomeric  subunits  of 
homotrimeric TL1A (Figure 3.11.). If it was located on the monomeric subunit of TL1A, 
TAN2 2 would bind to both forms of TL1A. There is evidence that injection of TAN2 2 
reduces clinical score in mice with collagen induced arthritis (102) which suggests that the 
homotrimeric  form  of  TL1A  has  a  biological  activity.  Furthermore,  homotrimeric 
recombinant  TL1A  and  homotrimeric  TL1A  expressed  by  J558L TL1A  cells  show 
biological activity (Chapter 4). Domains responsible for ligand binding and trimerization 
of  TNFSF  members  are  150  amino  acid  long,  C terminal,  TNF  homology    domains 
(THDs) (78). Since all of the three isoforms of TL1A – VEGI 174, VEGI 192 and the full 
length TL1A – share the same 151 amino acid long C terminal domain (113), it is possible 
that the binding partner for TL1A is one of its truncated isoforms – VEGI 174 or VEGI 
192. Possible differences in the secondary or tertiary structure of the THD domain in the 
three isoforms of TL1A may result from the fact that homotrimers of the isoforms bind to 
different receptors (the main receptor for VEGI 174 and VEGI 192 has not been identified 
yet,  although  it  is  different  than  DR3  (111))  but  still  may  allow  the  formation  of 
heterotrimers.  The  experiments  presented  in  this  thesis,  that  led  to  the  hypothesis  that 
TL1A exists in both homo  and heterotrimeric form were conducted on mice, on mice cells 
or using mice cDNA of TL1A. VEGI 174 and VEGI 192 were detected only in humans 





















THE ROLE OF TL1A/DR3 INTERACTIONS IN COSTIMULATION OF T CELLS 
 
4.1.  Introduction 
 
  The  research  presented  in  this  chapter  concentrates  mostly  on  analysis  of  how 
TL1A/DR3 interactions affect proliferation and effector functions of CD8
+ T cells. A study 
by Tan et al. (135) shows that DR3 mRNA is strongly up regulated in activated CD8
+ T 
cells but a role for DR3 in CD8
+ T cell responses has not been described so far. CD8
+ 
cytotoxic T cells play a critical role in tumour rejection in vivo. They kill tumour cells 
through secretion of granzymes, perforin or molecules belonging to the tumour necrosis 
factor  (e.g.  FasL)  (29,  30).  Treatment  of  melanoma  patients  with  CD8
+ enriched 
lymphocytes results in the regression of the tumour in most of the patients (167, 168). 
Also, the transfer of antigen specific CD8
+ T cells into tumour bearing mice results in the 
eradication of tumour (169). Furthermore, CD4
+ T cells can develop cytotoxic activity and 
mediate rejection of melanoma tumours based on MHC class II restricted recognition of 
tumours (170, 171) which indicates that cytotoxic T cells play a key role in anti tumour 
immunity.  
  The role of TL1A in CD8
+ T cell mediated antitumour immunity was examined in 
BALB/c mice injected subcutaneously with J558L tumour cells expressing transmembrane 
TL1A  (J558L TL1A)  or  control  J558L  cells  transfected  with  an  empty  control  vector 
(J558L PEF).  J558L  are  plasmacytoma  cells,  derived  from  BALB/c  mice,  which  form 
solid tumours following a subcutaneous injection. To determine whether CD8
+ T cells take 
part in TL1A mediated rejection of tumour, the mice were depleted of CD4
+ and/or CD8
+ 
T cells using the appropriate depleting antibodies. The influence of TL1A/DR3 interactions 
on  the  activity  of  CD8
+  T  cells  was  also  investigated  in  vitro  by  measuring  their 
proliferation, secretion of effector cytokines and expression of activation/memory markers 
in response to TL1A stimulation. 
  There are reports showing that TL1A enhances proliferation (136) of NK cells and 
their  cytotoxicity  (150);  furthermore,  the  initial  tumour  experiments  presented  in  this 
chapter  suggest  that  NK  cells  may  play  a  role  in  TL1A mediated  rejection  of  J558L 
tumour, therefore the influence of TL1A on the activity of NK cells was also investigated.  74 
 
  NK (natural killer) cells are cytotoxic lymphocytes that constitute a major part of 
the innate immune system and represent 5 15% of circulating blood lymphocytes, although 
they  make up  greater  proportion  in  some  tissues  (e.g.  liver)  (172).  NK  cells  play  an 
important role in rejection of tumours and in response against viral and parasitic infections 
and  act  during  the  first  4 6  hours  of  the  infection.  They  kill  target  cells  by  releasing 
perforin and granzymes (2) in a way similar to cytotoxic T cells (section 1.3.). NK cells do 
not express T cell receptor or CD3 molecules. So far, no universal marker of NK cells has 
been identified but they usually express CD16 and CD56 molecules in humans and NK1.1 
in  C57BL/6,  FVB/N  and  NZB  mice.  CD49b  and  asialo GM1  are  used  as  markers  for 
identification of NK cells in mice strains that do not express NK1.1 (e.g. BALB/c) (173), 
although the expression of asialo GM1 was detected also on a subpopulation of central 
memory  CD44
high  CD8
+  T  cells  (174).  Their  activity  is  strictly  regulated  to  prevent 
autoreactivity against the host. It is believed that the net balance of signals from activating 
and inhibitory receptors enables NK cells to provide effective killing of target cells, while 
maintaining self tolerance. Key regulators of NK cell activity are MHC class I molecules 
that provide NK cells with a means of identifying host cells. Down regulation of MHC 
class I molecules on tumour or virus infected cells permits activation of NK cells. MHC 
class I molecules are recognized by several inhibitory receptors expressed by NK cells – 
the most important are killer inhibitory receptors (KIRs) and CD94/NKG2A. The ability of 
NK  cells  to  lyse  target  cells  requires  both  the  lack  of  MHC  class  I  expression  and 
expression of appropriate ligands on target cells that are recognised by activating receptors 
of NK cells. These receptors include natural cytotoxicity receptors (NKp30, NKp44 or 
NKp46), immunoglobulin G receptor CD16 but also some receptors belonging to the KIR 
superfamily  (172).  Activating  receptors  recognise  ligands  or  cytokines  secreted  by  on 
accessory  cells  that  help  in  activation  of  T  cells,  such  accessory  cells  are  monocytes, 
macrophages and dendritic cells. It is also possible that NK cells directly bind pathogen 
associated molecular patterns (175).  75 
 
4.2.  Results 
 
4.2.1.  TL1A mediated rejection of tumours 
 
  To investigate whether TL1A enhances anti tumour response, wild type BALB/c 
mice  were  injected  subcutaneously  with  5x10
6  J558L  cells  transfected  with  a  plasmid 
carrying TL1A cDNA (J558L TL1A cells) or 5x10
6 control J558L cells transfected with an 
empty vector (J558L PEF cells). J558L TL1A cells used for tumour experiments were a 
mixture of equal amounts of three different clones of J558L TL1A cells – J558L TL1A 
#1.1, J558L TL1A #7.5 and J558L TL1A #19.2. All of the J558L TL1A clones showed 
equal, high expression of transmembrane TL1A, while J558L PEF cells did not express it 
(Fig. 4.1.A). The growth rate of all three clones of J558L TL1A cells and J558L PEF cells 
was measured by in vitro 
3H thymidine incorporation assay. In this method, 
3H thymidine 
is incorporated into DNA of proliferating cells and its accumulation inside the cells can be 
determined by measuring its β decay by liquid scintillation counting.  Even though the 
uptake of 
3H thymidine was low, the three clones of J558L TL1A and J558L PEF cells 
showed a similar growth rate (Fig. 4.1.B). Furthermore, J558L TL1A and J558L PEF cells 
grew at the very similar rate in BALB/c SCID mice (Fig. 4.3.). In wild type BALB/c mice 
J558L PEF tumour cells grew progressively and all of the mice had to be sacrificed 30 
days after the inoculation of tumour (median survival 25 days). In contrast, J558L TL1A 
cells were rejected in most wild type mice (Fig. 4.2.). In many cases, J558L TL1A tumour 
cells grew initially following the injection into BALB/c mice, but the tumours regressed 










 Figure 4.1. Expression of TL1A and proliferation of J558L
#19.2 and J558L PEF cells. (A) Expression of TL1A. The cells were stained with biotin
antibody  and  APC conjugated  streptavidin.  The  presented  cells  were 
presented results are representative of three separate experiments. (B) 
rate was measured by incorporation of 
presented results are mean values ±SE.
   
  
Figure 4.2. Survival and tumour growth in wild
J558L TL1A cells (4 or 5 animals per group, respectively). Animals were sacrificed when the tumour size 
reached  150  mm
2.    The  presented  results  are  representative  of  three  separate  experiments.  P  value  was 
calculated using log rank (Mantel
 




























Expression of TL1A and proliferation of J558L TL1A #1.1, J558L
PEF cells. (A) Expression of TL1A. The cells were stained with biotin
conjugated  streptavidin.  The  presented  cells  were  gated  on  a  viable  population.  The 
presented results are representative of three separate experiments. (B) In vitro proliferation assay. The growth 
rate was measured by incorporation of 
3H thymidine assay. The experiment was conducted in triplicates, the 
esented results are mean values ±SE. 
 
Survival and tumour growth in wild type BALB/c mice injected s.c.
TL1A cells (4 or 5 animals per group, respectively). Animals were sacrificed when the tumour size 
.    The  presented  results  are  representative  of  three  separate  experiments.  P  value  was 
rank (Mantel Cox) test. 

































TL1A #1.1, J558L TL1A #7.5, J558L TL1A 
PEF cells. (A) Expression of TL1A. The cells were stained with biotin conjugated TAN2 2 
gated  on  a  viable  population.  The 
proliferation assay. The growth 
thymidine assay. The experiment was conducted in triplicates, the 
s.c. with 5x10
6 J558L PEF or 
TL1A cells (4 or 5 animals per group, respectively). Animals were sacrificed when the tumour size 
.    The  presented  results  are  representative  of  three  separate  experiments.  P  value  was 
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  Similar experiment was conducted in T and B cell deficient BALB/c SCID mice. In 
this  case,  both  J558L PEF  and  J558L TL1A  cells  grew  progressively  following  the 
subcutaneous injection of tumour cells, although the survival of mice injected with J558L 
TL1A cells was slightly, but statistically insignificantly longer – median survival for the 
mice injected with J558L PEF cells was 12 days, while for the mice injected with J558L 
TL1A  cells  was  18  days  (Fig  4.3.).  These  results  show  that  TL1A mediated  tumour 
rejection requires adaptive immune response. 
 
Figure 4.3. Survival and tumour  growth in BALB/c SCID  mice injected s.c.  with 5x10
6 J558L PEF or 
J558L TL1A cells (5 animals per group). Animals were sacrificed when the tumour size reached 150 mm
2.
 
The presented results are representative of two separate experiments. P value was calculated using log rank 
(Mantel Cox) test. 
 
  To assess the role of T cell subsets in TL1A mediated anti tumour immunity, wild 
type BALB/c mice were depleted of CD4
+, CD8
+ cells or both of these populations and 
inoculated  s.c.  with  J558L TL1A  cells.  There  was  also  a  control  group  of  wild type 
BALB/c mice inoculated with J558L PEF cells. Depletion of CD4
+ and/or CD8
+ cells was 
confirmed in one randomly chosen mouse from each group by flow cytometry analysis of 
blood  samples  10  days  following  the  administration  of  depleting  antibodies.  The 
percentage of CD4
  T cells in mice depleted of CD8
+ cells decreased from 11.55% in non 
depleted mice to 1.56% and in mice depleted of both CD4
+ and CD8
+ cells to 1.09% while 
the percentage of CD8
  T cells decreased from 31.59% in non depleted mice to 0.69% in 
mice depleted of CD4
+ cells and to 0.92% in mice depleted of both CD4
+ and CD8
+ cells 
(Figure 4.4.A), showing that the depletion had worked according to the expectations. Only 
depletion of CD8
+ cells and both CD4
+ and CD8
+ cells resulted in prevention of tumour 















































rejection,  clearly  showing  that  CD8
+  cells  are  crucial  for  TL1A mediated  anti tumour 
immunity (Figure 4.4.B). 
  Slightly prolonged survival of BALB/c SCID mice inoculated with J558L TL1A 
tumour cells compared to the same mice inoculated with J558L PEF cells (Figure 4.3.) and 
longer survival of mice depleted of CD8
+ and/or CD4
+ cells and inoculated with J558L 
TL1A cells compared to wild type BALB/c mice inoculated with J558L PEF cells (Figure 
4.4.B) suggests that there may be also other cells of the immune system that take part in 
TL1A mediated tumour rejection. Since BALB/c SCID mice are devoid of T and B cells 
but have NK cells, these cells were potential candidates. To investigate this problem in 
more  detail,  NK  cells  were  isolated  from  spleens  of  BALB/c  SCID  mice,  which  have 
higher percentage of NK cells compared to wild type BALB/c mice, and stained for the 
presence  of  DR3  to  check  whether  these  cells  can  respond  to  TL1A  stimulation.  The 
isolation of the cells was based on the expression of CD49b which is known to be a marker 
of  NK  cells.  The  obtained  population  of  cells  contained  86.74%  of  CD49b
+  cells  and 
15.73%  of  them  expressed  DR3  (Figure  4.5.).  To  investigate  whether  TL1A mediated 
tumour rejection depends also on NK cells, wild type BALB/c mice were injected with 
anti asialo  GM1  antibody  and  inoculated  with  J558L TL1A.  In  contrast  to  the  control 
group (non depleted wild type BALB/c mice), NK depleted animals did not reject TL1A 
transfected tumours and showed relatively short survival rate – median survival for NK 
depleted mice was 16 days compared to undefined median survival time for the animals 
from the control group (Figure 4.6.). Because NK cells are the main effector cells that take 
part in the rapid anti tumour response mediated by the innate immune system, an in vivo 
killing  assay  was  performed  to  determine  whether  TL1A transfected  tumour  cells  are 
preferentially eliminated during the first hours after the injection into mice. BALB/c SCID 
mice were injected i.p. with a mixture of 5x10
6 J558L PEF and 5x10
6 J558L TL1A cells 
labelled with different concentrations of carboxyfluoresceine succinimidyl ester (CFSE; 
0.5   M  and  10   M,  respectively).  CFSE  is  a  fluorescent  cell staining  dye  used  for 
monitoring of cell division which binds to the cell surface and therefore cell divisions 
cause progressive halving of CFSE fluorescence on daughter cells. The cells were isolated 
from the peritoneal cavity of mice and the amount of CFSE
low (J558L PEF) and CFSE
high 
(J558L TL1A) cells together with the number of total population of tumour cells were 
assessed after 1h and 7h. Even though the overall number of tumour cells decreased with 
time, there was no difference between the amounts of J558L PEF and J558L TL1A cells 
(Figure 4.7.), which clearly shows that TL1A expression on tumour cells does not induce 79 
 
their selective killing by the cells of the innate immune system. The decrease in the total 
numbers of tumour cells can be explained by either non selective killing or migration of 
the tumour cells from the peritoneal cavity, while the decrease in the percentage of total 
population of the tumour cells can be additionally explained by the migration of the cells 
of the innate immune system into the peritoneal cavity. 
  To  check  whether  TL1A  can  induce  long term  memory,  mice  that  had  been 
inoculated with J558L TL1A cells and had rejected tumours were re challenged with wild 
type J558L cells 110 day after the initial inoculation. In contrast to the control group (wild 
type mice inoculated with J558L cells), the re challenged mice showed delayed tumour 
growth and significantly prolonged survival – median survival for the re challenged group 
was 48 day, while for the control group only 16 days (Figure 4.8.), suggesting that the 
initial injection of TL1A transfected tumour cells led to formation of memory cells and 









































Figure 4.4. (A) Staining of blood samples from naive, CD4 depleted, CD8 depleted or both CD4 and CD8 
depleted wild type BALB/c mice. The cells were stained with APC conjugated anti CD3 antibody and FITC 
conjugated  anti CD4  or  FITC conjugated  anti CD8  antibody  and  analysed  by  flow  cytometry.  The  cells 
presented on the histograms were electronically gated on viable cells. The presented results are representative 
of  two  separate  experiments.  (B)  Survival  and  tumour  growth  in  wild type  BALB/c  mice  or  wild type 
BALB/c mice depleted of CD4
+, CD8
+ or both CD4
+ and CD8
+ cells (5mice per group) and injected s.c. with 
5x10
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Figure 4.5. (A) Isolation of NK cells (CD49b
+) from two spleens of BALB/c SCID mice. The cells were 
stained  with  FITC conjugated  anti CD49b  antibody  and  analysed  by  flow  cytometry  before  or  after  the 
isolation on CD49b specific magnetic beads (CD49b
  and CD49b
+ fractions). The gates on histograms show 
the percentage of CD49b
high population in each fraction of cells. The presented cells were electronically gated 
on viable cells. (B) Expression of DR3 on NK cells (CD49b
+). The cells from the CD49b
+ fraction were 
stained  also  with  both  FITC conjugated  anti CD49b,  biotin conjugated  anti DR3  antibody  and  APC 
conjugated  streptavidin,  and  analysed  by  flow  cytometry.  The  gate  R1  represents  the  percentage  of 
CD49b
+DR3
+ cells in the total population of the cells in the CD49b
+ fraction. The presented cells were 
electronically gated on viable cells. 
 
Figure 4.6. Survival and tumour growth in wild type BALB/c mice either depleted or non depleted of NK 
cells and injected s.c. with 5x10
6 J558L PEF or J558L TL1A cells (5 animals per group). Animals were 
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Figure 4.7. In vivo killing assay of J558L PEF and J558L TL1A cells. A mixture of 5x10
6 J558L PEF cells 
(labelled with 0.5  M CFSE) and 5x10
6 J558L TL1A cells (labelled with 10  M CFSE) was injected i.p. into 
BALB/c SCID mice. The cells were counted and analysed by flow cytometry for the presence of CFSE 
before the injection and after the indicated time points. (A) The gate R1 represents the percentage of tumour 
cells in the whole population of the cells isolated from the peritoneal cavity. The cells present on the ‘1h’ and 
‘7h’ histograms were electronically gated on the gate R1. The histogram representing the cells before the 
injection  was  gated  on  the  whole  population  of  cells.  The  presented  results  are  representative  of  two 
experiments. (B) Total numbers of tumour cells isolated from the peritoneal cavity at the indicated time 
points. The presented results are average values from two experiments ± SE. 
Before the injection 1h 7 h
CFSE
23.36% 6.02%
Before the injection 1h 7 h
R1 R1












































Figure 4.8. Survival and tumour growth in wild type BALB/c mice re challenged with 5x10
6 J558L cells 
110 days after the initial challenge with J558L TL1A cells and in wild type naive BALB/c mice inoculated 
with 5x10


























































4.2.2.  Characteristics of soluble recombinant TL1A (TL1A.CD4(d3+4)) 
 
  Soluble,  recombinant  fusion  TL1A  protein  (sTL1A)  was  used  as  an  alternative 
approach  to  investigate  the  role  of  DR3  in  CD8
+  T  cells.  sTL1A,  consisting  of  the 
extracellular part of TL1A (amino acids 72 251) fused to rat CD4 domains 3 and 4, was 
generated to investigate the function of TL1A in details both in vivo and in vitro. The rat 
CD4(d3+4)  was  used  as  a  tag  necessary  for  purification  of  the  recombinant  protein. 
Furthermore, it does not form multimeric quaternary structures, therefore the recombinant 
protein should retain the quaternary structure of native TL1A. cDNA encoding the protein 
has the length of 1233 bp, while the protein is 388 amino acids long. It has the mass of 
43.3 kDa, but taking into account the presence of four glycosylation sites, the overall mass 
of sTL1A is approximately 55 kDa. 
  Following  the  purification,  sTL1A  was  analysed  by  SDS polyacrylamide  gel 
electrophoresis  under  both  reducing  and  non reducing  conditions.  According  to  the 
expectations, the size of the protein was approximately 55 kDa (Figure 4.9.A). To check 
whether the protein has biological activity, splenocytes isolated from a C57BL/6 mouse 
were  stimulated  in  vitro  with  anti CD3  antibody  with  or  without  sTL1A  for  72h.  The 
recombinant TL1A significantly increased proliferation and secretion of IL 4 and IFN γ 
from the cells (Figure 4.9.B). sTL1A was not contaminated with endotoxin, therefore this 


















     
 
     
 
Figure 4.9. (A) Analysis of 10  g of sTL1A by SDS PAGE under reducing and non reducing conditions. 
The size of sTL1A is approximately 55 kDa. (B) Evaluation of biological activity of sTL1A. Splenocytes 
isolated from a wild type C57BL/6 mouse were stimulated in vitro on a 96 well plate (1x10
5 cells/well) with 
indicated concentrations of anti CD3 antibody and 2  g/ml of sTL1A. Proliferation of the cells was measured 
by 
3H thymidine assay, secretion of IL 4 and IFN γ was measured by ELISA following 72 h of stimulation. 
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4.2.3.  TL1A/DR3 interactions co stimulate T cells in vitro 
 
  Splenocytes isolated from OTII mice (which express TCR specific for OVA323 339 
peptide) were stimulated in vitro with OVA323 339 peptide (ISQAVAAHAEINEAGR) with 
or  without  TL1A.CD4(d3+4)  and  TAN2 2  (anti mouse  TL1A)  antibody,  Mc39 16 
antibody (anti Bcl1 idiotype; isotype control for TAN2 2) or N22 (anti murine MHC class 
II) antibody. OVA323 339 peptide stimulates TCR expressed by OTII cells (CD4
+ T cells) 
present in the population. Even though the whole population of splenocytes from OTII 
mice was used in this experiment, the increase of 
3H thymide incorporation was due to 
increased  proliferation  of  OTII  cells  only,  which  was  confirmed  by  N22  antibody 
stimulation  that  completely  blocked  the  response  to  OVA323 339  peptide  (Figure  4.10.). 
Stimulation with sTL1A increases proliferation of OTII cells 1.15  to 1.75 fold depending 
on the concentration of OVA323 339 peptide (0.01 or 0.1  M, respectively). This effect was 
not present when the cells were stimulated with 1  M OVA323 339 peptide because the 
increase of OTII cells proliferation induced by the high dose of the peptide exceeded the 
effect induced by sTL1A which was possibly overrun by other costimulatory molecules 
present in the environment. The effect induced by sTL1A was specific because it was 
blocked by TAN2 2 antibody; furthermore, when the cells were stimulated with sTL1A in 
the  presence  of  the  control  monoclonal  antibody  Mc39 16  antibody,  the  increase  in 
proliferation was similar to the one achieved when the cells were stimulated only with 







Figure 4.10. Proliferation of OTII cells in vitro. Splenocytes isolated from an OTII transgenic mouse were 
stimulated on a 96 well plate (1x10
5 cells/well) in the presence or absence of indicated concentrations of 
OVA323 339 peptide, 2  g/ml of sTL1A, 50  g/ml of TAN2 2, 50  g/ml of Mc39 16 and/or 10  g/ml of N22. 
Following 72 h of stimulation, proliferation of the cells was measured by 
3H thymidine incorporation assay. 
The experiment was conducted in triplicates; the presented results represent mean values ± SE. 
 
  Because CD8
+, but not CD4
+ T cells, play a key role in TL1A mediated rejection of 
J558L tumour, their response to TL1A stimulation was examined more carefully. The role 
of  TL1A/DR3  interaction  in  antigen specific  CD8
+  T  cell  responses  was  examined  on 
OVA specific TCR transgenic OTI T cells. Unless stated otherwise in the figure legends, 
the  experiments  on  OTI  T  cells  were  performed  on  CD4
+  cell depleted  population  of 
splenocytes isolated from an OTI transgenic mouse. A representative result of CD4
+ cell 
depletion is presented in the Figure 4.11. Naive OTI T cells do not express DR3 on their 
surface,  however  its  expression  is  up regulated  following  stimulation  with  OVA257 264 
peptide  (SIINFEKL)  (Figure  4.12.),  showing  that  activated  CD8
+  T  cells  can  directly 
respond to TL1A stimulation. Addition of sTL1A to CD4
+ cell depleted OTI splenocytes 
enhanced proliferation of antigen specific CD8
+ T cells 1.5  to 1.97 fold depending on the 
SIINFEKL  concentration  used.  This  effect  was  abolished  by  anti TL1A  (TAN2 2) 
monoclonal  antibody,  but  not  by  the  isotype  control  monoclonal  antibody  Mc39 16, 
showing that it is specific for sTL1A (Figure 4.13.A). sTL1A also increased the CFSE 
dilution on OTI T cells stimulated with antigen for 48 h or 72 h. This effect was also 
inhibited by TAN2 2 antibody (Figure 4.13.B). Furthermore, stimulation of the cells in the 
presence of anti CD25 and anti IL 2 antibodies (PC61 and S4B6, respectively) or anti 
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Figure 4.11. Example of depletion of CD4
OTI transgenic mouse. The cells were stained with PE
antibodies  and  analysed  by  flow  cytometry  before  and  after  the  depletion.  The  presented  ce
electronically gated on viable population. 
Figure 4.12. Expression of DR3 on OTI T cells stimulated with SIINFEKL. CD4
isolated from an OTI transgenic mouse were stimulated 
pM SIINFEKL for 24 h, 48 h or 72 h. The cells were stained with APC
biotin conjugated anti DR3 antibody (black lines) or biotin
conjugated  anti DR3  antibody;  grey  histogr
stimulation. The presented cells were electronically gated on both CD8
 
 
CD86 antibodies (1610A1 and GL 1, respectively) and wi
showed  that  the  increase  of  OTI  T  cell  proliferation  in  response  to  TL1A  stimulation 
partially  depends  on  IL 2  and  CD80/CD86  stimulation  (Figure  4.13
investigation showed that sTL1A enhances production of IL 2 by OTI T cells
regulates expression of IL2Rα chain (CD25) on these cells (Figure 4.14.
2 may be involved in mediating TL1A induced increase in proliferation of CD8
Example of depletion of CD4
+ cells from the whole population of splenocytes isolated from an 
transgenic mouse. The cells were stained with PE conjugated anti CD4 and APC
antibodies  and  analysed  by  flow  cytometry  before  and  after  the  depletion.  The  presented  ce
electronically gated on viable population.  
Expression of DR3 on OTI T cells stimulated with SIINFEKL. CD4
transgenic mouse were stimulated in vitro on a 96 well plate (10
pM SIINFEKL for 24 h, 48 h or 72 h. The cells were stained with APC conjugated anti
DR3 antibody (black lines) or biotin conjugated goat IgG (isotype control for biotin
DR3  antibody;  grey  histograms)  and  PE conjugated  streptavidin  before  and  after  the 
stimulation. The presented cells were electronically gated on both CD8
+ and viable cells.
88 
1, respectively) and with or without sTL1A 
showed  that  the  increase  of  OTI  T  cell  proliferation  in  response  to  TL1A  stimulation 
80/CD86  stimulation  (Figure  4.13.A).  Further 
2 by OTI T cells and up 
5) on these cells (Figure 4.14.), indicating that 
induced increase in proliferation of CD8
+ T 
cells from the whole population of splenocytes isolated from an 
CD4 and APC conjugated anti CD8 
antibodies  and  analysed  by  flow  cytometry  before  and  after  the  depletion.  The  presented  cells  were 
Expression of DR3 on OTI T cells stimulated with SIINFEKL. CD4
+ cell depleted splenocytes 
well plate (10
5 cells/well) with 100 
conjugated anti CD8 antibody, 
conjugated goat IgG (isotype control for biotin 
conjugated  streptavidin  before  and  after  the 





Figure 4.13. (A) Proliferation of OTI cells. CD4
+ cells depleted splenocytes isolated from an OTI transgenic 
mouse  were  stimulated  in  vitro  on  a  96 well  plate  (10
5  cells/well)  with  indicated  concentrations  of 
SIINFEKL and 2  g/ml of sTL1A with or without 50  g/ml of anti TL1A (TAN2 2), 50  g/ml of anti Bcl1 
idiotype  (Mc39 16),  anti CD25  and  anti IL 2  antibodies  (10   g/ml  of  PC61  and  10   g/ml  of  S4B6, 
respectively) or anti CD80/anti CD86 antibodies (10  g/ml of 1610A1 and 10  /ml of GL 1). Proliferation of 
the cells was measured by 
3H thymidine incorporation assay after 72 h of stimulation. The experiments were 
conducted in triplicates, presented results are mean values ± SE. (B) CFSE dilution on OTI T cells. CFSE 
labelled, CD4
+ cells depleted splenocytes isolated from an OTI transgenic mouse were stimulated in vitro on 
a 96 well plate (10
5 cells/well) with 2.5 pM SIINFEKL with or without 2  g/ml of sTL1A and 50  g/ml of 
anti TL1A (TAN2 2). Following 48 h or 72 h of stimulation, the cells were stained with 1 g/ml of APC 
conjugated anti CD8 antibody and analysed by flow cytometry. The presented cells were electronically gated 
on both CD8
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Figure 4.14. (A) Secretion of IL 2 by OTI T cells. CD4
+ cells depleted splenocytes isolated from an OTI 
transgenic mouse were stimulated in vitro on a 96 well plate (10
5 cells/well) were stimulated with indicated 
concentrations of SIINFEKL peptide with or without 2  g/ml of sTL1A for 48 h. After that time, the cells 
were counted and the amount of IL 2 in the supernatant was measured by ELISA. The experiment was 
conducted in triplicates, the presented results represent mean values ±SE. (B) Expression of CD25 on OTI T 
cells stimulated with SIINFEKL peptide ± sTL1A. CD4
+ cells depleted splenocytes isolated from an OTI 
transgenic mouse were stimulated in vitro on a 96 well plate (2x10
5 cells/well) with 2.5 pM SIINFEKL 
peptide with (black line) or without (grey histogram) 2  g/ml of sTL1A for 24 h or 48 h. The cells were 
stained with APC conjugated anti CD8 antibody and FITC conjugated anti CD25 antibody before or after 
the stimulation. The presented cells were electronically gated on both CD8
+ and viable cells. 
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4.2.4.  TL1A/DR3 interactions co stimulate T cells in vivo 
  To determine how TL1A/DR3 interactions influence CD4
+ T cell responses in vivo, 
wild type C57BL/6 mice received an adoptive transfer of 5x10
6 OT II T cells. Following 
the adoptive transfer, OT II T cells represented ~3% of the total population of CD4
+ T 
cells. Administration of OVA323 339 peptide resulted in 1.33 fold increase in the numbers of 
OT II cells at the peak of the response (day 4), while administration of OVA323 339 peptide 
together  with  sTL1A  resulted  in  2.66 fold  increase  in  OT II  cells  at  the  peak  of  the 
response (day 4), although this difference was not statistically significant (Figure 4.15.). 
The difference in the response between the mice that were injected with OVA323 339 peptide 
alone and the ones which received OVA323 339 peptide together with sTL1A  was more 
significant  during  the  contraction  phase  (days  6 10)  (Figure  4.15.).  This  indicates  that 
TL1A/DR3 interaction enhances survival rather than proliferation of CD4
+ T cells. On day 
10, the mice from both groups received an injection of OVA323 339 peptide in complete 
Freund’s adjuvant to check whether previous stimulation with sTL1A can break tolerance 
to OVA323 339 peptide induced after the first injection. However, there was not any striking 










Figure 4.15. OT II T cell response in vivo. 3 wild type C57BL/6 mice adoptively transferred with OT II cells 
were injected i.v. with 100  g of OVA323 339 peptide on day 1 (white dots), another 3 mice received also i.v. 
injections of 200  g of sTL1A on days 1, 2 and 3 (black dots). Mice from both groups were injected s.c. at 
the base of the tail with 200  g of OVA323 339 peptide on day 10. Accumulation of OT II cells was determined 
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conjugated anti Vα2 and FICT conjugated anti Vβ5 antibodies on indicated days. P values were calculated 
using two tailed t test, n=3 mice per time point. 
  The effect of TL1A/DR3 interactions on CD8
+ T cell responses was determined in 
vivo in wild type C57BL/6 mice that received an adoptive transfer of 1x10
6 OT I cells. 
Following the adoptive transfer, OT I cells represented ~0.1% of the total peripheral blood 
lymphocytes (PBLs) and administration of SIINFEKL alone resulted in a 12 fold increase 
in their numbers at the peak of the response (day 3) while administration of SIINFEKL 
together with sTL1A resulted in 81 fold increase in the number of OT I T cells at the peak 
of the response (Figure 4.16.A). A similar effect was observed also in the spleens of mice 3 
days following the adoptive transfer and injection of SIINFEKL ± sTL1A; furthermore, the 
effect of sTL1A was abolished by concurrent injection of TAN2 2 (anti TL1A) antibody 
(Figure  4.16.B).  CFSE labelled  OT I  T  cells  adoptively  transferred  into  wild type 
C57BL/6 mice showed higher dilution of CFSE on day 3 after the adoptive transfer in mice 
injected with both SIINFEKL  and sTL1A than in mice injected only  with SIINFEKL. 
Again, this effect was not present in mice that were injected with SIINFEKL, sTL1A and 
TAN2 2 (Figure 4.16.C), showing that TL1A can directly enhance proliferation of CD8
+ T 
cells in vivo.  
  Experiments conducted in vitro showed that TL1A enhances production of IL 2 by 
CD8
+ T cells and that TL1A induced proliferation of these cells is partially dependent on 
IL 2.  However,  in  vivo  the  increased  proliferation  following  DR3  stimulation  is 
independent  of  IL 2,  since  administration  of  IL 2  neutralizing  antibodies  together  with 
sTL1A  did  not  change  the  accumulation  of  OT I  cells  or  the  intensity  of  CFSE 
fluorescence  on  OT I  T  cells  which  was  checked  at  the  peak  of  the  response  (day  3) 
following  the  adoptive  transfer  of  OT I  cells  into  wild type  C57BL/6  mice  and 
administration of antigen (Figure 4.17.). Expression of CD25 on CD4
+ T cells isolated 
from spleens of these mice was up regulated following administration of sTL1A together 
with antigen but when IL 2 neutralizing antibodies were administered concurrently, it was 
similar to the level of the cells stimulated with the antigen alone (Figure 4.18.A). A similar 
effect was observed on OT I T cells, although overall expression of CD25 was much lower 
than on CD4
+ T cells (Figure 4.18.B). This shows that IL 2 neutralizing antibodies worked 
properly and decreased the level of IL 2 which is known to up regulate the expression of 
its own receptor (CD25) (176). The response was assessed also by measurement of the 
level of expression of killer lectin like receptor G1 (KLRG1) and CD62L. KLRG1 is a C 93 
 
type lectin like inhibitory receptor predominantly expressed on effector T cells. Its main 
role  is  raising  the  activation  threshold  for  T  cells  and  NK  cells,  thereby  preventing 
autoreactivity (177). CD62L (L selectin) is an adhesion molecule which acts as a homing 
receptor to enter secondary lymphoid organs, therefore its expression is down regulated on 
activated T cells and effector memory T cells which are present in the periphery (2). In 
vivo stimulation with SIINFEKL and sTL1A with or without IL 2 neutralizing antibodies 
increased  the  percentage  of  CD4
+  FoxP3
+  regulatory  T  cells,  but  did  not  change  the 
expression of KLRG1 when compared to the cells isolated from mice stimulated only with 
SIINFEKL  (Figure  4.18.C  and  D).  sTL1A  significantly  increased  the  frequency  of 
CD62L
low OT I T cells in vivo and this effect was independent of IL 2 (Figure 4.18.E). 
Relative expression of granzyme B and perforin mRNA was measured in splenic cells of 
mice 3 days following an adoptive transfer of OT I cells and administration of SIINFEKL 
with or without sTL1A and IL 2 neutralizing antibodies. Expression was normalized to 
that of CD3δ which takes into account differences in OT I cell numbers between different 
groups of mice. sTL1A up regulated expression of granzyme B and perforin beyond that 
induced  by  administration  of  SIINFEKL  alone.  Furthermore,  sTL1A  also  induced 
expression of IL 2 mRNA and blockade of IL 2 signalling diminished the expression of 
granzyme B mRNA (Figure 4.19.).  
  To investigate whether TL1A can generate bona fide memory CD8
+ T cells, wild 
type C57BL/6 mice that had received an adoptive transfer of 1x10
6 OT I T cells and had 
been challenged with SIINFEKL with or without sTL1A were re challenged with anti 
CD40 antibody and SIINFEKL. The mice that had been initially injected with the antigen 
and sTL1A showed slightly higher response than the mice that had been injected with the 
antigen alone. The observed memory response in both groups was a true memory response, 
as it was much higher than the primary response in the mice from the control group (Figure 
4.20.). 
  The effect of sTL1A on the expansion of memory T cells was also investigated. 
First,  SIINFEKL specific  memory  CD8
+  T  cells  were  generated  by  priming  naive 
C57BL/6 mice with OVA protein, anti CD40 antibody and poly(I:C) as an adjuvant. Four 
weeks later, endogenous SIINFEKL specific memory CD8
+ T cells represented ~0.3% of 
the total peripheral blood lymphocytes (PBLs). The mice were subsequently challenged 
with SIINFEKL with or without sTL1A. In contrast to SIINFEKL alone, administration of 
SIINFEKL together with sTL1A induced a robust secondary response. To confirm that that 
it was a true secondary response, the response of the pre immunized mice was compared to 94 
 
the  response  of  naive  animals  in  which  no  significant  expansion  of  endogenous 
SIINFEKL specific CD8
+ T cells could be detected (Figure 4.21.). These results indicate 
that TL1A/DR3 interactions can boost secondary expansion of memory CD8
+ T cells. 
  Accumulation of antigen specific CD8
+ T cells was investigated also in peripheral 
blood of wild type and DR3
 /  C57BL/6 mice injected with OVA protein together with 
anti CD40 antibody and poly(I:C) which is known to up regulate TL1A expression (see 
Chapter 3). Wild type mice showed slightly higher accumulation of SIINFEKL specific 
CD8
+  T  cells  than  DR3
 /   mice  (Figure  4.22.A)  and  there  were  more  IFN γ producing 
CD8
+ T cells in the wild type mice compared to DR3
 /  after in vitro re stimulation with a 
mitogen   phorbol 12 myristate 13 acetate (PMA) and ionomycin (Figure 4.22.B). This 
shows that TL1A not only up regulates proliferation and/or survival of CD8
+ T cells but 


































Figure 4.16. (A) OT I T cell response in vivo. Wild type C57BL/6 mice were adoptively transferred with 
1x10
6 OT I T cells and injected i.v. with 30 nM of SIINFEKL on day 0 with or without 150  g of sTL1A on 
days 0, 1 and 2 (3 mice per group). Accumulation of OT I T cells was measured by flow cytometry analysis 
of peripheral blood samples stained with APC conjugated anti CD8 antibody and 5  l/tube of PE conjugated 
H 2K
b  SIINFEKL  tetramer  on  indicated  days.  P  values  were  calculated  using  two tailed  t  test.  (B) 
Accumulation of OT I T cells in the spleens on day 3 after the adoptive transfer and administration of 
SIINFEKL with or without sTL1A as described above (3 mice per group). Additionally, a group of 3 mice 
was injected also with 250  g of TAN2 2 antibody on days 0, 1 and 2. Following the isolation from mice, 
splenocytes were counted and analysed by flow cytometry as described above. Dot plots show representative 
results for each group, bar graph shows mean values ±SE for each group. (C) CFSE dilution of OT I T cells 
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SIINFEKL alone (black line), SIINFEKL + sTL1A (red line) or SIINFEKL + sTL1A/TAN2 2 (blue line) as 
described above. Grey histogram represents CFSE dilution on OT I T cells before the adoptive transfer. The 
cells  were  stained  with  APC conjugtaed  anti CD8  antibody  and  5   l/tube  of  PE conjugated  H 2K
b 
SIINFEKL  tetramer  and  analysed  by  flow  cytometry.  The  cells  presented  on  the  histogram  were 







Figure 4.17. (A) Accumulation of OT I T cells in the spleens on day 3 after the adoptive transfer and 
administration of SIINFEKL with or without sTL1A as described in the legend for Figure 4.16.A (3 mice per 
group). Additionally, a group of 3 mice was injected i.p. also with IL 2 neutralizing antibodies (75  g of 
JES6 1A12 and 250  g of S4B6) on days 0, 1 and 2. Following the isolation from mice, splenocytes were 
counted  and  analysed  by  flow  cytometry  as  described  in  the  legend  for  Figure  4.16.A.  Dot plots  show 
representative results for each group, bar graph shows mean values ±SE for each group. (B) CFSE dilution of 
OT I T cells from the spleens of mice adoptively transferred with CFSE labelled OT I T cells and injected 
with SIINFEKL alone (black line), SIINFEKL + sTL1A (red line) or SIINFEKL + sTL1A/anti IL 2 (blue 
line) as described above. Grey histogram represents CFSE dilution on OT I T cells before the adoptive 
transfer. The cells were stained with APC conjugated anti CD8 antibody and 5  l/tube of PE conjugated H 
2K
b  SIINFEKL  tetramer  and  analysed  by  flow  cytmetry.  The  cells  presented  on  the  histogram  were 
electronically gated on viable OT I T cells. Presented results are representative for each group (n=3). 











































































Figure 4.18. Expression of CD25 on CD4
+ T cells (A), OT I T cells (B), percentage of Treg cells (C), 
expression of KLRG 1 on OT I T cells (D) and CD62L on OT I T cells (E) in the spleens of mice adoptively 
transferred with OT I T cells and injected with SIIFEKL ± sTL1A or sTL1A and IL 2 neutralizing antibodies 
as described in the legend for Figure 4.17.A (3 mice per group). The cells presented on histograms were 
electronically  gated  on  viable  and  CD4
+  (A,  C),  OT I  T  cells  (B,  D  and  E).  Presented  results  are 
representative for each group (n=3). 
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Figure 4.19. Relative expression levels of granzyme B, perforin and IL 2 mRNA in the spleens of wild type 
C57BL/6 mice following adoptive transfer of OT I T cells and administration of SIINFEKL, SIINFEKL with 
sTL1A or SIINFEKL with sTL1A and IL 2 neutralizing antibodies as described in the legend for Figure 
4.17.A. Each bar represents mean fold change ±SE (n=6 mice per group for granzyme B and perforin, and 3 
mice per group for IL 2). 
 
Figure  4.20.  Secondary  response  of  OT I  T  cells  in  wild type  C57BL/6  mice  that  had  been  adoptively 
transferred with 1x10
6 OT I cells and injected with SIINFEKL ± sTL1A as described in the legend for Figure 
4.16A (3 mice per group).87 days after the primary challenge, the mice were re challenged with 30 nM of 
SIINFEKL  and  75   g  of  anti CD40  antibody.  The  mice  from  the  control  group  (black  triangles)  were 
injected  i.v.  with  30  nM  of  SIINFEKL  and  75   g  of  anti CD40  antibody  (3  mice).  Accumulation  of 
SIINFEKL specific CD8
+ T cells was measured by flow cytometry analysis of peripheral blood samples 
stained with APC conjugated anti CD8 antibody and 5  l/tube of PE conjugated H 2K
b SIINFEKL tetramer 
on indicated days. 
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Figure 4.21. Memory response of endogenous SIINFEKL specific CD8
+ T cells. Wild type C57BL/6 mice 
had been injected i.p. with 100  g of OVA protein, 100  g of anti CD40 antibody and 50  g of poly(I:C). 28 
days later, the mice were re challenged with 30 nM of SIINFEKL with or without 150  g of sTL1A. The 
mice from the control group (open circles) were challenged with 30 nM of SIINFEKL and 150  g of sTL1A 
(n=3 mice per group). Accumulation of SIINFEKL specific CD8
+ T cells was measured by flow cytometry 
analysis of peripheral blood samples stained with APC conjugated anti CD8 antibody and 5  l/tube of PE 
conjugated H 2K
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Figure 4.22. (A) Accumulation of SIINFEKL specific CD8
+ T cells in wild type and DR3
 /  C57BL/6 mice 
injected i.p. with 100  g of OVA protein, 100  g of anti CD40 antibody and 50  g of poly(I:C) on day 0 
(n=5 mice per group). Accumulation of SIINFEKL specific CD8
+ T cells was measured by flow cytometry 
analysis of peripheral blood samples stained with APC conjugated anti CD8 antibody and 5  l/tube of PE 
conjugated H 2K
b SIINFEKL tetramer on indicated days. (B) Percentage of IFN γ secreting CD8
+ T cells in 
spleens of wild type and DR3
 /  mice. The mice from the experiment described in point A were sacrificed on 
day 11, their splenocytes were re stimulated in vitro with 2  M PMA and 100 ng/ml of ionomycin for 4 h, 
stained intracellularly with APC conjugated anti CD8 APC antibody and PE conjugated anti IFN γ antibody 









































































































4.3.  Discussion 
   
  The data presented in this chapter show that TL1A expressing tumour cells are 
rejected by the adaptive immune system. Following the subcutaneous injection, they either 
grow  transiently  or  do  not  show  any  growth.  J558L TL1A  and  J558L PEF  cells  show 
similar  proliferation  rate,  as  measured  in  vitro  by 
3H thymidine  incorporation  assay, 
therefore the delayed growth of J558L TL1A cells in vivo was not the result of lower 
proliferation rate and was the consequence of enforced expression of TL1A on tumour 
cells. Further investigation showed that CD8
+ T cells are essential  for  TL1A mediated 
rejection of J558L tumour. 
  Previous  publications  concerning  the  role  of  TL1A in  co stimulation  of  T  cells 
concentrate mostly on its influence on CD4
+ T cells (see section 1.9.4.) and very little is 
known about its role in CD8
+ T cell mediated immune response. This chapter shows that 
TL1A can act as a direct co stimulatory molecule for both CD4
+ and CD8
+ T cells. The 
interaction between TL1A and DR3 enhances their proliferation and secretion of effector 
cytokines; the increase in proliferation following stimulation with sTL1A is more profound 
in CD8
+ than in CD4
+ T cells. In a more physiological setting, however, where wild type 
and  DR3
 /   C57BL/6  mice  were  injected  with  OVA  protein  together  with  anti CD40 
antibody and poly(I:C), which is known to up regulate TL1A expression, accumulation of 
SIINFEKL specific  CD8
+  T  cells  in  wild type  mice  was  only  slightly  and  statistically 
insignificantly higher than in DR3
 /  mice, even though that CD8
+ T cells isolated from the 
wild type mice produced higher amount of IFN γ than CD8
+ T cells isolated from DR3
 /  
mice following in vitro restimulation with PMA and ionomycin, showing that the role of 
TL1A  is  much  more  evident  in  experiments  involving  the  administration  of  soluble 
recombinant  TL1A.  This  is  the  consequence  of  the  presence  of  many  costimulatory 
molecules in living organisms, where the inability to respond to one of them – TL1A – 
does not result in significant reduction of the accumulation of effector T cells. On the other 
hand,  the  use  of  experimental  systems,  where  target  cells  are  stimulated  with  soluble 
recombinant TL1A allow to investigate its role in the development of immune response 
more clearly; they also show that TL1A can potentially act as an adjuvant, boosting T cell 
mediated immune response. 
Down regulation  of  expression  of  the  lymph  node homing  receptor  CD62L  on 
activated  CD8
+  T  cells  stimulated  with  TL1A  indicates  that  these  cells  acquire  the 
phenotype of effector cells. Finally, DR3 triggering on activated CD8
+ T cells during the 102 
 
primary response leads to formation of memory cells which contribute to the rejection of 
tumour during the secondary immune response.   
  Meylan et al. (123) show that TL1A enhances proliferation of CD4
+ T cells via up 
regulation of IL 2 production. The data presented in this chapter show that in vitro, the 
increase in proliferation of CD8
+ T cells is partially dependent on IL 2. In vivo, this effect 
was not observed but both in vitro and in vivo, TL1A enhances the production of IL 2 on T 
cells and the expression of CD25 (IL 2Rα chain) on these cells which is the consequence 
positive feedback loop of IL 2 signalling (176) and is consistent with previous findings 
(111). IL 2 acts as a growth factor for T cells and also can enhance their effector functions. 
The results presented in this chapter are consistent with findings of other groups showing 
that even though IL 2 is essential for T cell responses in vitro (178) and expression of its 
receptor appears on T cells early (4 6 h) after the activation in vitro (179), it appears to be 
dispensable for T cell immunity in vivo,  as effective immune responses occur in mice 
deficient  for  IL 2  (178,  180)  or  CD25  (181),  although  immune  deficits  are  sometimes 
noticed. Furthermore, Obar et al. (182) show that CD25 signalling is not required for early 
effector CD8
+ T cell differentiation in vivo but has a negative impact on late accumulation 
of CD8
+ T cells and generation of memory cells. These findings stand in agreement with 
the data presented in this chapter showing that TL1A induced early activation of CD8
+ T 
cells in vivo can occur in the absence of IL 2. 
  Quantitative PCR analysis of mRNA isolated from OT I T cells isolated from mice 
stimulated  with  SIINFEKL,  SIINFEKL  +  sTL1A  or  SIINFEKL  +  sTL1A  and  IL 2 
neutralizing antibodies showed that IL 2 expression is required for optimal induction of 
granzyme B transcript by TL1A which is in agreement with previous studies showing that 
expression of granzyme B by activated T cells depends on IL 2R signalling (183, 184). 
There are reports showing that expression of perforin depends on two transcription factors 
– STAT 5 and eomesodermin which are activated by IL 2 (184, 185). The data presented 
in this chapter show that neutralization of IL 2 did not down regulate the expression of 
perforin transcript induced by TL1A suggesting that, in contrast to induction of granzyme 
B  expression,  TL1A  can  by pass  the  requirement  of  IL 2R  signalling  and  can  induce 
perforin  expression in activated CD8
+ T cells  without any other stimuli. However, the 
question whether TL1A signalling can lead to activation of STAT 5 and eomesodermin 
remains unanswered.  
  Slightly delayed growth of J558L TL1A cells in BALB/c SCID mice and in wild 
type BALB/c mice depleted of CD8
+ and both CD4
+ and CD8
+ T cells compared to the 103 
 
growth of J558L PEF cells suggests that NK cells may also respond to TL1A stimulation 
and take part in the rejection of the tumour. Approximately 15% of NK cells isolated from 
BALB/c mice expressed DR3, which is consistent with findings of other research groups 
(125, 136) and shows that these cells can respond to TL1A stimulation. Depletion of NK 
cells  in  wild type  BALB/c  mice  resulted  in  the  lack  of  tumour  rejection  following  a 
subcutaneous injection of J558L TL1A cells. However, the depletion of NK cells in the 
mice was conducted using anti asialo GM1 antibody, while Slifka et al. (173) showed that 
administration of this antibody results also in removal of most activated CD8
+ and CD4
+ T 
cells.  In  vivo  depletion  of  NK  cells  is  difficult  because  many  naive  T  cells  and  most 
activated  T  cells  express  markers  typical  for  NK  cells  (NK1.1,  DX5  and  asialo GM1) 
(173); therefore the lack of tumour rejection in BALB/c mice injected with α asialo GM1 
antibody was probably the consequence of both T cell and NK cell depletion. An in vivo 
killing assay was performed to overcome this problem. NK cells act during the first 4 6 
hours of the immune response, however no preferential killing of TL1A expressing tumour 
cells  was  observed.  Even  though  some  research  groups  showed  that  TL1A  enhances 
cytotoxicity and proliferation of NK cells (136, 150), the data presented in this chapter 
show that NK cells play a minor role in TL1A mediated tumour rejection in vivo. 
    





CHARACTERIZATION OF CD11c TL1A AND CD2 TL1A TRANSGENIC MICE 
 
5.1.  Introduction 
 
  As  shown  in  chapter  3,  expression  of  TL1A  on  dendritic  cells  and  T  cells  is 
transient  and  activation dependent  which  makes  it  difficult  to  examine  the  function  of 
endogenously expressed TL1A in detail in vivo. Therefore, constitutive overexpression of 
TL1A on dendritic cells (in CD11c TL1A transgenic mice) and on T cells (in CD2 TL1A 
transgenic mice) was used as an alternative approach to reveal the role of TL1A in T cell 
mediated immunity in vivo. 
  The  data  presented  in  chapter  4  show  that  sTL1A  increases  the  frequency  of 
regulatory T cells and enhances activation of T cells. The percentage of regulatory T cells 
and the expression of activation/memory markers were investigated in the transgenic mice 
to  see  how  sustained  expression  of  TL1A  on  dendritic  cells  and  T  cells  affects  the 
activation of T cells and accumulation of regulatory T cells. 
  The  other  aspect  described  in  this  chapter  is  the  influence  of  the  constitutive 
expression of TL1A on the development of bowel inflammation in mice. TL1A is thought 
to  play  a  role  in  the  pathogenesis  of  inflammatory  bowel  disease  (IBD).  Its  elevated 
expression was detected on CD11c
high dendritic cells isolated from lamina propria in two 
murine models of chronic ileitis (144); TL1A was elevated also on human mononuclear 
cells  isolated  form  lamina  propria  in  IBD  (116).  Increased  expression  of  TL1A  was 
detected also on lamina propria macrophages, monocytes, dendritic cells and T cells in 
patients  with  Crohn’s  disease  (146,  149,  153)  and  on  plasma  cells  in  patients  with 
ulcerative colitis (116). IBD patients show also a higher proportion of DR3 expressing 
intestinal  lamina  propria  T  cells  than  healthy  subjects  (116,  117).  The  level  of  TL1A 
expression correlates with the severity of the disease (116); furthermore, it has been shown 
that neutralization of TL1A in vivo reduces the symptoms of bowel inflammation in mice 
(134, 146).  IBD is a group of inflammatory conditions of the gastrointestinal tract; its 
major  forms  are  ulcerative  colitis  (affecting  colon  and  rectum)  and  Crohn’s  disease 
(affecting  any  part  of  the  gastrointestinal  tract).  IBD  is  an  autoimmune  disease  which 
results from an inappropriate activation of the immune system driven by the presence of 
normal luminal flora. There are several genetic and environmental factors that contribute to 105 
 
the susceptibility to  IBD. It is not a uniform disease; for example, ulcerative colitis is 
mediated by Th2 cells, while in Crohn’s disease the inflammation is driven by Th1 and 
Th17 cells (186, 187). There are several forms of mouse ileitis which are murine models of 
IBD  and  can  be  induced  by  administration  of  chemical  agents  (188,  189),  transfer  of 
autoreactive T cells (190) or spontaneously developed as a result of the genetic background 
(144).  There  are  two  haplotypes  of  TL1A  gene  which  are  associated  with  increased 
expression of TL1A protein and susceptibility to IBD (153). 
  For these reasons, CD11c TL1A transgenic mice were investigated for any signs of 
ileitis and expression of cytokines associated with Th1 cells (IFN γ), Th2 cells (IL 4 and 
IL 13)  and  Th17  cells  (IL 17A)  which  was  also  investigated  in  CD2 TL1A  transgenic 
mice.  
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5.2.  Results 
 
5.2.1.  Expression of TL1A in CD11c TL1A and CD2 TL1A transgenic mice 
 
  CD11c TL1A  transgenic  (CD11c TL1A  tg)  mice  constitutively  express  TL1A 
under the control of CD11c promoter, therefore in these animals sustained expression of 
TL1A is present on dendritic cells. The transgenic mice were fertile, healthy and born at 
the  expected  Mendelian  frequencies;  the  total  cellularity  of  the  spleens  and  the  lymph 
nodes  of  CD11c TL1A  transgenic  mice  was  similar  to that  found  in  littermate  control 
mice. Constitutive expression of TL1A mRNA in splenocytes of CD11c TL1A transgenic 
mice was 10 fold higher than in control littermates and was comparable to that seen at the 
peak  of  the  LPS  stimulation  response  in  wild type  mice  (Figure  5.1.  and  Figure  3.4.), 
although the expression of transmembrane TL1A was only slightly higher on dendritic 
cells isolated from CD11c TL1A transgenic mice when compared to control mice (Figure 
5.2.).   
  CD2 TL1A transgenic (CD2 TL1A tg) mice constitutively express TL1A under the 
control of CD2 promoter which results in sustained expression of TL1A on T cells. Like 
CD11c TL1A  tg,  CD2 TL1A  tg  mice  were  fertile,  healthy  and  born  at  the  expected 
Mendelian  frequencies.  Constitutive  expression  of  TL1A  mRNA  in  the  spleens  of  the 
transgenic  mice  was  100 fold  higher  than  in  their  control  littermates  (Figure  5.1.). 
Peripheral blood samples from 4 CD2 TL1A transgenic mice and their control littermates 
were stained for the presence of CD3
+ TL1A
+ T cells. 6.88% ±1.41% of total peripheral 
blood lymphocytes from the transgenic mice expressed transmembrane TL1A, compared 
to 0.46% ±0.13% in the control mice. When the cells were electronically gated on T cells 
(CD3
+ cells), the expression of transmembrane TL1A was detected on 22.61% ±2.98% of 
T cells from the transgenic mice, compared to 1.01% ±0.2% of T cell from the control 
littermates (Figure 5.3.A) and the average mean fluorescence intensity of the peak was 
4.83±0.06  and  12.51±0.73  for  the  negative  littermates  and  CD2 TL1A  tg  mice, 















Figure 5.1. Expression of TL1A mRNA in the spleens of CD11c TL1A and CD2 TL1A transgenic mice. 
Total RNA was isolated from the spleen cells, genomic DNA in the RNA samples was digested, RNA was 
reverse transcribed and the amount of TL1A mRNA was determined by qPCR. Bar graphs represent mean 







Figure 5.2. Expression of TL1A on dendritic cells from CD11c TL1A mice (black line) or control littermates 
(red line). Dendritic cells were enriched on 14.5% Nycodenz gradient, stained with DR3.Fc construct or 
human IgG (isotype control for DR3.Fc; grey histogram) and PE conjugated anti human IgG antibody and 
analysed by flow cytometry. The cells presented on the histogram were electronically gated on a viable and 
CD11c














































Figure 5.3. Expression of TL1A on T cells from CD2 TL1A transgenic mice and control littermates. (A) 
Expression of TL1A on total population of peripheral blood lymphocytes. The cells were electronically gated 
on viable population. (B) Expression of TL1A on T cells from CD2 TL1A transgenic mice (black line) and 
control littermates (grey histogram). The cells were gated on both viable and CD3
+ population. The cells 
were stained with APC conjugated anti CD3 antibody, biotin conjugated anti TL1A (TAN2 2) antibody and 












5.2.2.   Analysis of T cell activation and accumulation of regulatory T cells in CD11c 
TL1A   and CD2 TL1A transgenic mice 
 
  Expression  of  CD25,  CD44  and  CD62L  on  CD4
+  and  CD8
+  T  cells  was 
investigated in both CD11c TL1A tg and CD2 TL1A tg mice to examine the influence of 
sustained TL1A expression on T cells. CD25 (IL 2Rα chain) is an early activation marker 
of T cells (179). CD44 is commonly used as a marker for distinguishing activated and 
memory  cells  from  their  naive  counterparts.  Activated  T  cell  up regulate  CD44  early 
during the clonal expansion phase and maintain its expression permanently. The functional 
role of CD44 remains unclear although a recent report shows that it regulates cell survival, 
therefore  CD44  promotes  effector  cell  survival  (191).  Lymph  node homing  receptor 
CD62L (L selectin) is used as a marker of effector memory T cells (2).  
  In  CD11c TL1A  tg  mice,  the  percentage  of  CD62L
low  CD4
+  T  cells  was  only 
slightly higher than in wild type mice and there was no difference in the percentage of 
CD62L
low CD8




+ cells was significantly elevated in CD11c TL1A tg mice (Figures 5.4. and 5.5.). 
This demonstrates that sustained expression of TL1A results in enhanced activation of both 
CD4
+ and CD8
+ T cells that presumably recognize environmental antigens. There was no 
change in the percentage of CD25
+ CD8
+ T cells in the spleens of CD11c TL1A tg mice 
(Figures  5.4.  and  5.5.)  but  the  frequency  of  CD25
+  CD4
+  T  cells  was  higher  in  the 
transgenic  mice  than  in  wild type  mice  (Figures  5.4.  and  5.5.)  which  may  reflect  the 
elevated level of regulatory T cells. Surprisingly, this increase was not observed in the 
peripheral blood (Figures 5.4. and 5.5.). 
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Figure 5.4. Expression of CD62L, CD44 and CD25 on CD4
+ or CD8
+ T cells from the spleens or peripheral 
blood from CD11c TL1A tg mice or control wild type mice. The cells were stained with APC conjugated 
anti CD4 or APC conjugated anti CD8 antibody and PE conjugated anti CD62L, PE conjugated anti CD44 
or FITC conjugated anti CD25 antibody and analysed by flow cytometry. Presented cells were electronically 
gated on viable and CD4
+ or CD8







































+ T cells in the spleens or peripheral 
blood from CD11c TL1A tg mice or control wild type mice. The presented results represent mean values 






























































































































































  The analysis of the expression of activation / memory markers on splenic T cells 
from CD2 TL1A tg mice was more detailed and based on the expression of regulatory T 
cell marker FoxP3 which allowed to distinguish conventional CD4
+ T cells from regulatory 
T cells.  
  Like in CD11c TL1A tg mice, CD2 TL1A tg mice did not show any difference in 
the frequency of CD62
low CD8
+ T cells when compared to control animals (Figures 5.6. 
and  5.8.).  There  was  also  no  difference  in  the  frequency  of  CD62L
low  CD4
+  T  cells 




  T cells in CD2 TL1A tg mice than in the control mice 
(Figures 5.7. and 5.8.). The comparison of the percentage of CD44
+ CD4
+ FoxP3
+ T cells 
in CD2 TL1A tg mice and in the control animals was not possible, because no clear peak 
of CD44
+ cells could be observed on the histograms, however the comparison of mean 
fluorescence intensity (MFI) values revealed that regulatory T cells from the transgenic 
mice show higher expression of CD44 than the control cells (Figures 5.7. and 5.8.). In 
contrast to CD11c TL1A tg mice, CD2 TL1A tg mice did not show an increase in the 
frequency of CD44
+ CD8
+ T cells when compared the wild type mice (Figures 5.6. and 
5.8.). Like CD11c TL1A tg mice, CD2 TL1A tg mice had a higher proportion of CD25
+ 
CD4





  cells, no difference in the frequency of CD25
+ 
cells was observed which confirms that the elevated level of CD25
+ CD4
+ T cells is the 
consequence of the increased level of regulatory T cells (Figures 5.7. and 5.8.). CD2 TL1A 
tg  mice  did  not  show  any  difference  in  the  percentage  of  CD25
+  CD8
+  T  cells  when 


















Figure 5.6. Expression of CD62L, CD25 and CD44 on CD8
+ T cells in the spleens of CD2 TL1A tg mice 
and control mice. The cells were stained with APC conjugated anti CD8 antibody and PE conjugated anti 
CD62L, anti CD44 or anti CD25 antibody. The cells presented on the histograms were electronically gated 
on both viable and CD8
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  or total population of 
CD4
+ T cells from the spleens of CD2 TL1A tg mice and control mice. The cells were stained with PE 
conjugated  anti CD4  antibody,  APC conjugated  anti FoxP3  antibody  and  FITC conjugated  anti CD62L, 
anti CD44 or anti CD25 antibody and analysed by flow cytometry. The cells presented on histograms were 




  or CD4
+ population. The presented results are 










































  T 
cells and the mean fluorescence intensity (MFI) of the FITC conjugated anti CD25 antibody staining of 
CD4
+ FoxP3
+ T cells from CD2 TL1A tg mice and wild type control mice. The presented results represent 






























































































































































































  In vivo stimulation with sTL1A increased the frequency of regulatory T cells in 
wild type C57BL/6 mice that received an adoptive transfer of OT I T cells and injection of 
SIINFEKL  peptide  (Figure  5.9.).  To  investigate  how  constitutive  expression  of  TL1A 
affects the accumulation of regulatory T cells, spleen cells from CD11c TL1A tg, CD2 
TL1A tg mice and control mice were stained for the presence of CD4
+ FoxP3
+ cells. In 
both strains of the transgenic mice the percentage of CD4
+ FoxP3
+ T cells was almost 2 







Figure 5.9. (A) Expression of FoxP3 on CD4
+ T cells from spleens of CD11c TL1A tg and CD2 TL1A tg 
mice and control animals. The cells were stained with APC conjugated anti CD4 and PE conjugated anti 
FoxP3 antibodies. The cells were electronically gated on viable and CD4
+ population. The presented results 
are representative of 4 (for CD11c TL1A tg mice) or 2 (for CD2 TL1A tg mice) separate experiments. (B) 
The frequency of CD4
+ FoxP3
+ regulatory T cells in CD11c TL1A tg and CD2 TL1A tg mice. The data 
represent mean values ±SE, n=4 mice for CD11c TL1A and 2 mice for CD2 TL1A tg mice. P values were 










































5.2.3.  The  influence  of  sustained  TL1A  expression  on  the  immune  homeostasis  of  the 
bowel  in CD11c TL1A tg and CD2 TL1A tg mice 
 
  In  order  to  investigate  whether  constitutive  expression  of  TL1A  affects  the 
production  of  Th1,  Th2  or  Th17 associated  cytokines  and  whether  it  can  polarize  the 
immune response to one of these types, the expression of IFN γ (Th1 cytokine), IL 4, IL 
13 (Th2 cytokines) and IL 17A (Th17 cytokine) transcripts was measured in the secondary 
lymphoid organs and the ilea of CD11c TL1A and CD2 TL1A tg mice. CD2 TL1A tg 
mice were additionally examined for the expression of IL 2 transcript. 
  In CD11c TL1A tg mice, the expression of IL 17A mRNA was elevated in the 
spleens (average 54.67 fold increase, compared to control littermates), mesenteric lymph 
nodes (average 2.56 fold increase) and ilea (average 3.39 fold increase) (Figure 5.10.). IL 
13 mRNA showed a trend toward higher expression in the spleens (average 8.17 fold), 
mesenteric lymph nodes (average 5.08 fold) and ileum (average 1.74 fold), although the 
increase was statistically significant only in the spleen (Figure 5.10.). The levels of IFN γ 
an IL 4 transcripts did not differ between CD11c TL1A tg mice and the control animals 
(Figure 5.10.), although it was not possible to detect IL 4 transcript in the spleens and the 
ilea of either CD11c TL1A tg or control mice, suggesting that the overall level of IL 4 in 
these organs is very low. 
  CD2 TL1A tg mice also show elevated level of IL 17A mRNA in the mesenteric 
lymph  nodes  (average  5.65 fold  increase,  compared  to  control  littermates)  and  a  trend 
toward higher expression of IL 13 mRNA in the mesenteric lymph nodes (average 3.83 
fold increase), although the increase of the level of IL 13 transcript was not statistically 
significant  (Figure  5.11.).  The  expression  of  IL 17A  and  IL 13  transcripts  was  also 
investigated in the ilea of CD2 TL1A tg mice, however the level of the cytokines’ mRNA 
was  too  low  to  obtain  reliable  results.  Furthermore,  there  was  no  difference  in  the 
expression of IL 2 and IFN γ transcripts in the mesenteric lymph nodes of CD2 TL1A tg 
and control mice (Figure 5.11.).  
  IL 13 and IL 17A are known to increase goblet cell and mucus production (192, 
193). Indeed, histological examination of the small intestine revealed an increase in the 
number of goblet cells in the ilea of CD11c TL1A transgenic mice (Figure 5.12.A and C). 
The  increase  in  the  numbers  of  goblet  cells  was  restricted  to  the  ileum  and  was  not 118 
 
accompanied by inflammation. No signs of inflammation or goblet cell hyperplasia were 
observed also in the colons of the transgenic mice (Figure 5.12.B). 
 
   
 
 
Figure  5.10.  Relative  expression  of  IL 13,  IL 17A,  IFN γ  and  IL 4  mRNA  in  the  spleens, 
mesenteric lymph nodes and ilea of CD11c TL1A tg mice as determined by qPCR. Each data point 
represents  the  relative  cytokine  expression  value  of  an  individual  mouse.  Relative  expression 











Figure 5.11. Relative expression of IL 13, IL 17A, IFN γ and IL 2 mRNA in the mesenteric lymph 
nodes  of  CD2 TL1A  tg  mice  as  determined  by  qPCR.  Each  data  point represents the relative 
cytokine expression value of an individual mouse. Relative expression values were calculated from 
















   












Figure  5.12.  Goblet  cell  hyperplasia  in  the  intestines  of  CD11c TL1A  transgenic  mice.  Representative 
(n=10) photographs (x 100 magnification) of sections from the ileum (A) and colon (B) of a 24 week old 
CD11c TL1A transgenic mouse or a control littermate. Paraffin sections were stained with H&E. (C) Total 
number of goblet cell per 10 small intestinal villi of 24 week old CD11c TL1A transgenic mice or control 
littermates.  Goblet  cells  were  counted  in  10  randomly  chosen  small  intestinal  villi  of  6  CD11c TL1A 





















































5.3.  Discussion 
 
  CD11c TL1A transgenic and CD2 TL1A transgenic mice have higher proportion 
of  CD44
+  CD4
+  and  CD8
+  T  cells  than  their  control  littermates.  The  percentage  of 
CD62L
low T cells was similar in the transgenic mice and the control littermates, although 
CD11c TL1A tg mice showed a trend toward higher frequency of CD62L
low CD4
+ T cells 
(Figure 5.5.). This shows that sustained expression of TL1A promotes enhanced activation 
of  naive  cells  and  accumulation  of  effector  /  memory  T  cells.  Expression  of  CD25  is 
transient  and  present  on  conventional  T  cells  only during  the  early  stage  of  activation 
(176). CD62L is shed from T cells early (6 8 h) after the activation, however later it may 
be re expressed on the cell surface of central memory T cells (194). CD44 is the only 
marker of activation that is permanently expressed on T cells which have encountered an 
antigen  (191).  This  explains  why  CD44  was  the  most  significantly  altered  activation 
marker in the TL1A transgenic mice. These results show that TL1A can co stimulate T 
cells responding to environmental antigens not only when it is expressed on dendritic cells 
but also when it is expressed on T cells which can take part in co stimulation of other T 
cells  during  the  clonal  expansion  phase  which  confirms  the  findings  described  in  the 
chapter 3.  
  Expression  of  the  transmembrane  form  of  TL1A  on  T  cells  from  CD2 TL1A 
transgenic mice is higher than on dendritic cells from CD11c TL1A transgenic mice which 
is  in  agreement  with  the  findings  of  other  research  groups  (119,  123)  and  the  data 
presented in the chapter 3 which indicate that TL1A is cleaved off dendritic cells but not T 
cells. The other possible explanation of this expression pattern is the fact that expression of 
TL1A  transcript  is  much  higher  in  CD2 TL1A  transgenic  mice  than  in  CD11c TL1A 
transgenic mice which, in turn, may be the consequence of the copy number that integrated 
into the genome of CD2 TL1A tg mice or the strength of the CD2 promoter. 
  Both  in  CD11c TL1A  transgenic  and  CD2 TL1A  transgenic  mice,  constitutive 
expression of TL1A results in elevated levels of IL 13 and IL 17A, without affecting the 
production of IFN γ, IL 4 or IL 2. Potential sources of IL 13 and IL 17A in the transgenic 
mice are CD4
+ and CD8
+ T cells, as constitutive expression of TL1A results in increased 
frequencies of these cells with effector phenotype. Like IL 13, IL 4 is a Th2 type cytokine 
but  recent  studies  showed  that  IL 13  plays  a  more  important  role  than  IL 4  in  a  Th2 
immune response directed against intestinal parasites (192). Moreover, during Th2 type 
immune response, production of IL 13 is higher and more prolonged than IL 4 (195) which 122 
 
explains  the  lack  of  IL 4  production  in  the  mesenteric  lymph  nodes  of  CD11c TL1A 
transgenic  mice.  Taken  together,  this  suggests  that  in  the  presented  transgenic  models 
TL1A is preferentially amplifying Th2 and Th17 type responses and the observed effect is 
independent of the cell type (dendritic cells or T cells) that produces TL1A in vivo.  
  IL 13 and IL 17A are one of the cytokines involved in the regulation of intestinal 
immunity. Maintaining immune homeostasis of bowels is a crucial process, since intestines 
are exposed to a variety of environmental and food antigens which can lead to severe 
immune  reactions.  There  are  several  reports  showing  that  IL 13  is  involved  in  the 
induction of goblet cell differentiation both in the airways and in the intestines. Receptor 
for IL 13 (termed “type II IL 4R”) is a heterotrimer composed of IL 13Rα1 chain and IL 
4Rα chain and binds both IL 13 and IL 4. IL 4α chain is present also in type I IL 4R which 
binds only IL 4 (196). Differentiation of goblet cells from intestinal epithelial cells in IL 
4Rα
 /  mice infected with worm Nippostryngylus brasiliensis was abrogated (197) and this 
effect was due to the inability of the mice to respond to IL 13, not to IL 4, stimulation 
because other report shows that IL 13
 /  mice, but with normal expression of IL 4, fail to 
develop  goblet  cell  hyperplasia  that  normally  occurs  coincident  with  N.  brasiliensis 
expulsion  (192).  Other  in  vivo  models  using  transgenic  mice  (198)  or  intratracheal 
injections of IL 13 (199) consistently show increased goblet cell hyperplasia in the airways 
of mice. Also the data presented in this thesis show that elevated expression of IL 13 is 
accompanied  by  increased  numbers  of  goblet  cells.  IL 17A  is  also  involved  in  the 
induction of goblet cell hyperplasia since it stimulates expression of mucin genes MUC5B 
and MUC5AC (193) which are considered to be markers of goblet cell metaplasia (200). 
Furthermore, neutralization of  IL 17A in mice infected with respiratory syncytial virus 
resulted in significant decrease in the mucogenic response and goblet cell numbers (201). 
  Goblet cells are found in the intestinal and respiratory tracts and their main role is 
secretion  of  mucin  which  protects  the  intestinal  barrier  from  infiltration  by  luminal 
contents and protects host organisms from parasitic worms (202, 203). In the intestines, 
goblet cells also produce resistin like molecule β (RELMβ) which has a direct effector 
function against parasitic infections and also plays a pathogenic role in promoting colitis 
and ileitis probably by inducing secretion of pro inflammatory cytokines such as TNF, IL 
6  and  RANTES  (204 206).  Production  of  RELMβ  is  directly  induced  by  IL 13  but 
inhibited by IFN γ. Other Th2 type cytokine, IL 4 does not play a role in induction of 
RELMβ expression (206, 207). Surprisingly, in humans, IBD is usually accompanied by 
the decreased level of goblet cells (208) and elevated production of antibodies directed 123 
 
against goblet cells (209). On the other hand, in SAMP1/YitFc mice that spontaneously 
develop  ileitis,  goblet  cell  hyperplasia  is  one  of  the  earliest  symptoms  of  intestinal 
inflammation (206) showing that goblet cells may play a dual, not fully understood yet, 
role in the pathogenesis of bowel inflammation.  
   Apart from the participation in the induction of goblet cell formation, IL 17A also 
inhibits Th1 type immune response which is responsible for the development of intestinal 
inflammation in certain settings (210) and it limits infiltration of the intestine by CD4
+ T 
cells  and  granulocytes  which  increase  the  severity  of  the  disease  (189).  In  a 
trinitrobenzenesulfonic  acid induced  model  of  colitis  IL 17A  appears  to  play  a  pro 
inflammatory  role  (188)  but,  on  the  other  hand,  in a  dextran  sodium  sulphate induced 
model of this disease IL 17A plays a protective role (189). This shows that the role of IL 
17A in pathomechanisms of bowel inflammation remains controversial and depends on the 
settings  of  the  experiments,  particularly  on  the  type  of  the  immune  response  that  is 
involved in the development of the disease, as bowel inflammation can be mediated by 
Th1, Th2 or Th17 type immune response (186, 187). 
  In CD11c TL1A transgenic mice used in the research presented in this thesis, no 
signs of bowel inflammation were observed, except for increased number of goblet cells 
which may be due to the elevated levels of IL 17A or increased accumulation of Tregs in 
these mice. CD2 TL1A transgenic mice were not investigated for the presence of bowel 
inflammation. On the other hand, a report published after the completion of the research 
presented  in  this  thesis  shows  that  transgenic  mice  constitutively  expressing  TL1A  on 
lymphoid and myeloid cells develop mild inflammation in the small intestine which is 
accompanied  by  elevated  levels  of  IL 13  and  IL 17A mRNA  in  the  mesenteric  lymph 
nodes and in the spleen (211). This inconsistency with the data presented in this chapter 
can be explained by different gut flora in the tested animals or by expression of TL1A 
under the control of different promoters – in the above mentioned report TL1A expression 
on myeloid cells was controlled by c fms promoter and was present not only on dendritic 
cells but also on macrophages and the total expression of TL1A protein was higher than in 
CD11c TL1A transgenic mice used in the research presented here (211). A recent report 
from  other  research  group  shows  that  CD2 TL1A  transgenic  mice  develop  IL 13 
dependent small bowel inflammation accompanied by goblet cell hyperplasia (212).  
  CD11c TL1A  and  CD2 TL1A  transgenic  mice  show  also  two  times  higher 
accumulation of Tregs when compared to negative littermates. Tregs were shown to be 
capable  of  suppressing  several  autoimmune  diseases,  including  inflammatory  bowel 124 
 
disease (213). Sustained expression of TL1A both on dendritic cells and T cells contributes 
to elevated accumulation of regulatory T cells in the transgenic mice, although data from 
our laboratory (214), show that TL1A attenuates the suppression imposed by regulatory T 
cells on effector T cells in vitro, therefore it is not clear whether the lack of intestine 
inflammation in CD11c TL1A transgenic mice is due to the elevated level of regulatory T 
cells or the activity of IL 17A. 
  In conclusion, this chapter demonstrates that TL1A promotes Th2 and Th17 type 
effector responses and activates T cells in vivo. It also contributes to the development of 
bowel inflammation most probably via induction of IL 13 and possibly IL 17A expression 






  The data presented in this thesis show that expression of TL1A is highly restricted 
and activation dependent. TL1A is transiently expressed on anti CD3 activated T cells, 
LPS activated  bone  marrow derived  dendritic  cells  and  total  population of  spleen  cells 
isolated from mice injected with ligands for TLR3 (poly(I:C)) and TLR4 (LPS and Lipid 
A), while no expression of TL1A was detected on naive bone marrow derived dendritic 
cells or T cells. Very little DR3 is expressed on non activated CD8
+ T cells (125). The data 
presented here show that DR3 is up regulated on CD8
+ T cells after their activation in vitro 
and is maintained at relatively high level even 72 h following the activation. In contrast to 
TNFR1, which is constitutively expressed in most tissues (83), expression of DR3 is  up 
regulated on activated immune cells, such as T cells, monocytes or NK cells (125, 134, 
135),  therefore  its  signalling  does  not  have  such  a  profound  effect  on  the  organism 
homeostasis as TNFR1 signalling. Other members of the TNF and TNFR superfamilies, 
which take part in co stimulation of T cells, like CD70 and CD27, OX40L and OX40 or 4 
1BBL and 4 1BB, are also expressed on activated antigen presenting cells and/or T cells 
(74).  Function  of  CD70/CD27,  4 1BBL/4 1BB,  OX40L/OX40,  CD30L/CD30  and 
LIGHT/HVEM interactions during an immune response is dependent on the timing of their 
maximal expression. Therefore HVEM, expressed on naive T cells, plays an important role 
during initial activation of T cells, while CD70 promotes proliferation of activated T cells. 
By contrast, expression of OX40, 4 1BB, CD30 and their ligands is maintained longer 
during the immune response on proliferating T cells and activated antigen presenting cells; 
consequently  they  also  act  later  (60,  215).  Thus,  the  unique  contribution  of  each 
TNF/TNFRSF  member  to  regulation  of  T  cell  responses  depends  not  only  on  their 
specialized  function  but,  more  importantly,  on  the  timing  of  their  action.  Expression 
pattern of TL1A, similar to that of CD70 (60), indicates that its role in the development of 
T cell mediated immune response is comparable to that of CD70. Transient expression of 
TL1A and the fact that it does not induce apoptosis of CD8
+ T cells (111) suggest that its 
interaction with DR3 does not play a role in quenching of the immune response; instead, its 
main function is co stimulation of T cells during the expansion phase. 
  The  differences  in  the  binding  specificity  of  TAN2 2  antibody  and  DR3.Fc 
construct  to  J558L PEF,  J558L TL1A,  HEK293T,  HEK293T TL1A,  EG.7  cells  and 126 
 
activated T cells and the ability of TAN2 2 antibody to ameliorate the clinical score of 
collagen induced arthritis in vivo (102), showing that it recognises biologically active form 
of TL1A, have led to a hypothesis that TL1A naturally exists in two different forms, homo  
and heterotrimeric. All  of the known TNFSF  members exist as trimers (75). The only 
known heterotrimeric member of the TNFSF is lymphotoxin β (LTβ), the other members 
of the TNFSF are homotrimeric proteins (76). There are two forms of LTβ – LTα1β2, 
consisting  of  one  α  chain  (monomer  of  lymphotoxin  α;  LTα)  and  two  β  chains,  and 
LTα2β1, consisting of two α chains and one β chain (76). LTα1β2 binds only to LTβ 
receptor (LTβR) but LTα2β1 binds to TNFR1 and TNFR2 (216). This suggests that one of 
the forms of TL1A (homo  or heterotrimeric), or both of them may bind also to receptors 
other than DR3. This hypothesis is supported by the fact that truncated forms of TL1A, 
generated  as  the  result  of  alternative  splicing,  VEGI 174  and  VEGI 192  bind  also  to 
receptors other than DR3 (111). Furthermore, several receptors belonging to the TNFRSF 
can bind multiple ligands (75, 76). For example, LIGHT binds both LTβR and HVEM 
(216)  and  soluble  decoy  receptor  3  (DcR)  binds  Fas,  LIGHT  and  TL1A  (118,  138). 
Therefore there is a possibility that not only can TL1A bind to receptors other than DR3 
but also DR3 can bind ligands other than TL1A. TNF homology domain (THD), present in 
the C terminal part of the TNFSF members is responsible for their trimerization. Proteins 
showing high level of homology in the THD are more likely to form oligomers than the 
proteins with lower level of homology (75, 76, 78).   
As described in chapter 1, death receptors can induce either apoptotic cell death or 
activation of pro survival genes. The final outcome of their stimulation depends on the 
balance between pro  and anti apoptotic factors inside the cell. Like TNFR1, DR3 recruits 
an adaptor protein TRADD which subsequently recruits TRAF2 and  FADD (82, 132), 
therefore its triggering can also result either in apoptotic death of a cell or in activation of 
transcription of pro survival genes. On the other hand, DR4, DR5 (receptors for TRAIL) 
and  Fas  do  not  bind  TRADD;  instead  they  bind  FADD  directly  to  their  cytoplasmic 
domains (217) which results in their inability to activate NF κB and therefore, in contrast 
to DR3, these receptors primarily induce apoptotic cell death. Apoptotic death of T cells 
induced by several death receptors, notably Fas, CD30 and TNFR1 (42 44), is crucial for 
contraction of the effector cell pool following the peak of the immune response. However, 
the data presented in this thesis shows that the primary role of TL1A/DR3 interactions is 
co stimulation of T cells but not the participation in activation induced cell death. Even 127 
 
though DR3 is capable of inducing apoptotic cell death (129, 131, 132), triggering of this 
receptor on T cells results in their enhanced proliferation and effector function (111). 
  Previous  publications  concerning  the  role  of  TL1A in  co stimulation  of  T  cells 
concentrate mostly on its influence on CD4
+ T cells and very little is known about its role 
in CD8
+ T cell mediated immune response, therefore most of the research presented in this 
thesis is concentrated on the role of TL1A in co stimulation of CD8
+ T cells. The other 
reason for that was the observation that CD8
+ T cells are responsible for TL1A mediated 
rejection of J558L tumour in BALB/c mice. The data presented in this thesis show that 
TL1A  acts  as  a  co stimulatory  molecule  for  both  CD8
+  T  cells  and  can  enhance  their 
effector  function.  TL1A/DR3  signalling  combined  with  TCR  engagement  leads  to 
increased proliferation of both CD4
+ and CD8
+ T cells which has been shown both in vitro 
and in vivo. Constitutive expression of TL1A on T cells and dendritic cells (in CD2 TL1A 
and  CD11c TL1A  transgenic  mice,  respectively)  results  in  an  increased  frequency  of 
activated,  CD44
+  CD4
+  and  CD8
+  T  cells.  Furthermore,  wild type  C57BL/6  mice  that 
received an adoptive transfer of OT I T cells and injection of SIINFEKL together with 




cells than the control animals. In vivo, TL1A directly increases production of perforin and 
IL 2 by CD8
+ T cells. It also directly elevates the production of granzyme B from CD8
+ T 
cells, although IL 2 is required for optimal induction of granzyme B. 
  These results show that function of TL1A/DR3 interactions is similar to that of 
other pairs of TNFSF/TNFRSF members which act as co stimulatory molecules for both 
CD4
+  and  CD8
+  T  cells  –  CD70/CD27,  4 1BBL/4 1BB,  GITRL/GITR,  OX40L/OX40 
(89).  In  vitro  data  show  that  stimulation  of  OT I  T  cells  with  sTL1A  together  with 
SIINFEKL  can  partially  by pass  the  requirement  for  CD28  signalling  to  enhance 
proliferation of CD8
+ T cells; also 4 1BB, GITR and OX 40 signalling can replace CD28 
signalling, although in its presence the effect of co stimulation is more profound (89, 90).  
  Very little is known about the influence of TL1A/DR3 signalling on memory T cell 
response. There is evidence that TL1A enhances proliferation of CD45
low CD4
+ memory T 
cells in vitro (116) but there are no reports published to date discussing the role of TL1A in 
expansion of CD8
+ memory T cells. The data presented here show that TL1A enhances the 
generation of endogenous antigen specific CD8
+ memory T cells and boosts the expansion 
of CD8
+ memory T cells in mice that received an adoptive transfer of OT I T cells as well 
as in an endogenous setting in vivo.  128 
 
  Wild type C57BL/6 mice that received an adoptive transfer of OT I T cells and 
injection of SIINFEKL and sTL1A have higher percentage of regulatory T cells (Tregs) in 
the spleens than the control animals. Sustained, constitutive expression of TL1A on T cells 
and dendritic cells results in elevated frequency of Tregs in CD2 TL1A and CD11c TL1A 
transgenic mice, respectively. Observations from our laboratory show that in CD11c TL1A 
transgenic mice there is a clear increase in the proportion of splenic Tregs that express the 
proliferation  antigen  Ki 67  (214).  In  vitro  experiments  showed  that  TL1A  directly 
enhances proliferation of Tregs which are stimulated also with anti CD3 and anti CD28 
antibodies (214). Taken together, these data indicate that TL1A enhances proliferation of 
Tregs.  Van  Olffen  et  al.  (218)  show  a  similar  occurrence  in  transgenic  mice  that 
constitutively  express  GITR  under  the  control  of  CD19  promoter  which  also  exhibit 
accumulation of Tregs as a result of their increased proliferation.  However, it is possible 
that  TL1A,  like  LIGHT  (219),  also  induces  differentiation  of  Tregs.  Since  there  is  no 
specific  marker  that  would  allow  distinguishing  inducible  Tregs  (differentiating  in  the 
periphery) from natural Tregs of thymic origin (9), it is not possible to determine whether 
these cells differentiate in the periphery from T cells or develop in the thymus. However, it 
is very likely that TL1A stimulates both ways of Treg development. Signals that influence 
the development of natural Tregs are not clear (4), but constitutive expression of TL1A in 
CD2 TL1A and CD11c TL1A transgenic mice may contribute to enhanced development of 
Tregs in the thymus as well as in the periphery. On the other hand, short term (3 days) in 
vivo stimulation of wild type C57BL/6 mice with sTL1A might lead to differentiation of 
Tregs from naive, conventional CD4
+ T cells in the periphery. Stimulation of GITR, OX40 
and 4 1BB present on Tregs results in loss of their suppressive activity and/or negatively 
regulates their differentiation (92, 99). The influence of TL1A/DR3 interactions on the 
biological activity of Tregs was not investigated here, although unpublished data from our 
laboratory show that TL1A attenuates the suppression of effector T cells by Tregs in vitro 
by direct stimulation of proliferation of both effector and regulatory T cells. However, 
because of transient nature of TL1A expression in vivo, Tregs are expected to regain their 
suppressive  activity  relatively  quickly,  therefore  the  net  effect  of  TL1A  on  activity  of 
Tregs  in  conditions  of  a  normal  immune  response  is  probably  positive  due  to  their 
increased accumulation.  
  Wang et al. (219) describe a function of LIGHT comparable to that of TL1A. Its 
overexpression on T cells in transgenic mice results in development of colitis which is 
accompanied by enhanced expansion of Tregs. This is due to ability of LIGHT to promote 129 
 
proliferation of Tregs as well as effector T cells even in a Treg abundant environment. 
Transgenic mice, overexpressing GITR on B cells, also show enhanced proliferation of 
Tregs  and  conventional  CD4
+  T  cells  (218).  In  a  similar  way,  TL1A  up regulates 
proliferation of both conventional effector T cells (CD4
+ and CD8
+) as well as regulatory T 
cells. 
  CD11c TL1A transgenic mice develop IL 13 induced goblet cell hyperplasia in the 
small intestine but do not show any other symptoms of bowel inflammation which may be 
the  consequence  of  elevated  expression  of  IL 17A  which  inhibits  Th1 type  immune 
response (210) and infiltration of the bowel by pro inflammatory cells (189); the other 
possibility is enhanced proliferation of Tregs, as discussed in Chapter 5.  
  Proteins belonging to the TNF and TNFR superfamilies are involved in directing 
the immune response towards Th1, Th2 or Th17 type (60, 74, 92). Several research groups 
showed that TL1A skews the immune response towards Th1 type by inducing secretion of 
a Th 1 type cytokine, IFN γ, from CD4
+ T cells (136, 144, 146, 147) and peripheral blood 
mononuclear  cells  in  vitro  (111,  117,  136,  142).  Meylan  et  al.  (123)  show  that  TL1A 
induces secretion of both IFN γ and IL 4 from activated CD4
+ T cells in vitro. On the other 
hand,  other  research  groups  demonstrate  that  TL1A  induces  secretion  of  Th2 type 
cytokines, IL 4 and/or IL 13, from peripheral blood monocytes (117) and NK cells (125) 
but has no effect on production of IFN γ by these cells in vitro. Moreover, TL1A can also 
up regulate secretion of IL 17 (Th17 type cytokine) from activated Th17 cells (145, 146, 
149) and induce differentiation of Th17 cells from naive CD4
+ T cells (145). The data 
presented here show that TL1A up regulates the production of both IL 4 and IFN γ from 
activated  T  cells  in  vitro,  furthermore  splenocytes  isolated  from  DR3
 /   mice  and 
restimulated in vitro with PMA and ionomycin secrete less IFN γ than splenocytes isolated 
from wild type mice. As described above, CD11c TL1A transgenic mice and CD2 TL1A 
transgenic  mice  show  an  increase  in  expression  of  IL 17A  mRNA  accompanied  by  a 
modest  increase  of  IL 13  mRNA  expression  in  the  secondary  lymphoid  organs  and 
intestine but do not up regulate the level of IFN γ. This demonstrates that the observed 
effects of TL1A are independent of the cell type that produces TL1A in vivo. However, the 
observed phenotype of CD11c TL1A and CD2 TL1A transgenic mice stands in contrast 
with  the  phenotype  of  transgenic  mice  overexpressing  TNF  or  LIGHT  where  severe 
intestinal pathology is accompanied by  elevated levels of  IFN γ and  IL 12 (220, 221). 
Elevated levels of IFN γ are present also in mice overexpressing CD70 and GITR (97, 130 
 
218). On the other hand, transgenic mice overexpressing OX40 show bias towards Th2 
type immune response and develop colon inflammation (222).  
  Taken together, these data suggest that TL1A does not skew the immune response 
to one, particular type. Instead, it can induce secretion of Th1, Th2 or Th17 type cytokines 
depending on the conditions of an experiment and differences in the cellular distribution 
and signalling capacity of DR3 in different types of an immune response. For example, 
Th17 cells show higher level of DR3 expression than Th1 and Th2 cells in vitro (145). 
Also, the lack of DR3 expression on CD4
+ T cells cultured in vitro under non polarizing 
conditions negatively impacts the production of Th2 type cytokines but not IFN γ (125). 
The observed impact of TL1A on secretion of Th1, Th2 and Th17 type cytokines is similar 
to the effect of OX40 which is known to induce differentiation of both Th1 and Th2 cells 
(92). 
  In conclusion, this thesis demonstrates that TL1A/DR3 interactions enhance T cell 
mediated immunity. Further investigation revealed that CD8
+ T cells play a critical role in 
TL1A mediated rejection of J558L tumour. TL1A acts as a direct co stimulatory molecule 
for CD4
+ and CD8
+ T cells which enhances their activation. It also enhances generation of 
CD8
+ memory T cells and boosts their expansion. This suggests that in future TL1A might 
by used as molecular adjuvant to enhance T cell responses to vaccines or to boost immune 
response  to  tumours  or  infections  with  pathogens.  Some  members  of  the  TNFSF  are 
already  used  as  molecular  adjuvants  to  vaccines.  GITRL  and  CD40L  augument  CD8
+ 
and/or CD4
+ responses to DNA vaccination (223). OX40L and CD40L boosts CD8
+ T cell 
responses to HIV 1 vaccine in mice (224). Furthermore, Kayamuro et al. (148) show that 
out  of  16  TNFSF  members  tested  as  mucosal  vaccine  adjuvants,  TL1A  induced  the 
strongest  response  to  intranasal  immunization  with OVA,  characterized  by  high  serum 
levels of IgG1 and elevated production of IL 4 and IL 5 from splenocytes. The ability of 
TL1A to act as a direct co stimulatory molecule for T cells indicates that it may potentially 
be  used  as  an  adjuvant  for  vaccines  or  in  anti tumour  therapy.  However,  considering 
application of TL1A in therapy it is important to pay attention that TL1A is involved in 
pathogenesis of several autoimmune diseases, such as inflammatory bowel disease (116, 
134, 146, 149, 153, 225), rheumatoid arthritis (102, 154, 155), experimental autoimmune 
encephalomyelitis (123) and autoimmune lung inflammation (123, 125, 145). 
  Most of the experiments presented in this thesis involve stimulation of animals or 
cells with recombinant TL1A or is conducted on mice constitutively expressing high levels 
of  TL1A.  In  physiological  conditions,  however,  the  expression  of  TL1A  is  tightly 131 
 
regulated and transiently present on activated cells of the immune system, including T cells 
(123,  125),  dendritic  cells  and  monocytes  (119).  Furthermore,  TL1A  is  one  of  many 
costimulatory molecules present in organisms of mammals, therefore it may seem that its 
role  in  the  development  of  the  immune  response  is  not  critical.  On  the  other  hand, 
neutralization  of  TL1A  prevents  the  development  of  experimental  bowel  inflammation 
(134)  and  attenuates  chronic  colitis  in  mice  (146);  it  also  protects  mice  from  antigen 
induced arthritis (a mouse model of rheumatoid arthritis) (102). In addition, DR3
 /  mice 
show  reduced  clinical  score  of  antigen induced  arthritis  (102)  and  experimental 
autoimmune encephalomyelitis (a mouse model of multiple sclerosis) (123). This shows 
that,  in  settings  that  do  not  involve  overexpression  of  TL1A,  it  still  is  an  important 
costimulatory molecule, required for triggering an immune response. Further investigation 
of the role of TL1A in physiological conditions would require the use of TL1A
 /  and/or 
DR3
 /  animals, however no such reports, except for the ones presented above, have been 




SUMMARY OF THE RESULTS 
 
The data presented in this thesis show that expression of TL1A is tightly regulated and is 
transiently present on activated dendritic cells and T cells. TL1A increases accumulation 
and/or proliferation of antigen stimulated CD4
+ and CD8
+ T cells both in vitro and in vivo. 
It also enhances functional activity of CD8
+ T cells and stimulation with high doses of 
TL1A results in acquisition of effector phenotype by CD4
+ and CD8
+ T cells. Furthermore, 
stimulation with high doses of TL1A in vivo results in elevated proportion of regulatory T 
cells; it also leads to elevated expression of IL 17A and IL 13 in TL1A transgenic mice 
which may contribute to the development of bowel inflammation. Below is the summary of 
the findings presented in this thesis. 
1) Expression of TL1A mRNA is transiently up regulated on splenocytes isolated from 
mice  injected  with  LPS,  Lipid  A  and  poly(I:C),  but  not  with  CpG,  Pam3CSK4,  α 
GalCer,  curdlan  or  anti CD40  antibody.  The  expression  peaks  after  4  hours  of 
stimulation with LPS or Lipid A (8 and 20 fold increase compared to non stimulated 
mice, respectively) and after 6 hours of stimulation with poly(I:C) (18 fold increase).  
 
2) Expression of TL1A mRNA is up regulated on bone marrow derived dendritic cells 
stimulated  in  vitro  with  LPS  or  poly(I:C)  for  4  hours  (442  and  177 fold  increase 
compared to non stimulated cells, respectively). 
 
3) Transmembrane TL1A is detected on bone marrow derived cells after 4 h and 24 h of in 
vitro stimulation with LPS. 
 
4) Transmembrane  TL1A  is  transiently  expressed  on  T  cells  after  24  h  of  in  vitro 
stimulation with anti CD3 antibody. 
 
5) Transmembrane TL1A is expressed on splenocytes isolated from 24 h following the i.v. 
injection with LPS. 
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6) Differences in the binding specificity of anti TL1A antibody (TAN2 2) and DR3.Fc 
construct to TL1A transfected cells and cells naturally expressing TL1A suggest that 
TL1A may exist as a homo  and heterotrimer. 
 
7) Rejection  of  TL1A transfected  J558L  tumour  cells  in  BALB/c  mice  is  mediated  by 
CD8
+ T cells, but not by CD4
+ T cells or NK cells. 
 
8) Initial s.c. injection of TL1A transfected J558L tumour cells into BALB/c mice results 
in long term protection from wild type J558L tumour. 
 
9) Expression of DR3 is present on antigen stimulated OTI cells but not on naive OTI 
cells. 
 
10) Soluble recombinant TL1A increases proliferation of antigen stimulated OTII and OTI 
cells in vitro (average 1.5 fold increase compared to cells not stimulated with TL1A). 
The increase of proliferation of OTI cells stimulated with soluble recombinant TL1A 
partially depends on IL 2 and CD80/CD86 stimulation. 
 
11) Soluble  recombinant  TL1A  enhances  the  production  of  IL 2  by  antigen stimulated 
OTI cells and up regulates the expression of IL 2Rα chain (CD25) on these cells in 
vitro. 
 
12) Administration of soluble recombinant TL1A increases the accumulation of antigen 
stimulated OTII and proliferation of antigen stimulated OTI cells in vivo. The effect of 
increased proliferation of OTI cells is independent of IL 2 in vivo. 
 
13) Administration of soluble recombinant TL1A increases the frequency of regulatory T 
cells in peripheral blood of wild type C57BL/6 mice (2 fold increase, compared to 
control mice). 
 
14) Soluble recombinant TL1A significantly increases the frequency of antigen stimulated 
CD62L
low OTI cells in vivo but does not change the frequency of antigen stimulated 
KLRG1
+ OTI cells. It also increases the expression of granzyme B, perforin and IL 2 
mRNA in antigen stimulated OTI cells in vivo; the increase of granzyme B mRNA 
expression depends also on IL 2. 134 
 
 
15) Administration of soluble recombinant TL1A during the initial priming of C57BL/6 
mice with an antigen does not result in a significant increase of memory CD8
+ T cell 
accumulation after a subsequent re challenge with the antigen and anti CD40 antibody 
but soluble recombinant TL1A significantly enhances the expansion of memory CD8
+ 
T cells when it is administered together with an antigen during the re challenge in an 
endogenous setting. 
 
16) CD11c TL1A transgenic mice have significantly higher proportion of CD44
+ CD4
+ T 
cells  and  CD44
+  CD8
+  T  cells  in  the  spleen  than  control  animals,  although  no 





+ T cells. CD11c TL1A transgenic mice develop goblet cell hyperplasia in the 
small  intestine  and  show  elevated  level  of  IL 17A  transcript  in  the  spleen,  small 
intestine  and  mesenteric  lymph  nodes;  they  also  show  a  trend  towards  higher 
expression of IL 13 mRNA the spleen, small intestine and mesenteric lymph nodes, 
although the increase is not statistically significant when compared to control animals. 
The mice did not show any change in the level of IL 4 mRNA in the mesenteric lymph 
nodes and IFN γ mRNA in the spleen, mesenteric lymph nodes and small intestine 
when  compared  to  control  animals.  CD11c TL1A  transgenic  mice  have  two  times 
higher proportion of regulatory T cells than control mice. 
 




+ T cells and CD44
+ FoxP3
+ CD4
+ T cells in the spleens and CD44
+ CD4
+ T cells 
in  peripheral  blood  than  control  animals,  although  no  significant  changes  were 
observed in the frequencies of CD44
+ CD8
+ T cells or CD62L
low T cells. CD2 TL1A 
transgenic mice have higher expression of IL 17A mRNA in the mesenteric lymph 
nodes, than control animals; they also show a trend towards higher expression of IL 13 
mRNA in the mesenteric lymph nodes than control animals. The mice did not show 
any difference in the level of IFN γ and IL 2 mRNA in the mesenteric lymph nodes 
when  compared  to  control  mice.  CD2 TL1A  transgenic  mice  have  also  two  times 
higher proportion of regulatory T cells than control mice. 
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